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Background: The incidence of chronic kidney disease (CKD) is rising and is the 12th most 
common cause of death worldwide. Currently, the only available treatments are renal 
replacement therapy and transplantation, both of which are significantly costly for the NHS. 
Therefore there is an unmet clinical need for new therapies which can tackle the manifestation 
of renal disease processes and progression to CKD. The pathophysiological process common 
to all CKDs, regardless of the initiating aetiology, is tubulointerstitial fibrosis (TIF). TIF leads 
to scarring of the kidney and results in loss of renal function and eventual end-stage renal 
disease. TIF is driven by a number of pathophysiological processes taking place in several 
cell types including the proximal tubule. The proximal tubule (PT) is sensitive to injury and in 
a damaged state has attracted attention as a driver of fibrotic disease due to de-differentiation 
and pro-inflammatory/ pro-fibrotic signalling. Argininosuccinate synthetase (ASS1), a rate-
limiting urea cycle enzyme, is highly expressed in the PT and has been reported to be 
downregulated in human CKD. Furthermore, urea cycle metabolites such as citrulline have 
been reported to be dysregulated in renal disease.  
Hypothesis: Loss of tubular ASS1 expression is critical in the induction of renal fibrosis. 
Results: Renal Ass1 expression was assessed and compared to sham operated animals in 
ischaemia-reperfusion injury (IRI), subtotal nephrectomy (STNx), obstructive (UUO) and 
reversible obstructive (rUUO) murine models. Ass1 expression was significantly 
downregulated in all models of injury. Ass1 loss occurred at early time points and preceded 
the manifestation of fibrosis. Single cell RNA-seq of the reversible UUO model was adopted 
to assess Ass1 expression during the progression and reversal of fibrosis. After obstruction, 
Ass1 was significantly depleted in fibrotic tubular epithelial cells. Upon reversal of fibrosis, 
Ass1 expression levels almost returned to normal.  
ASS1 is highly expressed in human proximal tubular epithelial cells (RPTEC/TERT1). To 
determine the consequences of ASS1 depletion, ASS1 was knocked-down in RPTECs. This 
induced upregulation of pro-fibrotic genes and downregulation of cell-cell contact genes. In 
RPTECs, ASS1 transcription was unaffected by pro-fibrotic, TGFβ. However, ASS1 
transcription was significantly reduced in a dose-dependent manner following TNFα treatment 
and hypoxia. 
In order to further interrogate the function of Ass1 in tubular epithelial cells in vivo, Ass1 was 
conditionally knocked out in renal tubular cells specifically using the Pax8 CreERT2 floxed Ass1 
transgenic mouse. The effect of Pax8 Cre x Ass1 flox/wt heterozygous knock-out was 
assessed to explore if partial loss of Ass1 exerted a haploinsufficiency effect. Heterozygous 
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mice did not demonstrate any renal phenotype distinct from controls. A small cohort of Pax8 
Cre x Ass1 flox/flox mice homozygous were assessed to interrogate the effects of full knock 
out of Ass1 in the kidney. Pax8Cre x Ass1 flox/flox female mice exhibited a decrease in ASS1 
protein in the kidney. This under-powered study did not reveal any pathological effects in the 
kidney in the unchallenged state in a period of 10 weeks.        
Conclusions: Downregulation of Ass1 is evident in 3 different models of fibrosis with different 
aetiologies. Replicating loss of ASS1 in vitro in human RPTECs induced a pro-fibrotic, de-
differentiated phenotype which is independent of TGF-β signalling but dependent on pro-
inflammatory and hypoxic stimuli. A small under-powered cohort of tubular specific Ass1 
knock-out mice did not exhibit fibrosis within the kidney in the basal state in a short time-frame. 
However, using a larger cohort and challenging the tubular Ass1 knock out mouse with an 
injury such as ischaemia reperfusion may result in an exacerbation of fibrosis. Overall, loss of 
ASS1 may provide a novel link between initial inflammatory/ hypoxic insult in tubular cells and 






Chapter: 1 Introduction 
1.1 Kidney Function 
The kidney is an essential organ which is responsible for maintaining 
physiological homeostasis through a number of mechanisms. The kidneys 
perform diverse roles including maintaining the body’s pH, regulating 
electrolyte balance, regulating fluid balance and regulating blood pressure. 
Additionally, the kidney is responsible for reabsorbing nutrients such as 
glucose and amino acids, producing hormones such as renin and 
erythropoietin and activating vitamin D. The specific structure and morphology 
of the kidney is essential for maintaining these physiological roles. Several 
functionally distinct cell types coalesce together to form the structurally unique 
functional unit of the kidney; the nephron. A single kidney contains around 1 
million nephrons which together filter around 180 litres blood every day.  The 
nephron is comprised of the glomerulus, proximal tubule, loop of Henlé, distal 
tubule and collecting duct (Figure 1.1). Each of these components performs a 
specific function (1).  
 
Figure 1.1: Segments of the nephron 
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1.1.1 The Glomerulus 
The glomerulus is the filtering unit of the nephron with multiple filtering layers 
situated between afferent and efferent resistance vessels. Specialised 
fenestrated endothelial cells form a bundle of capillaries which provide the first 
layer of filtration. Filtrate that passes through these fenestrations is further 
filtered by the glomerular basement membrane (GBM) (2). The GBM is 
comprised of an array of extra-cellular matrix proteins and serves to support 
the capillary bundle (3). Finally, specialised peri-vascular epithelial cells, called 
podocytes, with interdigitating foot processes wrap around the GBM providing 
the last layer of filtration. The membrane between podocyte foot processes, 
termed the slit diaphragm, functions to form a size selectivity barrier. It also 
contains transmembrane proteins that signal back to podocytes to regulate 
their form and function. Together, these components prevent the passage of 
red blood cells and large proteins into the urinary space (4). The filtrate, or pre-
urine, is then collected in the Bowman’s capsule and moves through the tubules 
for reabsorption of nutrients and fluid balance.  
1.1.2 The Tubules 
Tubules are luminal structures comprised of polarised tubular epithelial cells 
which vary in their transporter profile from the proximal tubule to the collecting 
duct. Each epithelial cell contains an apical and a basolateral membrane which 
are exposed to the lumen and peritubular capillaries respectively.  The proximal 
tubule (PT) is described in three segments; S1, S2 and S3 (5). S1 comprises 
the beginning of the proximal convoluted tubule (PCT) and is characterized by 
a thick brush border with the greatest number of microvilli which provides a very 
large luminal surface area. S1 also contains more mitochondria and endocytic 
compartments than S2 or S3. S2 comprises the remainder of the PCT and has 
a less pronounced brush border with shorter microvilli as well as fewer 
mitochondria other organelles. Segment 3 comprises the straight PT and 
terminates at the outer stripe of the medulla. S3 has the least pronounced brush 
border and the fewest number of mitochondria within the PT (6). The proximal 
tubule is responsible for the vast majority of tubular reabsorption (6). Glucose, 
amino acids, electrolytes and water (60-70%) are all reabsorbed by the PT with 
reabsorption greatest in S1 and to a lesser extent in S2 and S3. This extensive 
reabsorption requires energy and the PT is the most energy dependent 
component of the nephron (7).   
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The remaining segments of nephron, the loop of Henle, distal tubule and the 
collecting duct are responsible for the concentration of urine. After the majority 
of nutrients are absorbed by the PT, the loop of Henle descends into the 
medulla and is responsible for the concentration of pre-urine. The distal tubule 
and collecting duct are responsible for the fine balance of electrolytes and serve 
as a pathway to the ureter. Together the distal tubule and collecting duct 
contribute between 5-10% sodium reabsorption which is entirely dependent on 
dietary intake (8). These regions of the nephron rely on a fine balance provided 
by precise passive and active transport of electrolytes and water (9).  
Any disturbance to renal homeostasis results in pathological changes to the 
kidney itself as well as systemic changes such as blood pressure and acid-
base balance. One of the most severe pathologies of the kidney is chronic 
kidney disease which leads to renal failure and end-stage kidney disease for 
which the treatments are costly and in the exception of transplant, non-curative.  
1.1.3 Chronic kidney disease 
Chronic kidney disease (CKD) is the progressive loss of renal function and 
filtrative capacity of the kidney over time. CKD is defined as a decreased 
glomerular filtration rate (GFR), a measure of renal function, of less than 
60mL/min, or markers of renal damage for more than three months. Markers of 
renal damage include albuminuria, electrolyte imbalance and abnormal 
histology (10). CKD is diagnosed irrespective of cause and patients with CKD 
are classified into 5 stages based on their renal GFR. CKD is a progressive 
disease which ultimately leads to end-stage kidney failure (ESKF). ESKF 
requires renal replacement therapy with dialysis or ideally a renal transplant. 
The incidence of CKD is rising and is estimated to affect 11% of adults (11,12). 
This poses a massive financial burden on the NHS due to cost of kidney failure 
services comprising an estimated 1.3% of the NHS budget annually (13).   
Additionally, CKD is not just a disease of the kidney. Patients often present with 
complications such as anaemia due to decreased erythropoietin production 
and iron deficiency. Furthermore dysregulated vitamin D, calcium and 
phosphate metabolism results in mineral bone disease (10). Of note, CKD is 
highly interlinked with cardiovascular disease and patients often display co-
morbidities including hypertension, atherosclerosis and myocardial infarction 
(14).  Moreover, there is a significant correlation between declined GFR and 
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increased death from cardiovascular disease (15,16). The fact that CKD not 
only causes ESKF but also the aforementioned diseases, has prompted the 
World Health Organisation to name CKD as the 12th most common cause of 
death worldwide (17). 
There are a number of aetiologies and risk factors associated with CKD which 
include hypertension (18), diabetes, obesity, inherited disorders such as 
polycystic kidney disease, human immunodeficiency virus (19) and acute 
kidney injury (20) as well  as CKD of unknown cause (12,21).  However, 
regardless of the cause, there is always a common mechanistic pathway 
leading to CKD; renal fibrosis.  
1.1.4 Manifestations of renal fibrosis 
Renal fibrosis encompasses a number of pathological events including 
architectural changes within the nephron such as glomerulosclerosis (GS) and 
tubulointerstitial fibrosis (TIF). There are also several intracellular events which 
contribute to fibrogenesis such as myofibroblast activation, tubular de-
differentiation and metabolic dysfunction. Finally, infiltration of a variety of 
immune cells within the kidney is a common characteristic amongst all renal 
diseases. There is an unmet clinical need for efficacious therapeutics 
combatting the progression of CKD and the loss of functional filtration due to 
scarring. Therefore, deeper understanding of the various mechanisms involved 
in the progression of CKD will lead to improved therapies. The various factors 
which contribute to the progression of renal fibrosis and subsequent kidney 




Figure 1.2: Summary of the mechanisms contributing to the progression of renal fibrosis. After 
injury to the tubular epithelia a number of intracellular processes such as metabolic dysfunction, 
recruitment of immune cells and partial epithelial-to-mesenchyme-transition occur. Pathological 
signals induce proliferation of myofibroblasts from several sources and exacerbate chronic 
inflammation. Together these events lead to fibrosis, tissue dysfunction and inflammation which 
leads to progression of kidney failure. Diagram adapted from Ovadya et al. (22). 
1.1.5 Myofibroblast activation and extra-cellular matrix accumulation 
Renal fibrosis is caused by deposition of excess extra-cellular matrix (ECM) in 
the glomeruli and tubular interstitium. Renal fibrosis is characterised by 
recruitment of myofibroblasts resulting in excess accumulation of abnormal 
ECM leading to scar formation and impaired renal function (10). ECM proteins 
play a structural role in a normal, functioning kidney and the processes of 
accumulation and degradation of ECM components are tightly balanced. When 
homeostatic control of ECM production and degradation is lost in the kidney, 
perhaps due to injury, excess ECM proteins accumulate within the glomerulus 
and the tubular interstitium, leading to fibrosis and structural changes in the 
kidney. These structural changes progress to functional changes over time 
resulting in CKD.  
There are several families of ECM proteins, of which many have been 
described to play a role in the development of fibrosis. Collagens comprise a 
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large proportion of kidney ECM proteins and during the onset of renal fibrosis 
excessive deposition of Collagen I and Collagen III in the glomeruli and 
tubulointerstitium occurs. Furthermore, collagen fragments are found in the 
urine of patients with CKD which is correlated with serum creatinine and eGFR 
(23). In addition to collagens, other ECM components such as extracellular 
proteoglycans, glycoproteins and basement membrane proteins such as 
laminin are found to be upregulated in renal TIF (24). Matrix metalloproteinases 
(MMPs) are also thought to play a role in the development of fibrosis. Primarily 
MMPs are involved in the proteolytic degradation of ECM proteins, however, 
some MMPs such as MMP-2 and MMP-9 have been reported to be upregulated 
in animal models of renal fibrosis and human CKD. MMP-2 and MMP-9 have 
been reported to interact with inflammatory mediators such as tumour necrosis 
factor alpha (TNF-α) and monocyte chemoattractant protein (MCP-1) as well 
as activating growth factors such as transforming growth factor beta (TGF-β) 
and fibroblast growth factor (FGF) (25). Inflammation and activation of these 
growth factors are hallmarks of renal fibrosis and subsequent CKD. In order to 
prevent the progression of renal fibrosis we must understand the origins and 
stimuli of fibrosis. The main cell type responsible for secreting excess 
accumulation of ECM is the renal myofibroblast. 
The myofibroblast is the activated form of the fibroblast and is broadly 
characterised by its ability to proliferate, contract and secrete vast amounts of 
ECM. All myofibroblasts express alpha smooth muscle actin (α-SMA) the 
platelet derived growth factor receptor beta (PDGFRβ) which are used to 
identify myofibroblasts. However, these markers are not myofibroblast specific 
and several other cell types express these markers. (26,27). The number of 
myofibroblasts present within the kidney is an accurate indicator of poor 
outcome in CKD due to increased fibrosis and they are rarely present in the 
healthy kidney parenchyma (28). The origin of myofibroblasts has been a hotly 
debated topic. Fate mapping experiments in rodents have elucidated several 
origins which contribute to the renal fibroblast population differentially 
dependent on the disease model. Progenitors include Gli1+ pericytes, resident 
fibroblasts, bone marrow derived myeloid cells and endothelial cells (29,30). 
Epithelial cells were until recently thought to be a major contributor to the 
myofibroblast pool via epithelial to mesenchyme transition (EMT). Recently, 
this theory has been disproved, however, the role epithelial cells play in the 
pathogenesis of renal fibrosis will be covered in depth later (29,31).  
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Activation and proliferation of fibroblasts is a central event in the development 
of fibrosis. However, all the mechanisms that activate this cell type have yet to 
be fully understood. Transforming growth factor beta (TGFβ) is known as the 
master regulator of fibrosis and is a driver of fibrosis in all forms of CKD. TGFβ 
can bind TGFβ receptors on myofibroblasts resulting in activation of canonical 
(Smad dependent) and non-canonical (non-Smad dependent) pathways 
resulting in the transcription of ECM components and subsequently driving 
fibrosis (32). TGFβ has been reported to be upregulated in human CKD and 
animal models of renal fibrosis and exogenous administration of TGFβ 
exacerbates TIF and glomerulosclerosis (33,34). It has deleterious effects on 
most kidney cells in the setting of fibrosis. Furthermore, deletion of TGFβ 
receptors in mice has ameliorated excess collagen production and attenuated 
fibrosis (35-37). However, TGFβ is also involved in a number of central 
biological processes including proliferation, differentiation, apoptosis and 
immune signalling. Although targeting TGFβ signalling may provide a potential 
strategy to treat renal fibrosis, the adverse effects on the immune system pose 
serious concerns (38). However, myofibroblasts are not the only cell type which 
has been shown to contribute to the progression of fibrosis.  
1.1.6 Tubular epithelial cells and fibrosis 
Tubular epithelial cells (TECs) comprise the majority of renal mass and exist 
as highly differentiated cells which express a number of transporters and have 
a very high ATP demand. Our knowledge of the role that TECs play in the 
progression of fibrosis has developed in recent years. Previously, TECs were 
thought to be purely victims of fibrogenic signalling but now it is appreciated 
that TECs can act as drivers of fibrosis (27).  
Tubules and particularly proximal tubules are sensitive to repeated injury. Fate 
mapping techniques have revealed that after ischaemia reperfusion injury, 
surviving epithelial cells are able to proliferate and repair the injury and this 
repopulation is not mediated by any other progenitor population (39-41). While 
a single injurious event induces repair, multiple assaults to TECs lead to the 
initiation of fibrogenesis. This was shown by Takaori and colleagues who 
developed a targeted injury model specific to the proximal tubule. They found 
that a single mild injury induced adaptive repair mechanisms while repeated 
injuries led to maladaptive repair and the development of fibrosis within the 
interstitium and glomeruli (42). The mechanism whereby PT injury can induce 
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glomerular damage is not yet fully understood but there is evidence to suggest 
that epithelial cell cycle arrest in G2/M phase can induce fibrogenesis by 
increasing JNK activation (43).  These mechanisms are important as patients 
that are exposed to acute kidney injury (AKI) have an increased likelihood of 
developing CKD later in life. Moreover, the severity of the AKI increases the 
risk of developing CKD (44). Initial damage to tubules may pave the way for 
some individuals to develop progressive renal disease. Injuries sustained by 
TECs in patients can include continued inflammatory insult, hypoxia, ischaemia 
reperfusion injury as well as physical injury caused by albuminuria (45,46). 
Although the precise mechanisms whereby injured TECs initiate fibrosis have 
yet to be fully elucidated, TECs can undergo several pathogenic responses 
which may contribute to fibrosis.  
Injured TECs have been shown to undergo cell cycle arrest after injury. This 
could occur as a result of DNA damage, mitochondrial dysfunction, 
inflammation as well as other cell stressors (47). Cell cycle arrest is part of a 
maladaptive repair process which results in cells losing the ability to divide and 
is described as senescence. Damaged TECs re-enter the cell cycle in order to 
proliferate and repair themselves. Some of these cells become arrested in the 
G2/M phase and become senescent. Senescence has been observed in many 
CKDs such as diabetic nephropathy, hypertensive CKD and IgA nephropathy 
as well as mouse models of renal disease. Incidence of senescence also 
increases with age (27). Additionally, senescent TECs can adopt a secretory 
phenotype which can result in the secretion of pro-fibrotic and pro-inflammatory 
cytokines, chemokines and proteases which take part in paracrine signalling 
with other pro-fibrotic cell types in the interstitium (47).  
Another important phenotypic switch that can occur in the setting of fibrosis is 
tubular de-differentiation. Although there are parallels with cellular senescence, 
tubular de-differentiation or partial EMT is a distinct process which is emerging 
as an important cornerstone of fibrogenesis. Complete EMT is a process 
whereby epithelial cells lose their epithelial characteristics and adopt a 
mesenchymal, motile phenotype (48). Specifically it is defined as loss of e-
cadherin and ZO-1 expression as well as acquisition of collagen 1, vimentin, 
fibronectin and α-smooth muscle actin. This has long been observed in vitro 
with stimulation by TGFβ and was thought to be the main origin of the 
myofibroblast in the kidney. The complete EMT theory is now highly disputed 
as there is little evidence of this process taking place in vivo (31). However, 
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evidence of partial EMT is evident by positive staining of EMT markers in 
biopsies of patients with renal graft dysfunction as well as the presences of 
EMT mRNAs in the urine of patients with diabetic nephropathy (49,50). There 
is also evidence to suggest that partial EMT occurs in vivo, whereby epithelial 
cells lose some epithelial traits but do not transition fully into a myofibroblast. 
Tubular dedifferentiation and subsequent proliferation occurs in response to 
injury and is an attempt to resolve the injury. However, while dedifferentiating, 
TECs have been shown to secrete a number of pro-inflammatory factors and 
TECs have also been proven to secrete matrix components (51,52). If tubules 
continue to dedifferentiate due to ongoing injury this can lead to a self-
perpetuating cycle of maladaptive repair, inflammation and eventually fibrosis 
(24). Therefore, there is a fine balance to be struck between repair mechanisms 
and progressive scar formation and fibrosis which requires more in-depth 
understanding. 
As tubular injury and phenotypic switching is the initiating process in the 
development of CKD, finding strategies to combat pathological changes in 
tubular cells could provide a novel therapeutic approach to prevent patients 
from developing CKD.  
1.1.7 Metabolic dysfunction in CKD 
Recently, tubular metabolic dysfunction has become a well-recognised feature 
of renal fibrosis. The kidney is one of the most highly metabolic organs in the 
body and is mitochondria rich with a high energy demand (13). The kidney 
relies primarily on oxidative phosphorylation to produce enough ATP to satisfy 
this high energy demand. The predominant substrates for oxidative 
phosphorylation are fatty acids, which are metabolized to the greatest extent 
by proximal TECs (14). It is appreciated that nephron number is correlated with 
renal function and loss of functional nephrons in CKD leads to increased 
filtrating and reabsorbing demands in remaining cells to maintain homeostasis. 
This induces a higher energy requirement of remnant cells, particularly tubular 
epithelial cells. Eventually increased metabolic load of tubular cells results in 
hypertrophy and consequently cells exhaust themselves and become apoptotic 
(53). Defective metabolism affects the kidney at many levels, whether it be sub-
cellular mitochondrial dysfunction, lipid accumulation within the kidney 
parenchyma or metabolic syndrome associated renal disease (54-56).  
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Changes in cellular metabolism and fuel source preference are hallmarks of 
disease which have been well characterised in cancer, including the Warburg 
effect (57). Additionally, mitochondrial dysfunction is a commonly occurring 
event in several disease states including kidney disease (58,59). Mitochondrial 
dysfunction is an event which occurs early in TECs after injury. Lan and 
colleagues investigated metabolic switching in tubules undergoing atrophy and 
found that tubules which did not successfully regenerate exhibited decreased 
mitochondrial number and increase rate of glycolysis. They found this process 
to be governed by TGFβ (60). Mitochondrial dysfunction occurs in many 
disease states which triggers the increased production of reactive oxygen 
species which initiate cellular senescence, inflammatory and pro-fibrotic 
pathways which are highly relevant in the setting of CKD (27,58,61,62).  
During the progression of CKD and with increasing age, lipids accumulate 
within the kidney, further promoting the concept of metabolic dysfunction 
contributing to disease. Defective mitochondrial fatty acid oxidation (FAO) and 
decreased expression of Peroxisome Proliferator Activated Receptor Alpha 
(PPAR-α) have been implicated as mechanisms for excess lipid accumulation 
(63). Recent efforts have been made to elucidate the role of cellular metabolism 
within the kidney during fibrogenesis. Kang and colleagues conducted 
microarray analysis of kidneys and found that cellular metabolism and 
specifically FAO to be dysregulated in human CKD and mouse models of renal 
fibrosis. They implicated TGFβ as the main architect of FAO dysfunction and 
found that inhibiting TGFβ signalling rescued defective fatty acid oxidation. This 
was found to be beneficial in several models of fibrosis (64). Calorie restriction 
has also been found to rescue impaired FAO and therefore prevent the 
accumulation of lipid and slow the development of fibrosis (63).  
Another indicator of the link between renal fibrosis and metabolism is the strong 
relationship between obesity, metabolic syndrome and CKD. Rates of CKD 
have been rising in line with increased incidence of obesity and metabolic 
syndrome has been proven to contribute to the pathogenesis of progressive 
renal disease (54,65). Therefore, metabolic dysfunction is undoubtedly a 




1.1.8 Inflammation in CKD 
Inflammation is a driving factor of several chronic diseases and is important in 
inducing many pathological events that exacerbate renal fibrosis. Inflammation 
is a protective response which in most instances is resolved. However, when 
the kidney is injured and cannot be repaired, chronic activation of leukocytes 
ensues, resulting in pathological inflammation (66,67). The number of 
inflammatory infiltrates correlates with extent of fibrosis and a myriad of 
mediators are responsible for this (68). Upon sustained renal insult, recruitment 
of a number of immune cells occurs including macrophages, T cells, mast cells 
and dendritic cells. These leukocytes produce a plethora of pro-inflammatory 
and pro-fibrotic factors such as interleukin 1 beta  (IL-1β), inducible nitric oxide 
synthase, TGF-β and tumour necrosis factor alpha (TNF-α) (69). Some of these 
factors are involved in promoting the survival and activation of myofibroblasts, 
tubular dedifferentiation and microvascular rarefaction. Not only are cells 
recruited from the circulation but resident cells of the kidney can be activated 
and produce inflammatory cytokines and chemokines themselves (27). Tubular 
cells particularly can participate in the inflammatory response by recruiting 
leukocytes and promoting proinflammatory pathways such as NFκB and JNK 
pathways (67,70,71).  
It is evident that there are several cellular players in the setting of renal fibrosis 
and cross-talk between these cell types is important. Understanding how 
fibroblast activation, tubular de-differentiation, metabolic dysfunction and 
inflammation are all linked is essential for furthering our insights into 
mechanisms driving fibrosis and contributing to CKD. 
 
1.1.9 Current and future therapeutic strategies in CKD 
CKD incidence is on the rise, however, there have been very few recent 
developments in therapeutic strategies despite the increased numbers of 
patients suffering with this disease. The most advantageous strategies include 
addressing comorbidities and lifestyle choices that exist in the CKD 
populations. Cessation of smoking, weight loss and control of diabetes are 
effective methods to slow down the progression of CKD (72). Additionally, the 
most widely used pharmacological agents for use in CKD are inhibitors of the 
renin-angiotensin-aldosterone system (RAAS). Angiotensin converting enzyme 
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(ACE) inhibitors and angiotensin receptor blockers (ARBs) are both anti-
hypertensive agents which have been found to be effective drugs to slow the 
progression of fibrosis. As well as RAAS inhibition other blood pressure 
lowering drugs such as calcium channel antagonists have also been found to 
be effective in the treatment of CKD as a combination therapy (73). However, 
none of the current strategies are able to resolve renal fibrosis and stop the 
progression of CKD. Therefore with more preclinical research, the mechanisms 
driving renal fibrosis and subsequent CKD will be fully elucidated and novel 
drug targets will be revealed that may provide efficacious treatment for CKD.  
The pathogenic mechanisms that drive renal fibrosis are diverse and involve 
many cell types. Therefore, developing new strategies for the treatment of CKD 
has proved challenging. Finding new drug targets based on mechanisms 
elucidated by renal researchers is important to slow the progression of CKD 
and add to the limited pharmacological arsenal available to nephrologists. 
1.1.10 Targeting Transforming growth factor beta  
TGFβ has earned its title as the “master regulator of renal fibrosis” and is the 
predominant initiator of ECM production. TGFβ has been reported to be 
upregulated in several CKDs and overexpression of TGFβ in animal models 
induces glomerulosclerosis and tubulointerstitial fibrosis. Therefore, TGFβ has 
been identified as potential drug target and has been the focus of novel anti-
fibrotic therapies (32).  
However, promising as these anti-TGFβ treatments sound, the TGFβ pathway 
interacts with many other ubiquitous pathways such as MAP kinase signalling, 
Wnt; beta catenin signalling, epidermal growth factor receptor (EGFR) 
signalling, p53 signalling and others (74). The pleiotropic effects of TGFβ signal 
transduction mean that targeting TGFβ results in several off-target effects. 
Indeed, targeting TGFβ directly using monoclonal antibodies have not yielded 
promising results in clinical trials due to lack of efficacy (32,75). Furthermore, 
anti-TGFβ treatment has many concerns regarding adverse effects on the 
inflammatory pathways. Animal models have revealed that TGFβ receptor 2 
knockout curtailed fibrotic pathways but conversely promoted inflammatory 
pathways by induction of nuclear factor kappa b (NFκB) signalling (76). 
Although several clinical trials have been conducted which focus on anti-TGFβ 
therapy, none have been shown to improve clinical end-points and the risk of 
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adverse effects from pleiotropic signalling is a concern. As TGFβ has not yet 
proven to be a viable drug target despite its central role in the induction of 
fibrotic pathways, it is important to investigate other potential drug targets 
involving other pathways ongoing during fibrogenesis.  
1.1.11 Targeting Tumour necrosis factor  
Another cytokine which plays are major pathological role in the context of renal 
fibrosis is TNFα. This pro-inflammatory cytokine is known to be upregulated at 
early stages in animal models of renal fibrosis and is also elevated in patients 
with CKD (77-79). As inflammatory processes are thought to initiate 
fibrogenesis, anti-TNFα therapies have been investigated in animal models of 
CKD. Neutralisation of TNFα was found to attenuate fibrosis in the UUO model 
effectively (80). Additionally there have been promising results in clinical trials 
adopting anti-TNFα therapies. Anti-TNFα treatment was found to reduce the 
renal functional decline in a cohort of patients with rheumatoid arthritis (81). 
Moreover, as anti-TNF therapies are already approved by the Medicines and 
Healthcare products Regulatory Agency and the Food and Drug 
Administration, concerns over drug safety would be avoided if these agents 
were found to be beneficial in CKD.   
1.1.12 Targeting microRNAs 
A strategy that has potential as a novel target in the treatment of renal fibrosis 
and CKD is targeting microRNAs (miRNAs). MicroRNAs are small non-coding 
RNAs approximately 16-22 nucleotides long which are important mediators of 
post-transcriptional regulation in nearly all physiological and pathological 
processes. MiRNAs function to repress target mRNA expression whether by 
blockage of protein translation or direct degradation of their mRNA target. 
MiRNAs are attractive drug targets as each miRNA can bind to hundreds of 
mRNA targets and prevent their expression (82). Several miRNAs have been 
reported to be upregulated in renal fibrosis including miR-21, -214, -199, -433, 
-132 and -212 to name a few (83). Some of these miRNAs have been 
extensively investigated and some of their mRNA targets have been identified. 
MiR-21, for example, has been found to target and repress genes in a number 
of pathways including fatty acid oxidation, lipid oxidation, Wnt signalling, 
ERK/MAPK signalling and TGFβ inhibitory pathways. These processes have 
been shown to be dysregulated in fibrogenesis. Therefore inhibiting miR-21 
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would be able to de-repress these pathways and exert subsequent anti-fibrotic 
actions. Other miRNAs are downregulated in renal fibrosis such as the miR-29 
family, -126, -34, -30 family and let-7 family. These miRNAs have been 
reported to target ECM genes, TGFβ signalling and NFκB signalling. These 
anti-fibrotic miRNAs could, in theory, be overexpressed to ameliorate fibrosis 
(84).  
MiRNAs can be pharmacologically manipulated by inhibiting their expression 
with anti-miR oligonucleotides which target and block miRNA activity. 
Additionally anti-miRs tend to accumulate in the kidney which makes them very 
attractive for the treatment of renal disease. Levels of anti-fibrotic miRNAs can 
also be increased using miR-mimics which are chemically synthesised 
oligonucleotides (85).  Although these treatment strategies are in their infancy 
an anti-miR 122 has been developed against hepatitis C infection which is 
currently in phase II clinical trials (86,87). This gives hope that pro- and anti-
miR therapies may provide benefit to patients with CKD in the future.  
Metabolomics and renal disease   
A discussed earlier, defective cellular metabolism has been identified as an 
important pathological change that takes place during the progression of renal 
disease. Metabolomics can be used to measure levels of metabolites in specific 
organs as well as in blood and urine to reveal activity of metabolic pathways. 
Metabolomics has revolutionised how we detect changes in the metabolome 
during the onset of disease. Several studies have investigated changes in the 
metabolome to reveal novel biomarkers of renal disease and also to elucidate 
defective metabolic pathways that may be contributing to CKD (88,89). 
Metabolomics has been used to great effect to measure differences in the 











1.2 Hypothesis and aims of this thesis 
The studies presented in this thesis were conducted to gain further 
understanding of defective metabolic pathways occurring during renal injury. 
Studying several murine models of renal disease allows for more robust 
conclusions to be drawn and provides a more valid reflection of human disease. 
This thesis investigates the use of these three preclinical models to identify 
metabolic genes that may play a novel role in the development of fibrosis.  
I hypothesised that genes involved in metabolic pathways are downregulated 
in the progression of renal fibrosis in preclinical models and identification of 
specific genes that is downregulated in all three models would provide a robust 
candidate gene for further investigation. The hypothesis was tested using a 
number of aims: 
- To identify genes that are upregulated in a mouse protected from renal 
fibrosis using microarray data (anti-fibrotic anti-miR-214 treatment) 
- To identify genes that are downregulated in kidneys subjected to UUO 
and upregulated in reversed UUO using RNA-seq 
- To produce a curtailed number of candidate genes for further 
investigation 
- To measure expression levels of candidate genes in the STNx and IRI 
models of renal fibrosis 






Chapter: 2 Materials and Methods 
2.1  In Vivo experiments 
Male mice between eight and ten weeks were used throughout animal studies 
unless otherwise specified. All animals were housed in the animal unit at Little 
France at 21±1°C, humidity of 50±10% and a controlled light/dark cycle with 
light from 7am-7pm. The animals had access to water and standard chow ad 
libitum and all procedures were performed in accordance with the UK Home 
Office Animals (Scientific Procedures) Act of 1986 after ethical review by The 
University of Edinburgh.  
2.1.1 Metabolic Cages and Urine Analysis 
In order to perform urine analysis, timed metabolic cages were employed to 
harvest urine over a 24 hour period. Mice were singly housed within a metabolic 
cage (courtesy of Professor Matthew Bailey) for 24 hours and urine was 
collected and frozen at -20oC. Urine analysis was carried out by Dr Forbes 
Howie in the Specialist Assay Service at The University of Edinburgh.  
2.1.2 Assessment of blood pressure by tail cuff plethysmography  
Mice were placed in an incubator at 28oC for 15 minutes prior to blood pressure 
assessment in order to dilate vessels in the tail. Systolic and diastolic blood 
pressure were measured using the CODA high throughput system with 4 
activated channels (Kent Scientific, UK). Mice were subjected to tail cuff 
measurement twice on consecutive days to allow for habituation to the system. 
On the third run, measures were used for analysis. The runtime information 
was as follows: 15 total readings with 5 acclimatisation readings and 10 valid 
readings. The occlusion pressure within the tail cuff was 250 mmHg with a 
deflation time of 15 seconds. Mean ±SD systolic and diastolic valid readings 
were calculated for each mouse.   Mean arterial pressure was calculated as 
follows: 
Mean arterial pressure = systolic BP + 2 (diastolic BP) 
                 3 
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2.1.3 Assessment of urea cycle metabolites 
Whole blood was collected either by cardiac puncture at time of termination or 
by venopuncture in live animals. Whole blood was dropped onto predefined 
areas of a Guthrie Card and allowed to dry for 24 hours and frozen at -20oC. 
Levels of urea cycle metabolites in blood samples were kindly assessed by Dr 
Julien Baruteau at University College London according to the published LC-
MS/MS protocol (90).  
2.1.4 Surgical Procedures 
All surgical procedures were carried out on mice under inhalational anaesthetic 
(isoflurane) and the subcutaneous analgesics were used to relieve post-
operative pain. Mice were weighed and their general health assessed regularly 
for 1 week and thereafter checked and weighed weekly until culling. After 1 
week wound clips were removed. Mice were group housed after surgery to 
decrease recovery time. 
Termination was carried out by overdose of isoflurane. All animals were 
weighed and their tibia length measured. Cardiac puncture was performed to 
collect blood followed by perfusion of PBS through the left ventricle to remove 
as many red cells from the circulation as possible. Serum was extracted from 
whole blood by centrifugation at 5000g for 15 minutes. Various organs were 
harvested and stored appropriately for downstream analysis.  
2.1.5 Unilateral ureteric obstruction (UUO) and reversible unilateral ureteric 
obstruction (rUUO) 
UUO surgeries were carried out by either Dr Laura Denby, James O’Sullivan 
or myself on C57BL/6JOlaHsd male mice purchased from Charles River. After 
induction of anaesthesia, laparotomy was performed and the small and large 
intestines moved to the side using a damp cotton-bud and prevented from 
drying out with damp gauze. The right kidney and ureter were located and the 
ureter was separated from surrounding connective tissue by blunt dissection. 
Two sloops were tied around the ureter to prevent out-flow of urine from the 
kidney. The intestines were replaced carefully into the body cavity using a 
damp cotton-bud and the abdominal wall was closed using dissolvable sutures 
(Ethicon 6/0). The skin was closed using skin clips and the animal was allowed 
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to recover in a hot box at 37oC for 24 hours. Renal obstruction was maintained 
for up to 7 days after which the mouse was terminated and tissues collected.   
2.1.6 Reversible unilateral ureteric obstruction model (rUUO) 
As with the UUO model, C57BL/6JOlaHsd purchased from Charles River were 
used throughout rUUO procedures. rUUO surgery was carried out according to 
the protocol published previously by Gary Borthwick (91).  
2.1.7 Subtotal nephrectomy (STNx) 
Subtotal nephrectomy surgery was carried out either by Dr Laura Denby or 
James O’Sullivan and assisted by myself. Surgeries were carried out on 
SV/129 mice purchased from Envigo. SV/129 mice were used for these 
experiments as they are sensitive to subtotal nephrectomy and develop fibrosis 
to larger extent compared to C57BL mice (92). Animal cohorts were culled and 
assessed at several time points. Our group adopted the refined, one-step flank 
surgery method of subtotal nephrectomy developed by Dr Laura Denby (93). 
After induction of anaesthesia the right nephrectomy was carried out. A precise 
flank incision was made through the skin and fascia to reveal the right kidney. 
The ureter and renal artery and vein were clamped using a vascular clip before 
tying off the kidney using sloops. Once obstruction of the blood supply to the 
kidney was ensured, the kidney was removed and the wound closed using 
sutures and clips. The remaining contralateral kidney was accessed in the 
same manner as the first. After clamping of the renal pedicle, the superior and 
inferior poles of the kidney were removed using surgical scissors and weighed 
to ensure a similar mass of kidney was removed in each surgery. Bleeding from 
the resected kidney was prevented using SpongostanTM sponges (Ethicon, UK) 
which were applied to each cut end of the kidney. The vascular clamp was 
removed as quickly as possible to avoid excess ischaemia. Once bleeding had 
stopped the wound was closed using sutures and wound clips.  Sham surgery 
consisted of flank incisions and exposing the kidneys on each side before 
closing the wound.  
2.1.8 Ischemia-reperfusion injury (IRI) 
IRI surgery was performed by Dr Victoria Banwell and animal cohorts were 
assessed at several different time points post-surgery. C57BL/6JOlaHsd mice 
were purchased from Charles River and were used for all IRI surgeries. 
19 
 
Laparotomy was performed and the right kidney was rendered ischaemic using 
vascular clips around the renal pedicle for 18 minutes. After ischaemic injury, 
the vascular clips were removed allowing reperfusion. The wound was closed 
using sutures and wound clips.  After various lengths of time cohorts of mice 
were culled for tissue.  
2.1.9 Transgenic mice  
Pax8 CreERT2 mouse sperm (EM: 10364) and Ass1 flox/flox mice (EM: 05208) 
mouse embryos were purchased from the EMMA repository. International 
strain designations were C57BL/6J-Tg (Pax8-cre/ERT2) CAmat/AmatH and 
C.129P2 (B6)-Ass1tm1.1Ekoe/Cnbc respectively.  
Ai14 tdTomato mice on a C57BL/6J background were used which carry a Cre 
reporter allele with a loxP-flanked STOP cassette preventing transcription of 
CAG promoter driven red fluorescent protein (tdTomato). Ai14 tdTomato mice 
were kindly donated by the Conway group at Edinburgh University.  
2.1.10 Breeding of transgenic mice 
Ass 1 flox/flox mice were originally bred on a Balb/c background, therefore 
these mice were back-crossed to C57BL/6J mice for 5 generations. Ideally 
back-crosses would be carried out for 10 generations but due to time 
constraints in this project, that was not possible. Pax8 CreERT2 mice were 
originally bread on a C57BL/6J background.  
In order to obtain Pax8CreERT2 x Ass1 flox/flox crossed mice; Pax8-CreERT2 
homozygous mice were bred with Ass1 flox/flox homozygous mice. Their 
offspring were heterozygous for both the Cre expression (Cre/wt) and the Ass1 
flox expression (Ass1 flox/wt). These heterozygous offspring were bred 
together to obtain a mixture of genotypes including mice homozygous for both 
Pax8 Cre/Cre and Ass1 flox/flox which were used in tubular Ass1 knockout 
studies.   
In order to obtain Pax8CreERT2 x Ai14 tdTomato crossed mice; Pax8CreERT2 
homozygous mice were bred with Ai14 tdTomato homozygous mice. Their 
offspring were heterozygous for Cre and Ai14. These mice could be used in 
reported studies as only one copy of the Cre and one copy of the Ai14 tdTomato 
is necessary for assessment of tdTomato expression.  
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2.1.11 Pax8CreERT2 and Ass1 flox/flox genotyping  
Ear clips were taken from mice at 3 weeks of age and processed by Transnetyx 
which provided genotyping results.  
2.1.12 Activation of Cre recombinase with tamoxifen 
In mice which carried the Pax8 CreERT2 allele, tamoxifen was used to induce 
recombination of Cre within Pax8 expressing tissue. Tamoxifen (Sigma, UK) 
was made up at 20mg/mL in sunflower oil. Tamoxifen was dissolved in 
sunflower oil in a shaking incubator at 52oC until dissolved with occasional 
vortexing. Tamoxifen was kept in solution for up to 1 week and administered to 
mice at 200mg/kg by oral gavage. Three doses were given on alternate days 
and mice were monitored closely and weighed frequently after gavage.  
2.2 Ex Vivo Experiments 
2.2.1 Electrolyte analysis of serum and urine 
Serum or urine (Section 2.1.1) was assessed for levels of sodium, potassium 
and chloride ions using the Spotchem ELTM Electrolyte Analyser (Woodley 
Laboratory Diagnostics, UK). Urine was diluted 1 in 5 with water before 
measurement and serum did not require dilution. Electrolyte levels were 
measured according to manufacturer’s instructions.  
2.2.2 Kidney digestion for flow cytometry and fluorescence activated cell 
sorting (FACS) 
Mice were anaesthetised under isoflurane and exsanguinated by cardiac 
puncture. Animals were then perfused with 5mL ice cold PBS through the heart 
in order to remove as many red blood cells as possible. Kidneys were 
harvested and stored in ice cold PBS. A quarter or half a kidney was used for 
flow cytometry and FACS respectively. Kidney tissue was weighed prior to 
digestion. Digestion buffer was made up according to Table 2.1 in RPMI media 
(Gibco, Thermo Fisher Scientific, UK) supplemented with 10% fetal calf serum 






Manufacturer Concentration  
Collagenase V Sigma C6885 0.425mg/ml 
Collagenase D Roche 11088882001 0.625mg/ml 
Dispase Gibco 17105-041 1mg/ml 
DNase Roche 10104159001 30µg/ml 
Table 2.1: Reagents for Fluorescence Activated Cell Sorting kidney digest 
 
Using a scalpel, kidney tissue was cut up in a petri dish with the addition of 4mL 
Digestion Buffer before transferring to a gentleMACS C tube (Miltenyi Biotec, 
UK). Tissue was homogenised in gentleMACS tubes using the gentleMACS 
dissociator before tubes were transferred to a shaking water bath set to 37oC 
for 30 minutes. After incubation with collagenases, tissue was further 
homogenized using the gentleMACS dissociator (Miltenyi Biotech, UK).  
The enzymatic activity of the digestion buffer was neutralized by the addition of 
4mL FACS buffer (sterile PBS with 2% FCS and 0.2% EDTA). The kidney cell 
suspension was then filtered through three serially smaller cell strainers 
(100µm, 70µm and 40µm) to ensure a single cell suspension. The filtered cell 
suspension was then pelleted at 500xg for 5 minutes at 4oC using a HeraeusTM 
MegafugeTM (Thermo Fisher Scientific) and the supernatant discarded. Red 
blood cells were lysed by addition of 1mL red cell lysis buffer (Sigma, UK) for 
1 minute before neutralizing with 15mL FACS buffer. This was followed by 
pelleting at 500xg for 5 minutes at 4oC and ensuring red cells were absent and 
discarding the supernatant.  
Pellets were resuspended in FACS buffer and transferred to a round bottom 
plate (Corning) according to number of control wells and experimental wells: 
- Control wells: unstained controls for each tissue used, FMOs (fluorescence 
minus one: all antibodies used in the panel excluding one) and single stain 
controls for which beads are normally used (except LTL which requires cells 
for single stains).  
- Experimental wells: full antibody panel on each experimental kidney.  
Cells were pelleted in the in the plate at 1500xg for 3 minutes at 4oC. 
Subsequently, the supernatant was flicked off and the pellet disturbed by 
vortexing. Cells were then blocked for 20 minutes at 4oC using 25uL fc block 
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per well (BD Biosciences – purified rat anti-mouse CD16/CD32) diluted 1:25. 
Antibodies were made up 2x desired concentration and added directly to cells 
in block and mixed by vortexing (Table 2.2). Cells were incubated with pre-
conjugated antibodies for 30 minutes at 4oC protected from light. After 
incubation, 120µL FACS buffer was added to the cells which were pelleted at 
1500xg for 3 minutes at 4oC. The supernatant was flicked off and cells were 
vortexed to disturb the pellet. 200µL FACS buffer was added to each well and 
cells were washed by pipetting. This was repeated. Finally cells were 
resuspended in 150µL FACS buffer and transferred to FACS tubes before flow 
cytometry or FACS. 
Flow cytometry was carried out using the 5L LSRFortessa cell analyser (BD 


















102427 Biolegend 1:200 
Endothelial 
cells 






F4/80 PE Cy7 
25480182 
 
eBioscience 1:200 macrophages 
LTL FITC FL1321 Vector 1:400 Tubular cells 
Table 2.2: Antibodies used for fluorescence activated cell sorting of kidney cell suspension to 
fibroblasts, endothelial cells, myeloid cells; macrophages and tubular epithelial cells. 
2.2.3 Immunofluorescent staining of tissue 
Immunofluorescent staining was carried on tissue fixed in BD PharmigenTM zinc 
fixative (BD Biosciences). Fixed tissue was kept in fixative for 24 hours before 
transferring to 70% ethanol before paraffin embedding. Tissues were sectioned 
at 3μm using a microtome, transferred to slides and baked at 60oC overnight.  
Slides were de-waxed using xylene and rehydrated along an ethanol gradient. 
Antigen retrieval was achieved by boiling slides for 2 minutes in a microwave 
on full power followed by 8 minutes on 50% power in a 1:1 ratio of citrate buffer: 
tri-sodium citrate.  
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All incubations were carried out in a humidified chamber. Slides were washed 
3 times in PBS-T and subsequently blocked in 20% goat serum (Vector 
Laboratories, UK) in PBS-T for 1 hour at room temperature. After washing three 
times in PBS-T slides were incubated overnight at 4oC with primary antibody 
diluted 1:200 in block (see Table 2.4 for antibodies used).  
The next day, slides were washed in PBS-T three times and incubated with 
secondary antibody diluted in block for 1 hour at room temperature. Slides were 
mounted with coverslips using ProLong Gold Antifade Mountant with DAPI 
(Thermo Fisher Scientific, Paisley, UK). Images were taken using the Zeiss 
AxioScope or Andor Spinning Disk microscopes.     
2.3 Microarray 
This microarray was carried out as described by Denby et al. (94). Data were 
deposited in the National Center for Biotechnology Information Gene 
Expression Omnibus database (accession #GSE48194) available online at 
https://www.ncbi.nlm.nih.gov/geo/. 
Total RNA was extracted using miRNeasy kit (Qiagen) from kidneys of animals 
treated with control anti-miR (n=4) or anti–miR-214 (n=4); in vitro transcription 
was performed using the Ambion Illumina TotalPrep RNA Amplification Kit (Life 
Technologies). The microarray was performed using the Illumina MouseWG-6 
v2.0 Expression BeadChip Kit (Illumina, Braintree, UK) and data were 
generated using GenomeStudio (Illumina) (n=4 per group, 1 sample per 
animal). To assess the statistical significance of pairwise intergroup 
differences, RP39 was initially used. RP has been specifically developed for 
the analysis of microarray experiments and has been shown to perform very 
well with small sample sizes like that used in this study (n=4 per group). The 
significance cut-off was a FDR adjusted P value of <0.05 
2.4 RNA-sequencing 
RNA-sequencing (RNA-seq) was carried out on kidney tissue from mice 
subjected to sham, UUO and rUUO models using three different approaches; 
mRNA and small RNA sequencing of whole kidney cortex, mRNA sequencing 
of kidney cell sorted sub-populations and finally single cell RNA sequencing. 
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2.4.1  RNA-seq of kidney cortex 
RNA was extracted from the renal cortex of mice subjected to sham, 7 day 
UUO or rUUO surgery (1 week, 2 week or 4 week post reversal). Samples (n=4 
in each group) were selected for RNA-seq based on high KIM-1 expression 
levels in UUO kidneys and low KIM-1 expression in rUUO kidneys. RNA 
samples were sent to Genewiz for sequencing. Small RNA libraries and mRNA 
libraries were prepared by Genewiz and underwent RNA-sequencing using the 
Illumina HISeq 2500 platform. Raw reads were then trimmed to remove adaptor 
contamination and low quality reads using trimGalore (version 0.4.1). Small 
RNA and mRNA reads were then aligned to the mouse genome (GRCm38) 
before differential expression analysis. A platform was developed for analysis 
of log2fold change values and false discovery rates between groups. Kegg 
pathway data were linked to this dataset in order to visualise patterns in 
signaling pathways in each experimental group.  
2.4.2 RNA-seq of renal cell sub-populations  
Kidney cell sub-populations were sorted using FACS with the methodology 
described in Section 2.2.2. Tubular cells, endothelial cells, macrophages and 
fibroblasts were sorted and maintained in RLT buffer. RNA was then extracted 
from each population from each experimental group: sham, 7 day UUO and 4 
week rUUO (Table 2.3). The RNA concentration and RNA integrity number 
were calculated using the Bioanalyzer (Agilent). RNA samples were sent to 
Genewiz for sequencing. mRNA libraries were prepared and underwent RNA 
sequencing using the Illumina 2500 platform. Polyadenylated mRNA reads 
were then aligned to the mouse genome (GRCm38) and the fragments per 
Kilobase of million mapped reads (FPKM) was calculated for each cell sub-
















Sham  N=4 N=4 N=4 N=4 
UUO (7 days) N=4 N=4 N=4 N=4 
rUUO (4 
weeks) 
N=3 N=4 N=4 N=4 
Table 2.3: Renal cell sub-population numbers 
2.4.3 Single cell RNA-seq  
Single cell suspensions were prepared as in Section 2.2.2 from sham, 2 day 
UUO, 7 day UUO and 2 week-reversed UUO murine kidneys. Cell suspensions 
were run through the BD FACS Aria 11 (BD Biosystems). Single cell libraries 
from whole kidney digests of each group were prepared using a high-
throughput droplet-based library preparation workflow (10x). Sequencing was 
performed by Genewiz on a NextSeq 550 High Output Kit v2 (Illumina) for 150 
cycles at 400M PE reads comprising of 2x75bp and 8bp index reads. Alignment 
was performed by splicing aware aligner STAR 2.5.1b within the cellranger 
2.1.0 wrapper before downstream analysis in the R environment. R analysis 
was carried out by Dr Eoin O’Sullivan and Dr Katie Connor.  
2.5 In vitro experiments 
2.5.1 Cell Culture 
Human Renal proximal tubular epithelial cells (RPTEC/TERT1) were used 
throughout in vitro experiments (ATCC® CRL-4031™ LGC Limited, UK). Cells were 
maintained in DMEM: F-12 (1:1) Medium (2.5 mM L-glutamine, 15 mM HEPES, 
0.5 mM sodium pyruvate, and 1200 mg/L sodium bicarbonate). To this basal 
medium the hTERT Immortalized RPTEC Growth Kit was added (25 ng/mL 
Hydrocortisone, 3.5 µg/mL Ascorbic Acid, 8.65 ng/mL Sodium selenite, 5.0 
µg/mL Transferrin, 5.0 µg/mL insulin, 5 pM Triiodo-L-thyronine, 25 ng/mL 
Prostaglandin E1, 10 ng/mL rhEGF, 1.2 mg/mL Sodium Bicarbonate (ATCC® 
ACS-4007™LGC Limited, UK).  
For splitting cells, media was aspirated and 3mL trypsin added to each T75 
flask. Plates were then incubated at 37oC for 5 minutes until cells had visibly 
detached from the base of the flask. The flask was then washed vigorously with 
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media and the cell suspension was added to a 50mL falcon before spinning at 
1000xg for 5 minutes. The supernatant was aspirated and the cell pellet was 
resuspended in 3 mL media and cells were counted using a haemocytometer. 
Cells were plated according to the density desired.   
2.5.2 Immunocytochemistry 
Cells were seeded onto coverslips within a 12 well plate and grown in complete 
media until cells were 100% confluent. Cells were fixed using 4% 
paraformaldehyde for 30 minutes and washed three times in PBS. Cells were 
permeabilised for 20 minutes using 0.01% PBS-Tween. Cells were blocked in 
20% goat serum (Vector Laboratories, UK) for 1 hour at room temperature and 
then washed three times in PBS. Coverslips were subsequently transferred into 
individual humidified chambers and incubated overnight with primary 
antibodies overnight at 4oC.   
The next day, cells were washed in PBS three times and 100µL secondary 
antibody (1:500) was added to cells and incubated for 1 hour. After washing 
three times in PBS, coverslips were mounted on to slides with ProLong Gold + 
DAPI (Thermo Fisher Scientific, UK). Cells were imaged using the Andor 
Spinning Disk at 60x and x40, x60 or x100 magnification. Image analysis was 
carried out using ImageJ.  
2.5.3 Cytokine treatment of RPTECs 
RPTECs were treated once 80% confluent in 6 or 12 well plates. Prior to 
cytokine treatment, cells were maintained in serum deplete media for 48 hours 
to ensure all cells were in cell cycle arrest but still viable. Recombinant human 
TGF-β (R&D systems, UK) or recombinant human TNF-α (R&D Systems, UK) 
made up in 0.01% serum medium was added to 3 wells of each plate every 24 
hours in fresh media. Direct comparisons were made to cells kept in serum 
deplete media. Images were taken daily to observe any morphological 
changes. After several different time-points, cells were frozen at -80oC for RNA 
or protein analysis.  
2.5.4 Exposure of RPTECs to hypoxia 
RPTECs were seeded and grown until fully confluent in 12 well plates. Plates 
were exposed to hypoxic condition (1% O2) for 24 hours. Cells incubated in 
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normoxic conditions (20% O2) were used as controls. Hypoxia was induced in 
14500 Coy cabinet with an incubator at 37oC and water for humidification, with 
a gas mixture of 1% O2, 5% CO2 and 94% N2 (Coy Laboratory Products).  
2.5.5  Oxygen consumption rate and extra-cellular acidification rate 
RPTEC/TERT were seeded onto a Seahorse XFe 24 well microplate (Agilent, 
UK) ensuring they were confluent on the day measurements were taken. If 
seeded the night before, 100,000 cells were seeded into each well. On the day 
of analysis, cells were washed 3 times in Seahorse media and incubated in a 
CO2 free chamber for 1 hour. Oligomycin (2μM), FCCP (2.5μM) and 
antimycin/rotenone (1μM) were loaded into Seahorse injection ports.  
The Seahorse XFe analyser (Agilent, UK) was used for both oxygen 
consumption rate and extra-cellular acidification rate simultaneously. After 
optimisation, measurement cycles for the run for oligomycin and 
antimycin/rotenone were set to 3 minute mix, 2 minute wait, and 3 minute 
measure. Measurement cycles for FCCP were 4 minute mix, 2 minute wait and 
2 minute mix. Prior to any drug administration 3 ‘basal’ measurements were 
taken, oligomycin was then added followed by 3 measurement cycles. FCCP 
was then added followed by another 3 measurement cycles. Finally, a mixture 
of antimycin and rotenone were added followed by 3 measurement cycles. 
Measurements taken by the Seahorse analyser were normalized to protein 
content as measured by SRB assay. 
2.5.6 Sulforhodamine B Assay  
Media was removed from cells in Seahorse plate immediately after measures 
were taken and washed in PBS. Cells were fixed using 25μL cold 50% 
Trichloroacetic acid for 1 hour at 4oC. The plate was washed gently in running 
tap water 10 times, ensuring the cell layer was not disturbed. After washing the 
plate was allowed to air dry overnight in a covered container protected from 
dust. Subsequently 50μL 0.04% (wt/vol) SRB (Sulforhodamine B sodium salt) 
(Sigma-Aldrich, UK) solution was added to each well. The plate was left at RT 
for 1 hour and then washed with 200μL 1% (vol/vol) acetic acid to removed 
unbound dye. Once the washes appeared clear, the plate was allowed to air 
dry. Next, 100μL 10mM Tris(base) solution was added to each well and mixed 
by pipetting. 50μL solution was transferred to a flat bottom 96-well plate 
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appropriate for absorbance measurement. Absorbance was measured at 510 
nm using a microplate reader.  
2.5.7 Knock-down of ASS1 in RPTECs      
ASS1 was knocked down in RPTECs using Stealth siRNA against ASS1 
(Stealth HSS181354, (5’-AGC AGC UGA GCU CAA ACC GGA CCU-3’)) and 
compared to Stealth siRNA Negative Control lo GC (Scramble) (#12935) (both 
from Thermo Fisher Scientific, UK). (95) Cells were seeded into 6 or 12 well 
plates and were transfected when 80% confluent. siRNA against ASS1 and 
Scramble siRNA were transfected for various time points using RNAiMAX 
transfection reagent (Thermo Fisher Scientific, Paisley, UK) at 20nM according 
to manufacturer’s instructions. 
2.5.8 Western Blot 
Prior to immunoblotting, protein was extracted from cells or tissues as follows: 
Cells: RIPA buffer with cOmplete protease inhibitor cocktail tablets (Roche, UK) 
and phosphatase inhibitors cocktail 3 (Sigma-Aldrich, UK) was added to 
RPTECs (200 µL per well of a 6 well plate) and incubated for 1 hour, shaking, 
on ice. Once thoroughly lysed, cells were centrifuged at 10000g for 10 minutes 
to remove cell debris and the supernatant retained for protein quantification.  
Tissues: Snap frozen kidney tissue was homogenised in 500 µL RIPA and 
protease and phosphatase inhibitors with stainless steel balls using the 
TissueLyser II (Qiagen, UK). Samples were then incubated on ice, shaking for 
1 hour prior to spinning at 10 000g for 15 minutes. The supernatant was 
retained for protein quantification.  
Protein was quantified using the Pierce BCA Assay kit according to 
manufacturer’s instructions (Thermo Fisher Scientific, UK). The protein 
concentration was normalized across samples by diluting with RIPA buffer.  
Protein was prepared under reducing and denaturing conditions by boiling in 
laemelli buffer (Sigma) for 20 minutes in a 1:1 ratio, protein: buffer. 10 µg 
protein was added to each well of a 10% Bis-Tris pre-cast gel. One well was 
used for protein ladder (Amersham rainbow ladder, Thermo Fisher Scientific, 
UK). Electrophoresis was run at 150V for 40 minutes using the Bolt system 
(Thermo Fisher Scientific, UK). Transfer of protein to nitrocellulose membranes 
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was carried out in transfer buffer made up in distilled water (Table 2.4) for 1 
hour. Immediately after transfer, membranes could be stained for total protein 
using the Licor total protein stain kit according to manufacturer’s instructions. 
Total protein levels were assessed using the Licor Odyssey clx system using 
the 700 channel (Licor biosciences, UK). Subsequently membranes were 
blocked in 10% BSA for 1 hour at room temperature then incubated overnight 
with primary antibody (Table 2.5) at 4oC. 
Transfer buffer component Dilution  
Glycine 14.4g/L 
Tris(base) 6.06g/L 
Methanol 20% (vol/vol) 
Table 2.4: Reagents in transfer buffer for western blot. 
After washing 3 times for 10 minutes in TBS-triton the membrane was 
incubated for 1 hour at room temperature with Licor secondary antibody diluted 
in a 1% BSA solution. After two washes in TBS-T and a final wash in TBS the 
membrane was visualised using the Licor Odyssey clx. Signal intensity of the 
target protein was quantified and normalized to the total protein or loading 
control housekeeper using Image Studio software.    
2.5.9 RNA Extractions 
RNA was extracted from tissues and cells using the microRNeasy Kit according 
to manufacturer’s instructions (Qiagen, UK).  
2.5.10 Reverse Transcription of RNA 
The concentration of total RNA was assessed using the Nanodrop1000 
spectrophotometer and subsequently samples were diluted to the same 
concentration (200ng/μL if possible).  cDNA was generated using the 
Multiscribe reverse transcription kit (Applied Biosystems, Life Technologies, 
UK). Where possible 1μg was added to 2 μL 10x RT buffer, 2.2 μL MgCl2, 1 μL 
random hexamers, 0.4 μL RNase inhibitor and 0.5 μL Multiscribe reverse 
transcriptase and the total reaction was made up to 20 μL with RNase free H2O 
in a 96-well plate. Reactions were incubated on a Veriti thermal cycler 
(AppliedBiosystems, Life Technologies, UK) at the following thermal cycling 
conditions: 15 minutes at 42oC, 3 minutes at 95oC and forever at 4oC. Following 
reverse transcription, cDNA was stored at -20oC.  
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2.5.11 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
cDNA and appropriate Taqman probes were defrosted on ice. A mastermix 
consisting of 5 μL TaqMan gene expression master mix, 0.5 μL TaqMan® gene 
expression probe and 3.2 μL RNase free water was made up according to the 
number of reactions being carried out per gene being analysed. A list of the 
TaqMan® (AppliedBiosystems, UK) probes used can be seen below (Table 
2.6). 8.7 μL master mix was added to each well of a 385 well plate before 1.5 
μL template cDNA was added to make a final volume of 10 μL. The plate was 
then centrifuged at 1500xg for 2 minutes to ensure mixing of reagents. The 
plate was then placed in QuantStudio Real Time PCR System 
(AppliedBiosystems, UK) for amplification. Cycle threshold (Ct) values for 
genes of interest were normalized to housekeeper Ct value. Relative 
expression of a gene was calculated from the ΔΔCt: change in expression in 
an experimental group normalized to a housekeeper gene relative to a control.  
2.5.12 Housekeeper Selection  
For each qRT-PCR experiment, a small panel (>2) of housekeepers were run 
including Ppia, Hprt, Gapdh and 18S. The standard deviation across all 
samples was assessed for each housekeeper and the gene with the smallest 
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2.7 Taqman Probes 
Gene Mouse Human 
Acaa2 Mm00624282_m1   
Acta2 Mm01546133_m1  
Asl  Mm01197741_m1 Hs00902699_m1 
Ass1 Mm00711256_m1 Hs01597989_g1 
Ccl2  Hs00234140_m1 
Cdkn1a  Hs00355782_m1 
Cdkn2a  Hs00923894_m1 
Cldn2  Hs00252666_s1 
Col1a1 Mm00801666_g1 Hs00164004_m1 
Col3a1 Mm00802300_m1  
Col4a1 Mm01210125_m1 Hs00266237_m1 
Cubn Mm01325077_m1  
Gatm Mm00491879_m1 Hs00933793_m1 
Gcdh Mm00433541_m1  Hs00240811_m1  
Havcr1  Mm00506686_m1 Hs00930379_g1 
Icam1  Hs00164932_m1 
Ido2 Mm00524210_m1 Hs01589373_m1  
MKI67  Hs04260396_g1 
Mmp14 Mm00485054_m1  
Mmp2 Mm00439498_m1 Hs01548727_m1 
Mmp9 Mm00442991_m1 Hs00957562_m1 
Ocln  Hs05465837_g1 
Tgfbr1  Hs00610320_m1 
Timp1 Mm01341361_m1  
Tnf Mm00443258_m1 Hs00174128_m1 
Table 2.6: Taqman probes used with mouse and human probe numbers. 
 
2.8 Statistical Analysis 
Parametric testing was carried out on in vivo experiments that were adequately 
powered although normality testing was no carried out. For UUO, STNx and 
IRI the “n” for each group was ascertained from power calculations. For 
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comparison between two groups an unpaired Student’s t test was adopted. For 
comparison of three or more groups a 1-way analysis of variance (ANOVA) 
was carried with multiple comparison post-hoc tests. Post-hoc tests included 
Tukey’s test for comparisons between all groups or Dunnett’s test for 
comparison of all test groups with the control. For underpowered in vivo 
experiments statistical analysis was not carried out. For in vitro work, 
experiments were carried out three times in triplicate to give an n=3. Non-
parametric statistical tests were carried out on in vitro data as normal 
distribution could not be determined. In vitro experiments with less that n=3 
were not statistically analysed and instead trends were described. Statistical 
analysis was carried out using Graphpad-Prism 8. For statistical analysis of 
RNA-seq and single cell RNA-seq, statistical analysis was carried out in R by 








Chapter: 3 Ass1 expression in murine models of 
renal fibrosis 
3.1 Introduction 
3.1.1 Mouse models of renal disease 
Several in vivo models are used routinely in renal fibrosis research including 
the unilateral ureteric obstruction model (UUO) and the reversible UUO (rUUO) 
model, the subtotal nephrectomy model (STNx) and the ischaemia-reperfusion 
injury model (IRI). All three models lead to the development of tubulointerstitial 
fibrosis, the final common pathway of all chronic kidney diseases. Each model 
allows investigation of the mechanisms involved in renal disease with different 
aetiologies. Each model offers advantages and disadvantages. 
3.1.2 Unilateral ureteric obstruction model (UUO)  
The UUO model of renal fibrosis is a commonly used model which induces 
rapid onset of fibrosis within 1 week. It is performed by ligating a single ureter 
of a single kidney. This leads to build up of urine within the kidney, increased 
intratubular hydrostatic pressure and subsequent tubular injury (96). The initial 
tubular damage is followed by rapid tubulointerstitial fibrosis with 
accompanying infiltration of immune cells and inflammatory response (97). 
Renal obstruction ultimately leads to destruction of the architecture of tubules 
due to mechanical stretch. Histologically, tubules appear severely dilated and 
atrophic. Molecularly, tubular epithelial cells are known to undergo 
programmed cell death; be it either apoptosis or necrosis. Initial tubular 
damage is exacerbated by severe inflammation which is caused by substantial 
infiltration of immune cells, predominantly macrophages but also T cells and 
neutrophils (97-99). By seven days post-injury, fibrosis has ensued which is 
characterised by infiltration of myofibroblasts and accumulation of extra-cellular 
matrix within the tubular interstitium (100).  
However, in this model, glomeruli are unaffected and they retain their filtering 
capacity, therefore, the UUO cannot be used to assess glomerular disease or 
renal function. This procedure has several advantages including its short time 
frame in which severe fibrosis ensues. Additionally it has low fatality and the 
surgical procedure can be performed quickly which cuts down time under 
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anaesthesia which is better for animal welfare. A disadvantage of UUO is that 
the procedure is unilateral therefore, it does not induce any accompanying 
cardiovascular effects seen in patients with CKD. Furthermore, as one kidney 
is fully functional, clinical biomarkers of renal disease cannot be assessed in 
urine or plasma. 
3.1.3 Reversible UUO 
An extension of this protocol is the reversible UUO whereby the cut ureter is 
re-implanted into the bladder allowing resolution of fibrosis within the kidney 
over 4 weeks (101). The kidney regains normal morphology and, histologically, 
fibrosis is resolved. This model allows elucidation of the mechanisms involved 
in the reversal and resolution of renal fibrosis.  
3.1.4 The Subtotal Nephrectomy model of progressive renal fibrosis (STNx) 
The Denby lab have refined the STNx protocol to a one-step model of 
progressive hypertensive CKD in which one whole kidney and 2/3 of the other 
is removed by flank incisions (93). This procedure models renal insufficiency 
progressively and provides a more physiologically accurate model to represent 
chronic fibrosis compared to UUO. Over time (12 weeks) mice develop 
extensive tubulointerstitial fibrosis and glomerulosclerosis with concurrent 
hypertension, albuminuria, uraemia, left ventricular hypertrophy and cardiac 
fibrosis. These pathological events closely mimic what is observed in patients 
with CKD. This procedure allows assessment of the multi-organ effects 
observed in human CKD and provides several outputs for phenotypic 
assessment of renal disease. Blood and urine analysis is possible and 
therefore many measures that are commonly used in the clinic can be adopted 
with this model.  
3.1.5 Ischaemia-Reperfusion Injury (IRI) 
The unilateral ischaemia-reperfusion injury (IRI) model represents an acute 
kidney injury (AKI). AKI is highly clinically relevant as patients diagnosed with 
AKI are more likely to develop CKD later in life (44). The renal pedicle of one 
kidney is clamped and renal ischaemia can be induced for various durations 
depending on the extent of fibrosis desired (102). The progression of initial 
ischaemic insult to fibrosis has been thoroughly investigated. IRI results in 
hypoxia, decreased renal mass as well as initial influx of inflammatory cells. 
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This inflammatory phase is followed by the progressive development of renal 
damage and fibrosis. Histologically, tubules appear atrophic with the 
appearance of intratubular casts. After the inflammatory phase is the fibrotic 
phase, characterised by excessive deposition of extracellular matrix in the 
tubular interstitium. The exact mechanisms whereby acute kidney injury 
transitions in chronic injury are still to be fully elucidated. The murine unilateral 
IRI provides a clinically relevant model which can be used to investigate the 
mechanisms involved in fibrosis  
3.1.6 Metabolic dysfunction in preclinical models of renal disease 
Pathological metabolic changes occur during the progression of renal fibrosis 
and this has become a new focus for many in the field of renal research. As 
outlined in detail earlier (Section 1.1.7), metabolic dysfunction has been 
identified as a common pro-fibrotic mechanism in human disease as well as 
preclinical models. From intracellular mitochondrial dysfunction, to increased 
deposition of lipid in the kidneys, to systemic metabolic syndrome; metabolic 
dysfunction affects renal physiology and pathology at many levels. 
Investigating how metabolism is altered in multiple pre-clinical models will 
provide insight into common dysfunctional metabolic pathways in renal fibrosis 
models with different aetiologies.  
3.1.7 MicroRNAs and renal fibrosis 
MicroRNAs are small non-coding RNAs approximately 16-22 nucleotides long, 
which are important mediators of post-transcriptional regulation in nearly all 
physiological and pathological processes (103). MicroRNAs function by 
repressing mRNA target translation by blocking protein translation or direct 
mRNA degradation. miRNAs have the capacity to target hundreds of mRNAs 
which has gained attraction from a therapeutic stand point as manipulating one 
miRNA could exert multiple downstream effects in many pathways. Work by 
Denby and colleagues elucidated a novel driver of renal fibrosis which works 
independently of classical fibrotic cytokines such as TGF-β. MicroRNA-214 has 
been shown in vitro and in vivo to drive fibrosis. Furthermore, miR-214 
knockout mice are resistant to fibrosis and protected in UUO. Moreover, 
treatment with exogenous antagonist of miR-214, anti-miR-214, prevented 
renal fibrosis in mice subjected to UUO (94). miR-214 has been shown to 
contribute to the pathogenesis of fibrosis by targeting hundreds of target 
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transcripts revealed by microarray. However, the precise mechanism whereby 
miR-214 elicits its deleterious effects has yet to be revealed. This work will use 
datasets generated by Denby and colleagues to ascertain new pathways that 
are targeted by miR-214 which may provide new insight into mechanisms 
driving fibrosis. 
3.2 Hypothesis and Aims 
The hypothesis of this chapter was as follows: metabolic dysfunction is a 
fundamental pathological mechanism ongoing in murine models of renal 
fibrosis.  
The aims of this chapter sought to test this hypothesis using an unbiased 
approach using a number of large transcriptomics datasets to generated novel 
genes of interest that have a potential role in renal fibrosis: 
1. To determine which metabolic pathways are upregulated in kidneys 
protected from fibrosis (UUO treated with anti-miR 214) vs kidneys unprotected 
from fibrosis (UUO treated with control anti-miR).  
2. To determine if the same metabolic pathways elucidated in Aim 1 are 
downregulated in the UUO model of fibrosis vs sham and upregulated in the 
rUUO model vs UUO.  
3. To compile a list of candidate pro-fibrotic genes of interest and cross-
compare these genes with a publicly available human CKD transcriptomics 
dataset. 
4. To investigate the expression patterns of these genes of interest in two 
additional models of renal fibrosis, the subtotal nephrectomy and ischaemia 






3.3.1 Investigation of pathways involved in kidneys protected from fibrosis 
Previous studies from Denby et al. revealed that antagonism of miR-214 
prevented the development of fibrosis in mouse models of renal disease. miR-
214 antagonism de-represses miR-214 mRNA targets and therefore genes 
which are upregulated are likely targets of miR-214 binding. We sought to 
investigate pathways that were altered in kidneys from mice protected from 
fibrosis by the antagomiR anti-miR-214. A microarray was carried out on UUO 
kidneys from mice that had either been treated with anti-miR-214 (protected 
from fibrosis) or a control anti-miR (not protected from fibrosis) and differential 
expression was assessed between these groups (94). 
Genes which were downregulated included extracellular matrix genes such as 
Col3a1, Col4a1 and Mmp2 and Mmp14. This confirmed that anti-miR-214 
downregulated fibrotic pathways and in doing so protected kidneys from 
fibrosis. In order to reveal which genes/pathways were direct and indirect 
targets of miR-214, we investigated genes that were upregulated in the anti-
miR-214 group.  
In order to investigate the pathways that were upregulated in kidneys protected 
from fibrosis, gene enrichment analysis was carried out using the functional 
database KEGG (Kyoto Encyclopedia of Genes and Genomes) accessed from 
http://webgestalt.org/. A list of genes which demonstrated upregulation after 
anti-miR-214 treatment with their associated fold change values were uploaded 
via this platform which revealed pathways linked to these genes. This revealed 
several metabolic pathways enriched in this gene list which  included pathways 
such as “mannose type O-glycan biosynthesis”, “fructose and mannose 
metabolism” and “glycine, serine and threonine metabolism” (Figure 3.1A).  
Expression of genes involved in these specific pathways were visualized on a 
volcano plot of significantly up- and downregulated genes from the microarray 
generated using R studio. Lists of genes involved in the pathways generated 
from Figure 3.1A were downloaded and compared to up- and down-regulated 
genes generated from the microarray. Genes that are involved in metabolic 
pathways such as glycine metabolism were shown to be highly upregulated in 




Figure 3.1: Metabolic pathways are upregulated in kidneys protected from fibrosis. A microarray 
was performed on kidneys from mice treated with either anti-miR-214 (protective against fibrosis) 
or control anti-miR. (A) Kegg Pathway analysis was performed on genes that were upregulated 
in the anti-miR-214 group. Several metabolic pathways were upregulated in anti-miR-214 
protected kidneys. (B) Volcano plots shows significant genes that are upregulated and 
downregulated in anti-miR-214 treated kidneys compared to control treated kidneys subjected to 
UUO. Coloured dots represent genes involved in arginine, fructose, glycine, mannose and ppar 
pathways. 
 
As many metabolic pathways were upregulated in a model protected from 
fibrosis, it was important to determine how metabolic pathways are affected 
during the development of fibrosis and during reversal of fibrosis in a murine 
model. In this way, I sought to elucidate novel metabolic genes of interest which 
might provide further insight into the mechanisms driving and repairing fibrosis. 
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Metabolic pathways which were revealed from genes upregulated in the 
microarray data were investigated in the UUO and rUUO models.  
3.3.2 Selection of genes of interest  
In order to dissect metabolic genes that undergo changes in expression during 
progression and reversal of fibrosis, RNA-seq was performed on cortical kidney 
tissue from mice subjected to sham surgery, UUO (unilateral ureteric 
obstruction) or rUUO (reversed UUO). Groups assessed were sham, UUO, 1 
week post rUUO, 2 weeks post rUUO and 4 weeks post rUUO. RNA-seq 
analysis was carried out by Jonathan Manning who developed a platform for 
interactive analysis of the data including KEGG pathway analysis.  
RNA-seq volcano plots demonstrated significantly up- and down- regulated 
genes in sham vs UUO. We assessed genes that demonstrated an increase or 
decrease in expression by >2 fold and reached a significant corrected p value 
or “q” value of <0.01. We could confirm that UUO induced significant 
upregulation of injury and fibrosis associated genes such as Kim1 (Havcr1) and 
Col1a1 respectively.  We also observed significant downregulation of Egf, a 
marker of tubular remodelling, these genes served as internal positive controls 
as evidence that UUO kidneys were fibrotic (Figure 3.2A). 
Additionally, a number of metabolic pathways, including those revealed using 
the microarray data were investigated in this dataset. Two particular pathways; 
fatty acid metabolism and arginine/proline metabolism were found to be 
markedly disrupted after UUO, indicating their involvement in the development 
of fibrosis (Figure 3.2B,C).  
I adopted a robust triangulation methodology compiling multiple internal and 
external datasets to reveal metabolic genes which might have a role in the 
development of fibrosis. I sought to reveal genes that were downregulated in 
UUO compared to sham and upregulated in rUUO compared to UUO. Within 
metabolic pathways, genes of interest (GOI) were selected (Table 3.1) 
according to a number of criteria:  
1) Significantly downregulated in UUO with a fold change <-2 and upregulated 
in rUUO >2 
2) Upregulated in a UUO kidney protected from fibrosis (previous microarray 
data of kidney treated with anti-miR-214 compared to control (94)) 
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3) Presence of a single nucleotide polymorphism associated with renal disease 
assessed using a publicly available CKD GWAS search tool: 
https://www.ebi.ac.uk/gwas/efotraits/EFO_0003884. 
4) Downregulated in human CKD patient samples as reported by Kang et al 






Figure 3.2: Differential expression of genes in the unilateral ureteric obstruction model (UUO). 
RNA-seq was carried out on RNA extracted from kidneys from mice subjected to either sham or 
UUO surgery. Volcano plots demonstrates genes > 1 log2fold change increased or decreased 
in UUO compared to sham (x axis) with q value represented on the y axis. Coloured dots 
represent individual genes that are significantly differentially expressed. (A) Genes associated 
with renal fibrosis and tubular injury are depicted by arrows. (B) Volcano plot of sham versus 
UUO. Red dots represent genes involved in fatty acid metabolism pathways. (C) Volcano plot of 






Table 3.1: Genes of Interest dysregulated in renal fibrosis and repair. Gene ID, Name and 
function with fold change values in sham vs UUO and UUO vs 4wk rUUO (with corrected p 
value). Reported SNPs associated with renal disease from GWAS. Reported fold change from 
microarray in control patient biopsy versus CKD biopsy (64) and reported fold change in 
microarray in control murine kidney vs anti-miR-214 treated murine kidney (94). 
 
In order to validate findings from RNA-seq, cDNA was made from the same 
samples as the original experiment and qRT-PCR for Ass1, Gatm, Ehhadh, 
Ido2, Gcdh and Acaa2 was performed (Figure 3.3). Gene expression data 
revealed that all these candidates apart from Ehhadh demonstrated significant 
downregulation in sham vs UUO and significant upregulation in UUO vs rUUO 
after 4 weeks (One-way ANOVA with Tukey’s multiple comparison). Out of all 
the genes of interest, Ass1 demonstrated the highest expression level within 
the kidney and furthermore showed the largest negative fold change in UUO 




Figure 3.3: qPCR validation of RNAseq genes of interest. Relative mRNA levels of Ass1, Gatm, 
Ehhadh, Gcdh and Acaa2 in sham (n=6), UUO (n=6), UUO reversed after 1, 2 and 4 weeks; 
R1W (n=6), R2W (n=6) and R4W (n=6) respectively. Relative expression was calculated from 
ΔΔcT normalized to Hprt housekeeper and compared to sham. *, ** and *** represent p<0.05, 
0.01 and 0.001 respectively compared to sham by unpaired Student’s t test. 
3.3.3 Metabolic changes in the kidney are mediated by tubular cells 
RNA-seq data from kidneys provides a wealth of knowledge however, as the 
kidney is comprised of numerous cell types it is important to elucidate if 
particular cell types are driving these transcriptomic changes or if it is a global 
effect. To address this caveat, we adopted fluorescence activated cell sorting 
(FACS) to separate kidney cell sub-populations before RNA extraction and 
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RNA-sequencing. We sorted 4 subpopulations from whole kidney cell 
suspension including tubular cells (LTL+ cells), endothelial cells (CD31+ cells), 
resident macrophages (F480+ cells) and fibroblasts (PDGFRβ+ cells). 
Subpopulations were sorted from mouse kidneys subjected to either sham 
surgery, UUO or 4 week rUUO to assess which subpopulations contributed to 
gene expression changes seen from whole kidney bulk RNA-seq.  
Markers of each cell type were assessed by RNA-seq to ensure lack of 
contamination of one sub-population to another (Figure 3.4). Megalin (Lrp2) 
was used as a tubular marker, Pecam1 as an endothelial marker, Cd68 as a 
macrophage marker and Pdgfrb as a marker of fibroblasts. Expression of these 
markers was confined to their correct sub-population. Moreover these markers 
exhibited differential expression in sham, UUO and rUUO. Megalin exhibited a 
2.39 fold decrease in UUO compared to sham in tubular cells (P<0.001). 
Pecam1 showed a 1.3 fold increase in UUO compared to sham (P<0.05). Cd68 
exhibited a 1.45 fold decrease in expression in UUO compared to sham 
(P<0.05) and finally Pdgfrb exhibited a 1.81 fold decrease in UUO compared 




Figure 3.4: Kidney subpopulations express cell specific markers. Differential expression of Lrp2 
(A), Pecam1 (B), Cd68 (C) and Pdgfrβ (D) in sham, UUO 7 days and rUUO (2 weeks reversed) 
within kidney subpopulations; tubules, endothelial cells, macrophages and fibroblasts. Gene 
expression calculated from p-adjusted FPKM (Fragments per Kilobase of transcript per Million 
mapped reads) and analysed by 1 way ANOVA with Tukey’s multiple comparison. ** and *** 
represent p<0.01 and 0.001 respectively compared to sham. 
 
Next, it was determined which cell sub-population was responsible for the 
decreases and increases in expression in UUO and rUUO respectively in 
metabolism genes as seen in bulk cortical RNA-seq. We assessed expression 
levels of our genes of interest including Ass1, Gatm, Gcdh and Acaa2 (Figure 
3.5). Ass1 expression was detected predominantly in the tubular sub-
population and exhibited the same expression pattern as the kidney cortex 
RNA-seq with a decrease in UUO vs sham (-4.36 fold, p<0.001) and an 
increase in rUUO vs UUO (+2.54 fold, p<0.01). Gatm expression was seen in 
the macrophage sub-population but to a greater extent in the tubular 
population. Again, the previous expression pattern was replicated in the tubular 
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compartment with a decrease in UUO vs sham (-5.89 fold, p<0.001) and an 
increase in rUUO vs UUO (+2.99 fold, p<0.01). Gcdh demonstrated low level 
expression across endothelial, macrophage and fibroblast sub-populations and 
high levels of expression in the tubular population. Gcdh showed significantly 
decreased expression in UUO compared to sham (-2.38 fold, p<0.01) however, 
there was no significant increase in expression in the rUUO group compared 
to UUO. Finally Acaa2 was expressed across all sub-populations but only 
exhibited significantly differential expression in the tubular population with a 
decreased expression in UUO vs sham (-2.38 fold p<0.01). There was no 
significant upregulation of Acaa2 expression in the rUUO group vs UUO. The 
expression pattern of metabolism genes seen from kidney cortex RNA-seq of 
decreased expression in UUO compared to sham and increased expression in 
rUUO compared to UUO is replicated only within the tubular sub-population.  
 
Figure 3.5: Expression of genes of interest in kidney sub-populations in UUO and rUUO. 
Differential expression of Ass1 (A), Gatm (B), Gcdh (C) and Acaa2 (D) in sham, UUO 7 days and 
rUUO (4 weeks reversed) within kidney subpopulations; tubules, endothelial cells, macrophages 
and fibroblasts. Gene expression calculated as p-adjusted FPKM (Fragments per Kilobase of 
transcript per Million mapped reads) from RNA-seq data and analysed by 1 way ANOVA with 
Tukey’s multiple comparison. ** and *** represent p<0.01 and 0.001 respectively compared to 




3.3.4 Selection of Ass1 as primary gene of interest 
Ass1 was taken forward as our primary gene of interest as it is one of the most 
downregulated metabolic genes in UUO and one of the most highly upregulated 
in rUUO. This was demonstrated in both bulk kidney cortex and tubular 
subpopulation RNA-seq datasets. Furthermore, its expression is significantly 
decreased in patients with CKD vs healthy controls as seen in previous 
transcriptomics datasets (64,104). Ass1 was also significantly upregulated in 
kidneys protected from fibrosis by anti-miR-214 treatment and finally, it is 
confined to the tubular compartment of the kidney which enables further 
investigation in tubular epithelial cell models in subsequent in vitro 
experiments.  
3.3.5 Ass1 expression is depleted to a greater extent than tubular markers 
In order to measure proximal tubular number in UUO, the expression of two 
tubular markers Lrp2 (megalin) and Cubn (cubulin) were assessed from the 
FACS sorted tubular sub-population RNAseq dataset. Both Lrp2 and Cubn 
were significantly downregulated -2.39 and -2.10 fold respectively in tubules 
after UUO compared to sham. Ass1 expression was depleted to a greater 
extent with a -4.36 fold reduction in expression in UUO compared to sham. 
After rUUO neither Lrp2 nor Cubn showed significant elevation in expression 
while Ass1 demonstrated a significant 2.54 fold increase in expression after 





Figure 3.6: Expression of tubular markers kidney sub-populations in UUO and rUUO. Differential 
expression of Lrp2 (A) and Cubn (B) in sham, UUO 7 days and rUUO (4 weeks reversed) within 
kidney subpopulations; tubules, endothelial cells, macrophages and fibroblasts. Gene 
expression calculated as p-adjusted FPKM (Fragments Per Kilobase of transcript per Million 
mapped reads) from RNAseq data and analysed by 1 way ANOVA with Tukey’s multiple 
comparison. ** and *** represent p<0.01 and 0.001 respectively compared to sham.  
 








Ass1 -4.36 <0.001 +2.54 <0.01 
Lrp2  -2.39 <0.001 +1.43 ns 
Cubn -2.1 <0.001 +1.12 ns 
Table 3.2: Expression of tubular markers in renal subpopulations in UUO and rUUO. Fold 
change values of Ass1, Lrp2 and Cubn in Sham vs UUO and UUO vs 4 week rUUO with 
corresponding P values. 
 
3.3.6 Expression of Urea Cycle and Nitric Oxide Synthase Enzymes in 
subpopulations in the rUUO model 
ASS1 is an enzyme which plays its role within the urea cycle in the liver and 
also the citrulline-nitric oxide cycle in endothelial cells. We used RNA-seq data 
from kidney subpopulations in the UUO/rUUO models to ascertain expression 
profiles of these enzymes in the kidney.  
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Genes encoding the classical urea cycle including N-acetyl glutamate synthase 
(Nags), Carbamoyl phosphate synthase I (Cps1), Ass1, argininosuccinate 
lyase (Asl), Arginase I (Arg1) and finally ornithine transcarbamylase (Otc) were 
assessed in renal cell subpopulations. Nags, Cps1, Arg1 and Otc exhibited no 
expression within any population within the kidney. Ass1 and Asl were both 
expressed in the kidney. Ass1 was highly expressed in tubular cells. Asl 
expression was far less abundant than Ass1 within the tubular compartment. 
Asl expression was also observed in endothelial, macrophage and fibroblast 
populations. Furthermore Asl demonstrated a similar expression pattern to 
Ass1 in UUO and rUUO with a -2.8 fold downregulation in UUO compared to 
sham and a 2.22 fold upregulation in rUUO compared to UUO (Figure 3.7). 
 
Figure 3.7: Expression of urea cycle genes in kidney sub-populations in UUO and rUUO. 
Differential expression of Ass1 (A) and Asl (B) in sham, UUO 7 days and rUUO (4 weeks 
reversed) within kidney subpopulations; tubules, endothelial cells, macrophages and fibroblasts. 
Gene expression calculated as p-adjusted FPKM (Fragments per Kilobase of transcript per 
Million mapped reads) from RNA-seq data and analysed by 1 way ANOVA with Tukey’s multiple 
comparison. ** and *** represent p<0.01 and 0.001 respectively compared to sham and # 
represents p<0.01 compared to UUO.  
 
Arginine generated from ASS1 and ASL can be used in certain cell types for 
nitric oxide synthesis termed the citrulline-nitric oxide cycle. Genes encoding 
the three nitric oxide synthase enzymes Nos1, Nos2 and Nos3 were assessed 
in renal cell subpopulations in UUO/rUUO. All three enzymes demonstrated 
expression within the kidney however no expression was observed in the 
tubular subpopulation. Nos1 demonstrated limited expression in endothelial 
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cells and fibroblasts. Nos2 and Nos3 exhibited expression within the 
endothelial population only (Figure 3.8). Furthermore, there were no significant 
changes in expression of any nitric oxide synthase isoform in UUO or rUUO.   
 
 
Figure 3.8: Expression of nitric oxide synthase isoforms in kidney sub-populations in UUO and 
rUUO. Differential expression of Nos1 (A), Nos2 (B) and Nos3 (C) in sham, UUO 7 days and 
rUUO (4 weeks reversed) within kidney subpopulations; tubules, endothelial cells, macrophages 
and fibroblasts. Gene expression calculated as FPKM (Fragments Per Kilobase of transcript per 
Million mapped reads) from RNA-seq data and analysed by 1 way ANOVA with Tukey’s multiple 
comparison. ** and *** represent p<0.01 and 0.001 respectively compared to sham and # 
represents p<0.01 compared to UUO.  
 
3.3.7 Correlation between Ass1 and miR-214 in rUUO Model  
As Ass1 expression was found to be upregulated in anti-miR-214 treated 
kidneys, we sought to determine whether Ass1 and miR-214 had a negatively 
correlated relationship in kidneys from sham, UUO and rUUO interventions.  
Cortical RNA-Sequencing Data of mRNA and small RNAs was analysed to 
assess which predicted microRNAs target Ass1 and whether any of these 
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microRNAs are negatively correlated with Ass1 in the rUUO model. RNA-seq 
and correlation was carried out by Dr Katie Connor.  
Integrative miRNA-mRNA analysis was carried out as follows. Small RNA 
libraries and mRNA libraries were prepared by Genewiz and underwent RNA-
sequencing using the Illumina HISeq 2500 platform. Raw reads were then 
trimmed to remove adaptor contamination and low quality reads using 
trimGalore (version 0.4.1). Small RNA reads were then aligned to the mouse 
genome (GRCm38) and annotated to miRBase.  
In RStudio (R 3.6.1), lowly expressed reads were removed and normalized. 
Count tables for both gene and microRNAs were generated using DESeq2 and 
EdgeR respectively. MicroRNAs underwent differential expression analyses 
and the predicted gene targets of miRs with at least one significant comparison 
(Fold Change >1.5, False Discovery Rate <0.05; n=382) were identified using 
the R package multiMiR (Version 2.2.0). MultimiR acts as an interface for 
finding miR-mRNA interactions and searches the following databases: 
TargetScan, PicTar, PITA, MiRanda, miRDB, Diana-microT, EIMMo and 
MicroCosm.  
Eight of the investigated miRs were predicted to target Ass1, within this miR-















































































































To determine if the microRNA was likely to have a mechanistic effect on a 
predicted gene target, pairwise Pearson correlation coefficients were 
calculated for each predicted mRNA-miR interaction. Those with a correlation 
coefficient <-0.6 and FDR adjusted p value <0.05 were considered to be 
significantly negatively correlated. Using this approach, 28.1% (n=46642 out of 
n = 166260) of predicted mRNA-miR interaction pairs were considered to be 
significant within this study. Within this, the only miR significantly negatively 
correlated with Ass1 expression was miR-214-3p (R -0.896, FDR.Adj.Pval 






















































Figure 3.9: Correlation between miR-214 and Ass1 gene expression. RNA-seq analysis of small 
RNAs and mRNAs from cortical renal tissue in the UUO/rUUO model elucidated the only 
microRNA to be significantly correlated to Ass1 to be miR-214. (B) Coloured dots represent 
individual samples from sham (dark blue), UUO at 7 days (yellow), rUUO at 7 days (grey), rUUO 
at 14 days (red) and rUUO at 28 days (light blue). 
 
3.3.8 In-depth investigation of Ass1 in the rUUO model of renal fibrosis: 
single-cell RNA-seq 
The kidney is comprised of a myriad of cell types with resident cells and 
transient, infiltrating cells. The cellular milieu changes dramatically with the 
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onset of disease and the resolution of disease. It was important to assess 
exactly which cell types Ass1 is expressed in and how their expression profile 
changes according to disease state. Single cell RNA-seq allowed for the 
investigation of the transcriptome of each individual live cell within a sample. 
This enabled the investigation of Ass1 in specific cell types in different injury 
states. The expression profile of Asl (enzyme downstream of Ass1) was also 
assessed to ascertain whether these enzymes were always expressed in the 
same cell type.  
The rUUO model was adopted again to assess the expression patterns and 
abundance of Ass1 in live renal cells from a sham kidney, a fibrotic kidney and 
a kidney in which fibrosis has reversed. This experiment compared kidneys 
from mice subjected to sham, UUO (2 days), UUO (7 days) or 2 week reversed 
UUO surgeries. Feature plots enabled the investigation of how different renal 
cells form sub-clusters based on their gene expression signature. Clusters 
represent kidney cell population including proximal tubular cells (segments 1-
3), collecting ducts, endothelial cells and immune cells (Figure 3.10). Ass1 
expression was most abundant in the epithelial clusters of cells. Therefore 




Figure 3.10: Characterisation of Ass1 in the kidney using single cell RNA-seq. Single cell RNA-
seq analysis allowed clustering of different populations of renal cells according to their 
transcriptional profile (A). Ass1 demonstrated abundant expression in the epithelial clusters and 
low expression in some myeloid cell populations (B, C). Clusters in B are the same in cluster A 
PCT (proximal convoluted tubule), LoH/DCT (Loop of Henle/ Distal convoluted tubule), NK/T 
(natural killer/ T cell). 
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The expression pattern of Ass1 and Asl were investigated in epithelial cells of 
a sham mouse using tSNE plots (Figure 3.11). Epithelial cells were clustered 
according to their transcriptome signature. The sub-clusters can be described 
as  3 proximal tubular cell sub-clusters (blue, red and pink rings: PTa, PTb and 
PTc), the thick ascending limb (green ring: TAL), and finally distal tubules 
(orange ring: DT).  
Ass1 expression was very abundant within proximal tubular cells, particularly 
PTa, and expressed to a much lesser extent within PTb, PTc and distal tubules 
(Figure 3.11A). Asl, (Figure 3.11B) the neighbouring enzyme of Ass1, was 
expressed in fewer epithelial cells across the board and was far less abundant 
in the proximal tubular cells (PTa) compared to Ass1.  
 
Figure 3.11: Ass1 and Asl expression in epithelial cells. tSNE plots generated from single cell 
RNA-seq depict the log expression of Ass1 (A) and Asl (B) in epithelial cells from a sham mouse. 
Epithelial cells are categorised according to their transcript signatures in coloured rings: proximal 
tubules sub-clusters (blue, red and pink rings), the thick ascending limb (green ring), and distal 
tubules (orange ring).  
 
Pearson correlation analysis of epithelial cells from scRNA-seq was carried out 
to determine which cells co-expressed Ass1 and Asl and which cells were 
Ass1-positive but Asl-negative a vice versa. There was a poor correlation 
between Ass1 and Asl expression of 0.31. A proportion of epithelial cells co-
expressed Ass1 and Asl simultaneously. However, there were 2 other 
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populations of epithelial cells which expressed either Ass1 only or Asl only 
(Figure 3.12).  
 
Figure 3.12: Pearson correlation of Ass1 and Asl expression in epithelial cells derived from 
single cell RNA-seq. Individual epithelial cells (coloured spots) were plotted according to their 
expression of Asl and Ass1. Blue line represents trend line with R2 value of 0.31. Coloured rings 
depict 3 populations: Asl-positive (blue), Asl, Ass1-double positive (red) and Ass1-poisitive 
(green). 
 
Subsequently, the abundance of Ass1 and Asl expression was assessed in all 
experimental injury groups within epithelial cells and depicted using Violin Plots 
(Figure 3.13). In sham, epithelial Ass1 expression was highly abundant. 
Following UUO, Ass1 expression levels were significantly depleted as soon as 
2 days after surgery and further depleted 7 days after surgery. After 2 weeks 
reversal, the log fold expression of Ass1 were significantly upregulated 
compared to UUO day 7 (Wilcox Test). Epithelial Asl expression was far less 
abundant in sham than Ass1 but Asl still exhibited a significant decrease in 
expression in both UUO groups and a significant increase in the rUUO group 




Figure 3.13: Ass1 and Asl expression in epithelial cells from kidneys subjected to UUO/rUUO. 
Single cell RNA seq was used to determine the expression of Ass1 and Asl in renal epithelial 
cells from mice subjected to sham, UUO (2 days), UUO (7 days) or 2 week-reversed UUO.  
    
3.3.9 ASS1 protein expression in UUO/rUUO 
To determine if ASS1 protein reflects what is seen at the mRNA level, western 
blot analysis was carried out on kidney tissue lysates from sham, UUO (2 days), 
UUO (7 days) and rUUO and normalized to housekeeping protein GAPDH. 
Protein levels were measured using Licor and quantified using Image StudioTM 
(Figure 3.14).  ASS1 protein was highly expressed in renal tissue in sham 
kidneys. After 2 days of UUO there was no significant difference in ASS1 
expression compared to sham (p=0.3801, unpaired Student’s t test). However 
7 days post-UUO there was significant depletion in ASS1 protein levels 
(p<0.001). 2 weeks after reversal of UUO, ASS1 was elevated compared to 
UUO, however, this did not reach statistical significance (p=0.233, One-way 




Figure 3.14: Protein analysis of ASS1 in Unilateral ureteric obstruction (UUO) and reversal of 
obstruction (rUUO). Immunoblot and respective signal intensities of ASS1 protein levels 
normalized to GAPDH loading control in (A) sham and UUO after 2 days and (B) sham, UUO 
after 7 days and rUUO after 2 weeks (n=5 per group). Signal intensity of protein bands were 
determined using ImageStudio Lite software relative to loading control. *** represents p<0.001 
with one way ANOVA with Dunnett’s multiple comparison test. 
 
Finally, ASS1 expression was assessed in kidney slices by immunostaining. 
Sections of sham and UUO kidney tissue sections were stained for ASS1. 
ASS1 positive staining was abundant in the tubules of the sham kidney and 
was absent within the glomeruli. In UUO kidney sections, ASS1 staining was 
less abundant and some tubules demonstrated no ASS1 positive staining 




Figure 3.15: ASS1 immunostaining in sham and UUO kidney. Representative images of ASS1 





3.3.10 Investigation of Ass1 expression in translational models  
The UUO model of fibrosis allows investigation of renal fibrosis in just 7 days. 
This rapid onset of fibrosis is confined to the tubules due to ureteric obstruction 
and the glomeruli are unaffected by UUO. We sought to investigate our findings 
in two other models of renal fibrosis with distinct aetiologies; the subtotal 
nephrectomy model and the ischaemia reperfusion injury model. These models 
reflect human renal disease to a better extent and therefore provide more 
robust models which are more translational than UUO. 
3.3.11 Refined subtotal nephrectomy  
To provide evidence that Ass1 plays a role in the pathogenesis of CKD we 
conducted further experiments in a more clinically relevant model of CKD; the 
subtotal nephrectomy model (STNx). The STNx models progressive 
development of fibrosis over 10 weeks that reflects human CKD more 
accurately than the rapid onset model of fibrosis; UUO. This refined pre-clinical 
mouse model undergoes systemic changes as a result of renal fibrosis such as 
increased blood pressure, cardiac hypertrophy and increased urinary 
albumin/creatinine ratio (93).  
At sacrifice, the body mass and the mass of kidney, liver and heart was 
measured in each animal. There was no significant difference in body weight 
between sham and STNx at either time point (One way-ANOVA). Additionally, 
there was no significant difference in the organ mass of the kidney or liver in 
either 6 week or 10 week cohort between sham animals and STNx animals. 
However there was a significant increase in heart mass (normalized to body 
weight) in STNx animals compared to sham at both time points (p<0.01 and 





Figure 3.16: Body weight and heart weight in STNx vs sham. Body and heart mass was 
measured at sacrifice in shams and STNx animals at 6 and 10 weeks post-surgery. Heart weight 
was normalized to body mass. * and ** represent p<0.05 and 0.01 respectively compared to 
sham by unpaired Student’s t test. 
The gene expression levels of fibrosis markers were assessed in order to 
confirm the development of fibrosis in this model in the kidney at 6 weeks and 
10 weeks post-surgery (Figure 3.17). Different time points were investigated to 
reveal the differential expression of genes during the early phase of the fibrotic 
response (6 weeks post-surgery) and after fibrosis had established within the 
kidney and cardiovascular impairments had occurred (10 weeks post-surgery). 
We assessed a panel of fibrosis markers (Col1a1, Col3a1, Mmp2, Mmp9, 
Timp1, and Acta2) and found that there was significant elevation in expression 
of all these markers 10 weeks post STNx and most markers (Col1a1, Col3a1, 
Mmp9, Timp1 and Acta2) were significantly elevated 6 weeks post STNx 
(unpaired Student’s t test).  
Histological analysis of collagen deposition was assessed by picro-sirius red 
staining of kidney tissue slices Quantification of positive red staining using 
Image-Pro Plus revealed significantly elevated levels of total collagen after 6 
and 10 weeks post-STNx demonstrating the progressive nature of this model. 
(Figure 3.17B,C) Image analysis was carried out by James O’Sulliven). 
The subtotal nephrectomy model allows for the biochemical analysis of urine 
and serum which is not possible with other pre-clinical models such as UUO 
which have a remaining functional kidney. Albuminuria is a clinically relevant 
indicator of renal disease and was measured in STNx compared to sham. Urine 
was collected at baseline before surgery and 1 week before sacrifice in shams 
and STNx animals in both 6 week and 10 week cohorts and the extent of 
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albuminuria was measured. Urine albumin was undetectable in both baseline 
and sham groups and there were significant increases in urine albumin in both 
early phase (6 week) and late phase (10 week) STNx animals compared to 
baseline measurements (One way ANOVA with Dunnett’s multiple comparison) 
(Figure 3.16D). Plasma urea provides another clinical marker of renal disease. 
Plasma extracted from blood taken at sacrifice at both time points was 
assessed. Plasma urea was significantly elevated in both early and late phase 
STNx plasma compared to sham (One way ANOVA with Dunnett’s multiple 




Figure 3.17: The subtotal nephrectomy (STNx) model of progressive renal fibrosis reflects 
human disease. (A) Relative mRNA levels of genes related to fibrosis in sham (n=4), STNx 6wk 
(n=6) and STNx 10wk (n=6). Relative expression was calculated from ΔΔcT normalized to Hprt 
housekeeper and compared to sham. *, ** and *** represent p<0.05, 0.01 and 0.001 respectively 
compared to sham by unpaired Student’s t test. (B) Representative image of picrosirius red 
stained kidney tissue of sham and STNx at 10 weeks. (C) Corresponding quantification of 
picrosirius red staining of renal tissue from sham (n=7), 6wk STNx n=4) and 10wk STNx (n=8) 
mice. Quantification was carried out using Image-Pro Plus.* and *** represent p<0.05 and 0.001 
respectively compared to sham by 1-way ANOVA with Dunnett’s multiple comparison. (D) Urine 
(n=20) was collected with metabolic cages at baseline, in shams and STNx animals at 6 and 10 
weeks and assessed for presence of albumin. * and ** represent p<0.05 and 0.01 respectively 
compared to baseline/sham by 1 way ANOVA with Dunnett’s multiple comparison. (E) Plasma 
urea was measured in sham, 6wk and 10wk animals (n=16). ** represents p<0.01 compared to 




After confirmation of the development of renal fibrosis and systemic 
pathologies associated with CKD, we assessed whether the expression of our 
candidate gene, Ass1, was altered in both early (6 weeks) and late phases (10 
weeks) of STNx compared to sham. Gene expression analysis by qPCR 
demonstrated that Ass1 mRNA expression was significantly decreased at both 
time points in STNx compared to sham (One way ANOVA with Dunnett’s 
multiple comparison) (Figure 3.18A). Another STNx cohort was carried out to 
measure the expression of Ass1 at early time points (1, 2 and 4 weeks following 
surgery). Ass1 mRNA expression was consistently depleted at all time points 
compared to sham (One way ANOVA with Dunnett’s multiple comparison) 
(Figure 3.18B). 
Immunofluorescent staining for ASS1 in renal tissue slices from 10 week STNx 
animals revealed that ASS1 was confined to the proximal tubules within the 
kidney cortex and was not expressed in the glomerulus. Furthermore, ASS1 
expression appeared to be depleted in tubules in 10 week STNx kidneys 




Figure 3.18: ASS1 downregulation in the subtotal nephrectomy (STNx) model of progressive 
fibrosis. RNA was extracted from kidneys from mice subjected to either sham or STNx surgery  
and tissue was harvested at mid (6 weeks) and late (10 weeks) time points (A).  Tissue was 
harvested at early time points; 1 week, 2 weeks and 4 weeks (B).  qPCR was carried out and 
Ass1 expression was assessed in these samples and relative expression was calculated from 
ΔΔcT normalized to Ppia housekeeper compared to sham. (C) Representative image of ASS1 
immunostaining in sham and 10 week STNx cortical kidney tissue with IgG control. Images were 
taken at 20x magnification on the Zeiss Axioscope 2 MOT Plus. * and ** represent p<0.05 and 




3.3.12 Ischemia Reperfusion Injury Model  
Ischaemia reperfusion injury (IRI) models acute kidney injury by unilateral 
clamping of the renal pedicle for variable durations to induce ischaemia within 
the kidney. Reperfusion is enabled by removal of the clamp and the animal is 
allowed to recover. Over time the injured kidney develops fibrosis. 
A time course experiment was carried out in order to investigate how the IRI 
model develops fibrosis over time. IRI kidneys (n=7/8 at each time point) were 
harvested at 2, 7, 14 and 21 days and gene expression analysis and western 
blot analysis were carried out compared to sham animals at the corresponding 
time point (n=4 at each time point). 
Markers of fibrosis were assessed by qPCR at all time points. Col1a1, a 
hallmark of fibrosis, was significantly elevated after IRI at all time points 
compared to sham. As soon as 2 days post-IRI Col1a1 was 12 fold increased 
and subsequently it was upregulated by 31, 28 and 44 fold at 7, 14 and 21 days 
respectively compared to sham values at the same time point (unpaired 
Student’s t test, p<0.001). Col4a1 was not found to be significantly elevated at 
2 days post-IRI but after 7 days mRNA was significantly increased by 5 fold 
compared to sham and this significant elevation was sustained at 15 and 21 
days. Finally, Mmp2 was not significantly elevated 2 days post-IRI but by 7 
days post injury mRNA was significantly upregulated by more than 20 fold at 7, 




Figure 3.19: Markers of fibrosis are elevated in the ischaemia reperfusion injury model (IRI). (A-
C) Relative mRNA levels of genes related to fibrosis in sham (n=4), or IRI (18min) surgery at a 
number of time points; 2 days (n=8), 7 days (n=8), 14 days (n=8) and 21 days (n=7) post-surgery. 
Relative expression was calculated from ΔΔcT normalized to Hprt housekeeper and compared 
to sham. *, ** and *** represent p<0.05, 0.01 and 0.001 respectively compared to sham by 
unpaired Student’s t test). 
 
Ass1 mRNA expression was found to be significantly depleted as early as 2 
days post-IRI (p<0.01) compared to sham and this depletion was sustained at 
7 days (p<0.001), 14 days (p<0.01) and 21 days (p<0.05) post-IRI (unpaired 
Student’s t test).  
Western blot analysis demonstrated that ASS1 protein was significantly 
depleted as soon as 2 days after IRI surgery and this loss was sustained at all 
time points as fibrosis progressed (P<0.01, One-way ANOVA with Tukey’s 




Figure 3.20: ASS1 depletion in the ischaemia reperfusion injury model (IRI). (A) Relative mRNA 
levels of Ass1 in sham (n=4) or IRI (18min) surgery at a number of time points; 2 days (n=8), 7 
days (n=8), 14 days (n=8) and 21 days (n=7) post-surgery. Relative expression was calculated 
from ΔΔcT normalized to Hprt housekeeper and compared to sham. *, ** and *** represent 
p<0.05, 0.01 and 0.001 respectively compared to sham by unpaired Student’s t test.  (B) Western 
blot was carried out on kidney lysates from sham and IRI at all time points (all n=3). Protein 
expression was measured using the Licor system and normalized to GAPDH housekeeper. ** 
and *** represent p<0.01 and 0.001 respectively compared to sham by 1 way ANOVA with 
Dunnett’s multiple comparison.   
 
The expression of tubular marker, Cubn, was assessed by qRT-PCR at all time 
points. Cubn expression did not exhibit significant downregulation until 14 days 
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after IRI. This reduced expressed was sustained at 21 days (one way ANOVA 
with Dunnett’s multiple comparison) (Figure 3.21). 
 
Figure 3.21: Marker of tubular number in ischaemia reperfusion injury. Relative mRNA levels of 
Cubn in sham (n=4) or IRI (18min) surgery at a number of time points; 2 days (n=8), 7 days 
(n=8), 14 days (n=8) and 21 days (n=7) post-surgery. Relative expression was calculated from 
ΔΔcT normalized to Hprt housekeeper and compared to sham. *, ** and *** represent p<0.05, 










3.4 Discussion  
Pre-clinical murine models provide much insight into the on-going mechanisms 
driving renal fibrosis and subsequent CKD. Here, three different models have 
been adopted to explore mechanisms common to fibrosis regardless of 
aetiology. Using a variety of transcriptomics techniques, it was elucidated that 
fibrosis is linked to a downregulation in metabolic processes. Moreover, 
reversal of fibrosis induced an upregulation of genes involved in metabolic 
pathways. Ass1 was revealed to be an important gene of interest, highly 
expressed in tubules, which demonstrated depleted expression in 3 models of 
renal fibrosis and upregulation of expression when fibrosis was reversed. 
Furthermore, Ass1 was shown to be upregulated in kidneys protected from 
fibrosis by anti-miR-214 and Ass1 expression and miR-214 demonstrated a 
strong negatively correlation indicating that Ass1 may be a target of pro-fibrotic 
miR-214.  
Dysregulated metabolism has been reported to be an important driver of renal 
fibrosis. Here, we found fatty acid oxidation/metabolism to be a metabolic 
pathway that was shut down in the UUO model of fibrosis. Research conducted 
by Kang and colleagues supports this finding. Their work demonstrated 
decreased expression of genes involved in fatty acid oxidation in a genetic 
murine model of fibrosis (over-expression of Notch 1 in TECs) as well as the 
folic acid-induced injury model. Furthermore their findings were recapitulated 
in human studies. Transcriptomics studies and pathway analysis from patients 
with CKD compared to healthy controls showed an overall decrease in genes 
pertaining to the fatty acid oxidation pathway (64). Other groups have 
demonstrated defective fatty acid metabolism in renal fibrosis associated with 
aging and excess lipid accumulation (63) and AKI followed by exposure to 
angiotensin 2 (105). As tubular epithelial cells use fatty acid oxidation as their 
primary mode of generating ATP, losing the ability to metabolise fatty acids is 
detrimental to TECs which drives injury and subsequent fibrosis.  
This work also identified the pathway; arginine biosynthesis and metabolism to 
be perturbed in UUO. Previous work has identified several amino acids 
involved in arginine metabolism to be dysregulated in chronic renal failure in 
rodents and humans. Arginine biosynthesis is achieved in the kidney by 
conversion of circulating citrulline to arginine which is released from the kidney. 
Several studies have reported circulating citrulline levels to be upregulated in 
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renal failure in CKD patients and animal models (106-108). Arginine levels have 
been reported to be depleted within renal tissue in renal failure, however 
circulating levels of arginine remain physiologically normal (109-111). Arginine 
metabolism pathways include the production of nitric oxide (NO) from nitric 
oxide synthase which is very important in vasodilatation and inflammation. 
Studies have reported decreased production of NO in patients with renal failure 
and this depletion could contribute to increased risk of cardiovascular events 
observed in patients with CKD (108,112).  
A large metabolomics study conducted by Rhee and co-workers followed a 
group of patients with heart disease of which 10% developed CKD. Of the CKD 
population, metabolomic screening was conducted in plasma and urine. 
Citrulline was detected as a top ranked metabolite that was significantly 
upregulated in plasma of patients with CKD compared to healthy controls. 
Furthermore, higher plasma citrulline levels proved to be a more significant 
indicator of patients with CKD than creatinine (111). Another study also found 
high citrulline levels in urine to be a predictor of CKD. Additionally they found 
citrulline to be negatively correlated with estimated glomerular filtration rate and 
positively correlated with creatinine levels (107). High citrulline levels have also 
been seen in pre-clinical models of CKD (113). This supports my finding that 
arginine metabolism is dysregulated during the progression of renal disease. 
Ass1 was selected as a gene with a potential role in the development of CKD. 
We compiled several transcriptomics datasets from our lab and others which 
consistently reported Ass1 to be downregulated in murine models of fibrosis 
and importantly in human CKD. Moreover, for the first time, Ass1 was identified 
as a gene that exhibited marked increases in expression in the rUUO model, 
where renal fibrosis is largely resolved. Measurement of protein levels of ASS1 
revealed that ASS1 was not significantly depleted in UUO kidney after 2 days 
although Ass1 mRNA expression was significantly decreased in epithelial cells 
after 2 days. Seven days after UUO, ASS1 expression was significantly 
depleted at both mRNA and protein levels. Furthermore, in rUUO ASS1 protein 
levels were increased after 2 weeks but this did not reach significance. 
However, Ass1 mRNA was significantly upregulated after 2 weeks rUUO 
compared to UUO. Unfortunately protein was not available from 4 week rUUO 
kidneys so we cannot definitively ascertain whether protein levels are 
significantly increased in rUUO compared to UUO at this time point. However 
mRNA levels of Ass1 are significantly elevated after 4 weeks of rUUO. This 
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suggests that changes in ASS1 protein levels occur later than changes seen at 
the transcript level. This may be explained by the half-life of ASS1 which has 
been revealed to be ~40 hours in collecting duct cells in vitro. (114). This 
relative stability of ASS1 means that transcriptional changes are not seen at 
the protein level immediately.   
Additionally, in this project, Ass1 was found to be significantly depleted in the 
STNx and IRI models of fibrosis. Therefore, Ass1 is consistently depleted in 
three different models of renal fibrosis. This Chapter explored the outcomes 
from the newly refined subtotal nephrectomy that was developed in the Denby 
lab. This model results in reliable progressive renal fibrosis over 10 weeks with 
accompanying renal inflammation, cardiac hypertrophy and elevated blood 
pressure (93). This model was a great asset to this body of work as it accurately 
models the progression of CKD in a manner akin to human disease.  Another 
group have also reported ASS1 to be downregulated in the subtotal 
nephrectomy model as soon as 2 weeks after surgery. They identified early 
depletion of ASS1 and its partner enzyme ASL as the cause for upregulation 
of circulating citrulline in chronic renal failure (115). As mentioned previously, 
elevated citrulline is correlated with both human and rodent CKD. Our data 
supports this finding as both Ass1 and Asl are depleted in the UUO model of 
renal fibrosis investigated in this project. Future work investigating these 
models should include measurement of circulating citrulline and arginine in 
serum. In this way we could establish whether changes in these amino acids 
are detectable in unilateral models such as UUO and unilateral IRI or only in 
models which lack a fully functioning kidney.  
Here, it was identified that tubular epithelial cells are the predominant cell type 
expressing Ass1 in the kidney. Using RNA-seq data from both FACS sorted 
subpopulations and single cell sequencing has allowed investigation of Ass1 
expression patterns in UUO and rUUO exclusively in tubular epithelial cells. As 
the kidney is comprised of many cell types, it is important to identify which are 
responsible for gene expression changes seen in whole kidney homogenate. 
As Ass1 expression is predominantly tubular, gene expression analysis from 
other models such as STNx and IRI could be assessed from whole kidney with 
the knowledge no other renal cell types were contributing significantly to Ass1 
gene expression patterns.  
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Single cell RNA-seq has also allowed the investigation of expression profiles 
from individual cells. Focussing on epithelial cells allowed the observation that 
Ass1 and Asl are not always expressed in the same cell. tSNE plots as well as 
Pearson correlation demonstrated that there are 3 populations of cells 
expressing Ass1 and Asl; Ass1 positive, Ass1-Asl double positive and Asl 
positive. The classical role of ASS1 is its role in converting citrulline to 
argininosuccinate which is in turn converted to arginine. It is perhaps an 
indication that Ass1 and Asl have roles other than citrulline metabolism if they 
are expressed singly in certain cells. Lee and colleagues also found Ass1 and 
Asl to be distinctly expressed in different regions of the nephron. They carried 
out deep sequencing on micro-dissected nephrons and found Ass1 to be highly 
expressed exclusively in the proximal tubule while Asl exhibited lower level 
expression diffusely through most sections of the nephron (116). Their work 
supports our findings from tSNE plots which showed Ass1 to be confined 
mostly to proximal tubular cells while Asl exhibited lower level diffuse 
expression throughout epithelial cells. This evidence could suggest that these 
genes are playing a role out with their traditional role in the urea cycle.    
Another study identified Ass1 to be downregulated in autosomal dominant 
polycystic kidney disease (ADPKD). This group found Ass1 to be depleted in 
genetic knockout mouse models of ADPKD and human ADPKD. The authors 
attributed loss of Ass1 to loss of tubular mass which occurs during the onset of 
ADPKD. They showed that Ass1 depletion led to changes in arginine levels in 
the kidney which interfered with glutamine metabolism which they suggested 
contributes to cyst growth (117). ADPKD is an inherited condition which 
manifests in cystogenesis but also fibrosis. Trott and colleagues work supports 
this study as Ass1 is yet again observed to be downregulated in a fibrotic renal 
disease. However, in my body of work, tubular loss does not seem to be the 
only cause of Ass1 depletion. Another study investigating the characteristics of 
hepatorenal syndrome, found that Ass1 mRNA and protein were depleted in a 
mouse model of bile-duct ligation. This model of hepatorenal syndrome 
induced renal injury, inflammation and fibrosis. This model provides evidence 
that Ass1 is downregulated in models of renal injury in which indirect kidney 
injury is a downstream effect of hepatic injury (118). This suggests that 
regardless of aetiology, Ass1 is consistently downregulated with the advent of 
renal injury.   
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Tubular loss is a pathological trait of all three models investigated here. Tubular 
atrophy occurs for a number of reasons and contributes significantly to renal 
disease. Loss of Ass1 was demonstrated in all three models and therefore, the 
fact that Ass1 loss could be explained purely by tubular loss must be 
addressed. In the UUO model, Ass1 loss was confined to the tubular 
compartment. In order to assess the extent of tubular loss in UUO, expression 
of tubular markers Lrp2 and Cubn were investigated in live sorted tubular cells 
for use as a proxy for tubular loss. Both Lrp2 and Cubn showed downregulation 
after 7 days UUO, however, Ass1 demonstrated a greater negative fold change 
in expression in UUO vs sham compared to tubular markers. Therefore, Ass1 
was depleted to a greater extent compared to 2 tubular makers. Both tubular 
markers demonstrated very similar expression patterns. Furthermore, neither 
tubular marker exhibited significant elevation in expression after rUUO 
compared to UUO. This demonstrated no significant increase in tubular number 
after reversal of obstruction. Conversely, Ass1 demonstrated significant 
increases in expression after reversal of obstruction. This suggests that 
although there are no significant increases in tubular number after rUUO, 
upregulation of Ass1 is required in the remaining tubular population during 
resolution of fibrosis. 
The extent of tubular loss was also investigated in IRI. Here, Cubn expression 
was measured at various time points following IRI and its expression was not 
found to be significantly decreased until 14 days post-IRI. This is in contrast to 
Ass1 which demonstrated significant depletion as soon as 2 days following IRI. 
This shows that Ass1 loss occurs prior to tubular loss, indicating Ass1 depletion 
is an important event independent of and preceding tubular loss.  
This work has revealed a potential interaction between Ass1 and miR-214. Not 
only was Ass1 significantly upregulated in kidneys treated with anti-miR-214 
but Ass1 also demonstrated a very strong negative correlation with miR-214 in 
UUO/rUUO. As microRNAs function by repressing their target genes, it 
provides evidence that Ass1 may be a target of miR-214 due to increased 
expression of miR-214 correlating strongly with decreased Ass1 expression in 
UUO. However, proving direct interaction and repression of an mRNA target 
by a microRNA is challenging. In mammals microRNAs tend to bind their 
mRNA targets through imperfect sequence complementarity. Therefore, using 
computational algorithms to predict miRNA-mRNA binding can be misleading. 
In order to prove a direct physical interaction between miR-214 and Ass1 a 
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reporter based assay could be used. In this way the luminescent signal intensity 
of a luciferase reporter could be used to detect Ass1 mRNA target binding by 
miR-214 (119,120). 
This chapter has elucidated metabolic pathways to be dysregulated in renal 
fibrosis. Ass1, part of arginine biosynthesis and metabolism pathway was found 
to be consistently downregulated in three different models of renal fibrosis. 
Ass1 depletion was an event that occurred early in the progression of renal 
fibrosis and Ass1 loss was found to occur prior to tubular loss and was found 
to be depleted to a greater extent than markers of tubules. Furthermore, Ass1 
expression was lost in live transcriptionally active epithelial cells after UUO. 
Additionally Ass1 expression is rescued in rUUO kidneys in which fibrosis has 
resolved despite the fact that the number of tubular cells does not significantly 
increase. This shows that Ass1 expression patterns observed in these models 
is not entirely a result of tubular loss or gain. This indicates that Ass1 loss is a 
molecular mechanism that occurs at the onset of renal fibrosis and the role that 




The role of ASS1 in human renal proximal tubular 
cells 
3.5  Introduction 
3.5.1 Argininosuccinate synthetase (ASS1) 
ASS1 is the rate limiting step of the urea cycle and is expressed ubiquitously. 
Its pattern of expression varies according to which cell type it is expressed in. 
The liver exhibits very high expression of ASS1 and is the main site of urea 
production. Within the liver, ASS1 localises to the mitochondria. Within 
endothelial cells, ASS1 associates with calveolae and is expressed at low 
levels and provides arginine for nitric oxide synthesis (121,122). Within the 
kidney, ASS1 is highly expressed but confined primarily to the proximal tubule 
(123). Microdissection of human kidneys has revealed that ASS1 RNA is highly 
expressed in all 3 segments of the proximal tubule but very lowly expressed 
throughout the remainder of the nephron. However, the subsequent enzyme in 
the urea cycle, argininosuccinate lyase, did not  express the same expression 
pattern within the nephron and exhibited expression in the distal nephron as 
well as the proximal nephron (116). However the subcellular expression of 
ASS1 within the kidney is poorly defined and generally referred to as cytosolic 
(121).  
ASS1 functions as part of the urea cycle. However the urea cycle functions 
differentially depending on the organ. Within the liver, the urea cycle occurs in 
its entirety but within the kidney only a portion of the urea cycle is carried out.  
3.5.2 The Urea Cycle 
The urea cycle was the first metabolic cycle to be discovered by Hans Kreb 
and Kurt Henseleit and functions to detoxify cells by converting ammonia into 
urea (124). The full urea cycle is carried out by 5 enzymes: carbamoyl 
phosphate synthetase (CPS), ornithine transcarbamylase (OTC), 
argininosuccinate synthetase (ASS1), argininosuccinate lyase (ASL) and 
arginase 1 (ARG1) which are localised within mitochondria and the cytoplasm. 
Ammonia and bicarbonate are produced in the mitochondria and combined by 
CPS to give carbamoyl phosphate which is converted by OTC to citrulline. 
Citrulline is shunted out of the mitochondria and with the addition of aspartate 
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is converted to argininosuccinate by ASS1. Subsequently this is converted to 
arginine by argininosuccinate lyase (ASL). Arginine is then converted to urea 
waste, water and ornithine which is recycled back into the urea cycle (Figure 
3.22) (125).  
The complete urea cycle takes place primarily in the liver. However, within the 
kidney, there is very little expression of CPS1, OTC or ARG1 and a truncated 
version of the urea cycle takes place. Circulating citrulline enters the kidney via 
the renal artery and is converted to arginine by ASS1 and ASL. Arginine is then 
excreted via the renal vein and used for a number of processes. The kidney is 
the main site of arginine production in the body. Production of arginine is 
essential for protein synthesis in all cell types and plays varying tissue specific 
roles such as urea production, nitric oxide synthesis, polyamine synthesis, and 
creatine synthesis (121,122) (Figure 3.23).   
 
Figure 0.1: Schematic of the urea cycle. CPS (carbamoyl phosphate synthetase), OTC (ornithine 
transcarbamylase), ASS1 (argininosuccinate synthetase), ASL (argininosuccinate lyase) and 





3.5.3 Urea Cycle Disorders  
There are several urea cycle disorders which occur due to deficiencies in the 
activity of the urea cycle enzymes including ASS1 and ASL. Urea cycle 
disorders are rare inherited disorders which often result in hyperammonemia 
which is neurotoxic. This results in a large number of patients with urea cycle 
disorders dying shortly after birth (126).  
Deficiency of ASS1 is characterised as citrullinemia type I and its severity 
depends on the extent of enzymatic deficiency. CTLN1 is autosomal recessive 
and symptoms occur shortly after birth and can be fatal. CTLN1 has been 
associated with liver disease however robust evidence of kidney abnormalities 
in CTLN1 is lacking. One study reported evidence of renal disease in a small 
percentage of their cohort with ASS1 deficiency, however, the GFR measuring 
technique varied within the study cohort and no details of renal function or 
histology were assessed (127,128).  
Another urea cycle disorder, argininosuccinate lyase deficiency, is 
characterised by dysfunction or absence of the enzyme ASL. The incidence of 
this inherited disorder is 1:70 000 births which makes it the second most 
common urea cycle disorder. As well as neurological defects, gastro-intestinal 
symptoms and liver dysfunction, some patients with ASL deficiency develop 
some renal pathologies (129-131). Tubulopathies have been reported in a 




Figure 0.2: The urea cycle in different cell types. Bicarbonate (HCO3-), Ammonia (NH4+) are 
converted to urea via the urea cycle in hepatocytes of the liver. Circulating citrulline is converted 
to arginine by argininosuccinate synthetase (ASS1) and argininosuccinate lyase (ASL) in tubular 
epithelial cells of the kidney. Citrulline is converted to nitric oxide by ASS1, ASL and nitric oxide 
synthase (NOS) in nitric oxide producing cells. 
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presenting with hypokalaemia (132). However, in depth diagnoses of potential 
renal phenotypes is sorely lacking in these patients.  
Although insight into renal dysfunction associated with urea cycle disorders is 
lacking it is interesting to note that some patients with these diseases do 
develop some renal disease, if poorly described. Together, with the evidence 
from metabolomics data highlighting elevated citrulline to be a marker of CKD, 
there is cause to investigate how urea cycle enzymes behave in the context of 
kidney function and CKD.  
3.5.4 The proximal tubule in chronic kidney disease 
The proximal tubule comprises the majority of the renal cortex and is made up 
of proximal tubular epithelial cells (PTEC). The proximal tubule is an essential 
segment of the nephron and is the main site of electrolyte reabsorption, protein 
and glucose uptake and pH balance. Therefore, these hard-working cells have 
a high energy demand and are densely packed with mitochondria. The proximal 
tubule is highly sensitive to injury and responds to stimulation with a number of 
pro-fibrotic and pro-inflammatory cytokines and is therefore instrumental in the 
progression of acute kidney injury to chronic kidney disease (see section 1.1.6).  
As demonstrated in Chapter 3, ASS1 is a highly abundant protein in the 
proximal tubule as seen in mice. The intracellular localisation of ASS1 has not 
been described fully in PTECs and in addition, the role ASS1 may play in 
PTECs has not been investigated in the setting of tubular injury and fibrosis. 
This chapter will characterise the expression of ASS1 in an in vitro cell model 
and will assess how ASS1 transcription and translation are affected in a fibrotic 
or inflammatory environment.  
3.5.5 RPTEC/TERT1 cells provide an improved model for investigating 
tubular epithelial cell biology 
In vitro cell models of tubular epithelial cells have been used extensively to 
investigate the mechanisms of renal fibrosis, including, HK-2 cells, HKC8 cells, 
IRPTC and NRK-52E cells. Cell lines can be derived from many species 
including, human, rat and pig. Cell lines are immortalised by different methods 
including immortalization by HPV-16 (human papilloma virus-16) 
transformation, SV40 (adeno-12 simian virus-40) transformation and also by 
spontaneous immortalization in the case for NRK-52E cells (133). In vitro 
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models are an invaluable tool to assess how renal cells behave in pathological 
environments. They allow manipulation with drugs as well as biological 
mediators to elucidate ongoing mechanisms that would be impossible to tease 
out in vivo. However, these in vitro cell models have some caveats. In vitro 
models are reductive and do not address the complex interactions that exist 
between tubular epithelial cells and other cell types such as endothelial cells 
and cells of the interstitium. Additionally, in vitro cell lines often do not 
demonstrate features of tubular epithelial cells in vivo such as ability to polarise, 
expression of primary cilia and an ability to transport electrolytes (133). Newer 
in vitro models are necessary in order to better model tubular physiology.  
RPTEC/TERT1 cells are an in vitro model derived from healthy human renal 
proximal tubular epithelial cells (RPTECs). The RPTEC/TERT1 cell line has 
been immortalized and made suitable for tissue culture using the human 
telomerase reverse transcriptase subunit (hTERT) (134). RPTECs are a 
relatively new cell model and have been used to great success in the field of 
nephrotoxicity testing (135-137). Additionally, several research groups have 
been adopting RPTEC/TERT1 cells in place of other in vitro tubular epithelial 
models due to their ability to retain true tubular characteristics. These include 
the ability to form 3 dimensional tubular structures (138), presence of primary 
cilia, their ability to transport electrolytes (133) and their ability to endocytose 
albumin (134). In this chapter, RPTECs will be utilised to investigate the role of 
ASS1 within proximal tubular epithelial cells. 
3.5.6 Metabolic activity of proximal tubular cells  
As covered previously in section 1.1.7 metabolic dysfunction is an important 
pathological event in the progression of tubular injury and subsequent renal 
fibrosis. Several measures can be used to infer mitochondrial activity in vitro 
such as mitochondrial number and ATP production. However, an improved 
technique to assess cellular respiration is direct assessment of oxygen 
consumption rate (OCR) to assess mitochondrial respiration and assessment 
of extracellular acidification rate (ECAR) to measure glycolytic ATP production. 
This technique is made possible by the Seahorse XFe Analyser which enables 
these measures to be made in a 96-well format in real time. Additionally, the 
Seahorse Analyser allows injection of drugs which manipulate mitochondrial 
function during OCR and ECAR measurements. In this way, specific questions 
regarding basal respiration, ATP-linked respiration, maximal respiration and 
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proton leak can be addressed. The Seahorse Analyser has been successfully 
adopted as a method for measuring cellular respiration in HK-2 cells as well as 
isolated podocytes (64,139,140). This chapter will include data generated by 
the Seahorse Analyser from the more physiologically accurate RPTEC/TERT1 
cell model.   
3.5.7 Transforming growth factor β signalling in proximal tubular epithelial 
cells 
Transforming growth factor beta (TGFβ) is known as the classical pro-fibrotic 
cytokine for which the signalling pathway is described in sections 1.1.5 and 
1.1.10. TGFβ has long been known to elicit pro-fibrotic effects on fibroblasts, 
however, its effects in tubular epithelial cells are yet to be fully understood. As 
the extent of tubulointerstitial fibrosis is the best histologic predictor of CKD 
severity, the role that tubular cells play in the development of fibrosis warrants 
investigation. The effects of TGFβ on tubular epithelial cells has been 
investigated extensively in primary tubular epithelial cells, HK-2 cells and NRK-
52E cells. Upon stimulation with TGFβ, epithelial cells undergo morphologic 
changes and adopt an elongated and spindle shape. Cell-cell contacts are lost 
and there is a marked rearrangement of the cytoskeleton (141). Additionally 
TGFβ treatment has been found to decrease albumin uptake in cultured 
immortalized rat proximal tubular cells which could account for proteinuria seen 
in vivo in models of renal disease and human CKD (142). TGFβ has also been 
found to promote apoptosis in TECs in vitro by p38 MAP kinase signalling, 
independent of canonical Smad signalling. This may be a mechanism whereby 
tubular atrophy occurs in vivo (143). Furthermore, TGFβ has been found to 
have an adverse effect on PTECs in vitro by impeding fatty acid oxidation and 
ultimately causing metabolic dysfunction (64). It is clear that TGFβ induces a 
deleterious effect on TECs with a compounding set of pathological intracellular 
effects. Characterising the effects of TGFβ signalling in RPTEC/TERT1 cells 
will be important to elucidate how a more physiologically relevant cell model 
responds pro-fibrotic signalling. 
3.5.8 Tumour necrosis factor alpha in proximal tubular epithelial cells 
Inflammation is an essential driver of renal fibrosis and tumour necrosis factor 
alpha (TNFα) is a central pro-inflammatory cytokine which has been shown to 
be increased in the circulation and urine of patients with CKD (144).  TNFα is 
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known to stimulate proximal tubular cells in vitro and in vivo and has been 
reported to induce antigen presentation in PTECs as well as upregulating a 
number of chemoattractant proteins such as MCP-1 and ICAM1 which promote 
recruitment and adhesion of leukocytes (144,145). TNFα activates both TNF 
receptor I and TNF receptor II which propagate a number of intracellular 
processes. The canonical signalling pathway functions to activate the 
transcription factor NFκB which in the basal state is retained in an inactivated 
state in the cytoplasm by inhibitors of NFκB signalling. Once activated, NFκB 
exists as a homo- or hetero-dimer of NFκB subunits. There are 15 different 
possible combinations of 5 different subunits which bind to response elements 
on DNA and initiate transcription of a number of pro-inflammatory mediators 
(70). TNFα signalling also activates pro-apoptotic pathways and mitogen 
activated protein kinases (MAPK) which are responsible for a myriad of cell 
responses (146). TNFα is secreted by monocytes and macrophages but it also 
synthesized by resident renal cells including PTECs (147). In response to 
injury, PTECs are believed to produce TNFα and kick start inflammatory 
processes which are highly interlinked with fibrotic pathways.  
TNFα has also been reported to exert effects on mitochondria and cellular 
respiration. TNFα has been shown to perturb mitochondrial respiration in 
hepatocytes as well as cardiomyocytes (148,149). TNFα is thought to increase 
oxidative stress and therefore cause mitochondrial damage. Dogs treated with 
etanercept (a TNFα inhibitor) demonstrated increased activity of mitochondrial 
enzymes and improved heart function in a model of heart failure (150). 
Furthermore TNFα was found to decrease basal mitochondrial respiration in 
cultured neuronal cells. Oxygen consumption rate was used to accurately 
measure aerobic respiration with a Seahorse Analyser (151). The effect of 
TNFα on mitochondrial respiration of PTECs has not been directly investigated. 
In this chapter I investigate the direct effects of TNFα treatment on RPTEC 
mitochondrial respiration to address this.   
3.5.9 Ischaemic insult and hypoxia in proximal tubular epithelial cells 
During the course of renal fibrosis, the normal tubular interstitium is replaced 
with fibrous deposits. This results in peritubular microvascular rarefaction and 
therefore decreased oxygen supply to tubules and resultant ischaemia. The 
exact mechanism whereby peritubular capillary loss occurs is not fully 
understood, however, an imbalance of pro- and anti-angiogenic factors may be 
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to blame. In patients with CKD, there is a negative correlation between capillary 
density and severity of fibrosis (152). In addition, PTECs have a high oxygen 
demand due to high ATP demand generated by oxidative phosphorylation (53). 
Hypoxia not only triggers pro-inflammatory and pro-fibrotic transcription by 
stabilisation of HIF1α but it also increases production of reactive oxygen 
species. Therefore investigating the effects of hypoxia on PTECs is an 




3.6 Aims and Hypothesis 
As revealed by Chapter 3, ASS1 is lost in three models of renal fibrosis which 
all have differential aetiologies with fibrosis developing over different time 
courses. Therefore, I hypothesised that depletion of ASS1 within tubular 
epithelial cells was critical in the induction of renal fibrosis. However, in order 
to decipher how loss of ASS1 might lead to the promotion of fibrosis it was 
required that experiments were carried out in vitro. This would allow the 
elucidation of the potential fibrosis-driving mechanisms that may occur as a 
result of ASS1 depletion. As ASS1 is highly expressed in the proximal tubule, 
the cell line, RPTEC/TERT1 was adopted to further investigate the role that 
ASS1 plays in tubular epithelial cells.  
The overarching aim of this chapter was to elucidate the mechanisms whereby 
loss of Ass1 in tubular epithelial cells may promote the development of renal 
fibrosis.  
The individual aims of this chapter were as follows: 
- Characterise the expression of ASS1 in RPTEC/TERT1 
- Characterise the metabolic activity of RPTEC/TERT1 and how 
respiration is influenced by fibrotic and inflammatory stimuli  
- Reveal the upstream modulators of ASS1 expression 
- Investigate the effect of ASS1 depletion in RPTEC/TERT1 in the 




3.7 Results  
3.7.1 Characterisation of human renal proximal tubular epithelial cells 
(RPTECs) 
RPTECs have recently been adopted as an improved in vitro model when 
investigating proximal tubular epithelial cells. We investigated how RPTECs 
may vary depending on their proliferating vs differentiated state. Once split, 
RPTECs grow in colonies while proliferating before forming a monolayer. 
During the proliferation stage, cells adopt an elongated morphology. Once fully 
differentiated RPTECs begin to form domes which are an indicator of salt 
transport. Additionally, cells become more rounded and adopt the classical 
cobblestone morphology. Figure 4.1 A-B shows the morphological difference 
between proliferating and fully confluent RPTECs. The gene expression profile 
was assessed in both proliferating (3 days post-split) and fully confluent 
RPTECs (14 days post-split). Gene expression analysis was conducted in 
proliferating and confluent RPTECs. Two cell contact genes CLDN2 and OCLN 
demonstrated increased expression in 14 day confluent cells compared to 
proliferating cells. ASS1 mRNA expression was also increased in confluent 
RPTECs compared to differentiating cells. WNT7A, which is associated with 
proliferating cells, exhibited decreased expression in confluent cells compared 




Figure 0.3: RPTEC/TERT cells in a proliferative and fully confluent state. (A, B) Representative 
bright field images of RPTECs grown for 3 days and 14 days in tissue culture taken at 20x (A) 
and 10x (B) magnification with evidence of dome formation (arrows). (C) Relative mRNA levels 
of CLDN2, OCLN, ASS1 and WNT7A in RPTECs grown for 3 days (proliferating) and 14 days 
(confluent) in optimal cell culture conditions (n=2). Relative expression of mRNA in differentiating 
cells was calculated from ΔΔcT normalized to GAPDH housekeeper and compared to mRNA 
expression in proliferating cells.  
 
3.7.2 Characterisation of intracellular ASS1 expression in RPTEC/TERT1 
In order to discern the expression patterns of ASS1 within RPTECs, 
immunofluorescence was carried out to observe the subcellular localisation of 
ASS1 in proliferating and confluent cells. Figure 4.2 depicts ASS1 staining in 
cells fixed 3 days after seeding. ASS1 was stained in conjunction with nuclear 
stain, DAPI, and F-actin stain, Phalloidin. In proliferating RPTECs, ASS1 
positive staining (green) was observed around the nucleus and in the 
cytoplasm. In actively dividing cells (Figure 4.2 D), ASS1 staining was observed 




Figure 0.4: ASS1 expression in proliferating RPTECs. A selection of representative z-projected 
images of RPTECs stained for DAPI (nuclei in blue), F-actin (magenta) and ASS1 (green) taken 
at 100x magnification with a z-stack using the Andor Spinning disk microscope with IgG control 
(A). Images were analysed with ImageJ software. 
 
In order to determine the expression pattern for ASS1 in differentiated 
RPTECs, cells were grown on filters for 14 days to ensure cells were fully 
differentiated and polarised. When grown on filters, RPTECs have been shown 
to polarise and microvilli are visible on the apical side of the cells. ASS1 
immunostaining was carried out on differentiated RPTECs grown on filters. 
ASS1 staining was abundant within polarised RPTECs and it was present 





Figure 0.5: ASS1 expression in polarised, differentiated RPTECs. Representative image of 
RPTECs grown on filters to induce polarisation. Cells were stained for DAPI (nuclei in blue) and 
ASS1 (green) taken at 40x magnification with the Sp8 Confocal microscope with IgG control (A). 
Images were analysed with ImageJ software. 
 
3.7.3 ASS1 staining does not co-localise with mitochondria 
It has been reported that ASS1 is localised in the vicinity of mitochondria due 
to part of the urea cycle taking place within the mitochondria. However, this has 
not been investigated in proximal tubular cells. RPTECs were cultured until 
confluent and co-stained for ASS1 and live mitochondria. It was observed that 
ASS1 displayed cytoplasmic staining (green) with some positive staining 
present around the nucleus. Mitochondria demonstrated abundant positive 
staining (red) predominantly in the interior of the cell around the nucleus. ASS1 
staining was evident in regions of the cell where mitochondrial staining was 




Figure 0.6: ASS1 and mitochondrial expression in RPTECs. A representative z-projected image 
of RPTECs (B) stained for DAPI (nuclei in blue), mitochondria (red) and ASS1 (green) taken at 
60x magnification with a z-stack using the Andor Spinning disk microscope with IgG control (A). 
Images were analysed with ImageJ software. 
 
3.7.4 RPTECs are highly metabolically active 
As the kidneys and the proximal tubule in particular are highly metabolic, we 
assessed the metabolic activity of RPTECs to ensure they were a reliable 
cellular model for mirroring the physiology of the PT. The metabolic activity of 
the RPTECs was assessed using the XFe Seahorse Analyser which measures 
oxygen consumption and rate (OCR) and extracellular acidification rate (ECR), 
representing ATP-linked respiration and anaerobic respiration respectively. 
The Seahorse analyser allows the interrogation of specific components of ATP-
linked respiration using a MitoStress test. Three drug treatments (oligomycin, 
FCCP and antimycin/rotenone) allow investigation of basal respiration, ATP-
linked respiration, maximal respiratory capacity and proton leak. Using this 
technique can reveal how cells respire under different conditions.  
Several preliminary experiments were conducted using the Seahorse Analyser 
to ascertain the optimal seeding density of RPTECs for each experiment as 
well as optimising the concentration of the drugs used during the MitoStress 
test. 
RPTECs demonstrated an average basal OCR of 583.4523± 119.0912 
pmol/min (normalized to protein content) when 100,000 cells were seeded the 
night before measures were taken under optimum conditions. A MitoStress 
Test was conducted in order to determine how these cells respire to produce 
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ATP. After optimisation of drug concentrations, 2 μM oligomycin was added to 
inhibit ATP synthase and block the production of ATP. Then 2.5μM Carbonyl 
cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) was added to uncouple 
oxygen consumption from ATP production in order to assess maximal 
respiratory capacity. Finally, a 1μM mixture of Antimycin A and rotenone (A/R) 
was added to inhibit complexes I and III to attenuate mitochondrial respiration.  
Treatment of RPTECs with oligomycin exerted a decrease in OCR from 
583.45± 119.09 to 184.3± 68.5 pmol/min oxygen consumed. FCCP treatment 
increased the OCR substantially to 1105.7± 337.2 pmol/min and A/R abrogated 
respiration to 118.01± 48.02 pmol/min. Figure 4.5 And Table 4.1 summarise 
the biological relevance of these data.  
Measure OCR (pmols/min) 
Basal respiration 463.5711 
ATP-linked respiration 400.9968 
Maximal respiration 960.1784 
Proton leak  62.5743 
Table 0.1: The oxygen consumption rate of RPTECs. Basal, ATP-linked and maximal respiration 
as well as proton leak were calculated from a MitoStress test carried out on RPTECs which had 




Figure 0.7: Effect of the MitoStress test on the oxygen consumption rate of RPTECs. RPTECs 
were seeded on to Seahorse XFe 24 well plates and left overnight. The oxygen consumption 
rate of RPTECs was measured using the Seahorse XFe analyser (4 replicates). Additionally, a 
MitoStress test was carried out using 2µM oligomycin, 2.5µM FCCP and a 1mM mixture of 
antimycin A and rotenone. Oxygen consumption rate was normalized to protein content of cells, 
measured by SRB assay.  
 
During the MitoStress test the extra-cellular acidification rate (ECAR) was also 
measured to assess anaerobic respiration. Upon treatment of oligomycin the 
ECAR increased from 113.12± 11.45 to 254.1±27.75 mpH/min. This increased 





Figure 0.8: Extracellular acidification rate of RPTECs. RPTECs were seeded on to Seahorse 
XFe 24 well plates and incubated overnight. The extracellular acidification rate of RPTECs was 
measured using the Seahorse XFe analyser (4 replicates). Additionally, a MitoStress test was 
carried out using 2µM oligomycin, 2.5µM FCCP and a 1mM mixture of antimycin A and rotenone. 
Extracellular acidification rate was normalized to protein content of cells, measured by SRB 
assay. 
 
3.7.5 Upstream mediators of Ass1 expression 
As Ass1 was found to be downregulated in three models of renal fibrosis we 
sought to elucidate which upstream signalling molecules may be responsible 
for depletion of Ass1 expression in vivo. A number of factors have been 
reported to contribute to the progression of fibrosis including molecular 
signalling cytokines such as TGFβ and TNFα as well a physical drivers such 
as hypoxia. By reflecting the fibrotic environment seen in vivo using cell models, 
we could ascertain which upstream mediators impact Ass1 expression.  
3.7.6 Transforming growth factor beta induced a fibrotic phenotype in 
RPTECs without influencing ASS1 expression 
TGFβ is described as the classical fibrotic cytokine that predominates in CKD. 
RPTECs were treated with increasing doses (5, 10, 20 and 50ng/mL) of 
recombinant TGFβ for 72 hours in order to assess which dose induced a fibrotic 
phenotype. COL1A1 and TGFBR1 mRNAs were adopted as markers of TGFβ 
stimulation. Both markers were significantly upregulated compared to control 
cells with all concentrations of TGFβ apart from the highest concentration 
(50ng/mL). 10ng/mL was the dose carried forward and used in subsequent 
TGFβ stimulation experiments (Figure 4.7A). Subsequently, RPTECs were 
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stimulated with 10ng/mL TGFβ for varying durations of time: 24, 48, 72 and 120 
hours. COL1A1 mRNA was used as a marker of TGFβ signalling and its 
expression was determined at each time point. COL1A1 expression was 
significantly upregulated at all time points compared to control. 72 hours 
treatment induced a significantly higher expression level of COL1A1 compared 
to 120 hours TGFβ stimulation so 72 hours was the time point assessed in 
subsequent experiments (Figure 4.7B). 
The morphology of the cells were assessed using a light microscope. 
Stimulated cells adopted an elongated phenotype and cells appeared to lose 
contacts with one another (Figure 4.7C).  RPTECs responded to 10ng/mL 
TGFβ stimulation for 72 hours by upregulating transcription of a number of 
fibrotic genes such as COL1A1, COL4A1, MMP2 and MMP9 compared to 
control (p<0.01, Mann Whitney test, Figure 4.7D).  
After confirmation of a fibrotic phenotype in RPTECs, the expression of ASS1 
was assessed. However, there was no significant difference in the expression 
level of ASS1 in TGFβ stimulated cells compared to control cells (p=0.62, Mann 




Figure 0.9: Effect of TGFβ stimulation on RPTECs  Relative mRNA expression of COL1A1 
mRNA in RPTECs stimulated with TGFβ  at increasing doses (A) and increasing length of 
stimulation (B) compared to control (both n=1). (C) Representative bright field images of 
untreated RPTECs and TGFβ treated RPTECs taken at 10x magnification. (C) Relative mRNA 
levels of genes related to fibrosis in RPTECs stimulated with 10ng/mL TGFβ for 72 hours (n=3). 
(D) Relative expression of ASS1 expression in RPTECs stimulated with 10ng/mL for 72 hours 
(n=3). Relative expression was calculated from ΔΔcT normalized to GAPDH housekeeper and 
compared to sham. ** and *** represent p<0.01 and 0.001 respectively compared to control 
measured by Mann Whitney test. 
 
3.7.7 TGFβ treatment alters the metabolic profile of RPTECs 
Subsequently we investigated the effect of TGFβ treatment on the OCR and 
ECAR in RPTECs to assess its potential actions on metabolic activity. Kang 
and co-workers found TGFβ treatment to decrease the respiration rate of a 
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human tubular cell line (64). We sought to assess whether the same effect was 
seen in human RPTECs.  
RPTECs were treated with 10ng/mL TGFβ for 72 hours. Their response to a 
MitoStress test was assessed and compared to cells kept in control media. 
Cells treated with TGFβ showed no significant difference in their baseline OCR 
before stimulation with drugs compared to control media. Furthermore, there 
were no significant differences in either group upon stimulation with oligomycin 
(ATP-linked respiration). However, with FCCP treatment, TGFβ stimulated 
cells exhibited a significant decrease in OCR compared to control media. 
Antimycin/Rotenone abolished respiration equally in all experimental groups 
(Figure 4.8). TGFβ stimulation significantly decreased the maximal respiratory 
capacity of RPTECs compared to control media (p< 0.01, Mann-Whitney Test) 





Figure 0.10: Effect of TGFβ on the metabolic activity of RPTECs. (A) Representative trace of 
oxygen consumption rate of RPTECs stimulated with 10 ng/mL TGFβ or left untreated for 3 days. 
Where indicated oligomycin (2µM), FCCP (2.5µM) and antimycin/ rotenone (1µM) were added. 
OCR was measured using the Seahorse XFe analyser and normalized to protein content 
measured as optical density from SRB assay. (B) Percentage change of OCR in RPTECs in 
response to drug treatment (n=3). *** represents p<0.001 compared to control media, Mann-
Whitney test.  
 
3.7.8 TNFα stimulation of RPTECs induced downregulation of ASS1 
expression 
As TGFβ was found not to effect Ass1 expression, the promoter region was 
investigated to elucidate potential transcription factor binding sites in order to 
reveal upstream mediators that affect transcription of Ass1. After running the 
human ASS1 promoter sequence through AliBaba 2.0, an online tool for 
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transcription factor binding predictions, I found two potential NFκB binding 
sites. Therefore RPTECs were stimulated with TNFα, which initiates the NFκB 
inflammatory signalling cascade. RPTECs were treated for 72 hours with 10, 
20 and 40ng/mL TNFα and gene expression assessed by qPCR. ASS1 mRNA 
expression was dampened by TNFα stimulation in a dose-dependent manner. 
The dose of 20ng/µL was used for subsequent experiments. At this 
concentration, with n=3, ASS1 expression was found to be significantly 
depleted. Additionally, the expression of its neighbouring enzyme ASL 
exhibited no significant change in expression after TNFα treatment. Finally, 
ICAM1, a positive control for TNFα stimulation, was found to be significantly 




Figure 0.11: Effect of TNFα stimulation on RPTECs. (A) Relative mRNA levels of ASS1 in 
RPTECs stimulated with TNF at increasing doses (10, 20 and 40ng/mL) (n=1 with 3 technical 
replicates) (B) Relative mRNA levels of ASS1, ASL and ICAM1 in RPTECs stimulated by 
20ng/mL for 72 hours (n=3). Relative expression was calculated from ΔΔcT normalized to 
GAPDH housekeeper and compared to sham. ** represents 0.01 respectively compared to 
control measured by Mann-Whitney test. 
 
3.7.9 TNFα exerts no respiratory changes in RPTECs 
We sought to investigate whether TNFα influences the metabolic activity of 
RPTECs as stimulation with TNFα induced a depletion of Ass1 which is a 
metabolic enzyme. Furthermore, TNFα has previously been shown to affect the 
mitochondrial activity of cardiomyocytes (153). RPTECs were treated with 
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20ng/mL TNFα or cultured in control media for 72 hours and a Mitostress test 
was carried out as before and the OCR was assessed. TNFα did not 
significantly alter the OCR of RPTECs compared to control conditions. Basal 
respiration, ATP-linked respiration, maximal respiratory capacity and proton 
leak were not significantly changed with TNFα treatment (Figure 4.10) (Mann-
Whitney Test).  
 
Figure 0.12: Effect of TNFα on the metabolic activity of RPTECs. (A) Representative trace of 
oxygen consumption rate of RPTECs stimulated with 20 ng/mL TNFα or left untreated for 3 days. 
Where indicated oligomycin (2µM), FCCP (2.5µM) and antimycin/ rotenone (1µM) were added. 
OCR was measured using the Seahorse XFe analyser and normalized to protein content 
measured as optical density from SRB assay. (B) Percentage change of OCR in RPTECs in 
response to drug treatment (n=3).  
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3.7.10 Hypoxic conditions induced downregulation of ASS1 expression 
In the setting of fibrosis, secreted inflammatory and pro-fibrotic mediators 
induce changes to tubular epithelial cells. In addition to secreted mediators, 
tubules are subjected to an ischaemic environment due to microvascular 
rarefaction and insufficient blood supply to the renal cortex. These ischaemic 
conditions can be modelled in vitro by exposing RPTECs to a hypoxic 
environment using a hypoxic chamber.  
In order to assess the effect of hypoxia on RPTEC phenotype and specifically 
ASS1 expression, RPTECs were maintained in a hypoxic chamber at 1% 
oxygen for 24 hours and compared to cells maintained in normoxic conditions. 
After exposure to these conditions, there was visible evidence of cell death in 
hypoxic cells compared to normoxic cells. Gene expression analysis was 
carried out by qPCR in both conditions. ASS1 gene expression was 
significantly downregulated in RPTECs exposed to hypoxia compared to 
normoxic cells (p<0.001) while its neighbouring enzyme ASL exhibited no 
significant change in transcription (p=0.77). Additionally, endogenous TNF 
mRNA expression was assessed which demonstrated a significant 
upregulation in expression compared to normoxic cells (p<0.001, Mann-
Whitney test).  
 
Figure 0.13: Effect of hypoxia on RPTECs. Relative mRNA levels of ASS1, ASL and TNF in 
RPTECs exposed to hypoxia (1% oxygen) for 24 hours (n=3). Relative expression was 
calculated from ΔΔcT normalized to 18S housekeeper and compared to sham. *** represents 




3.7.11 Knock-down of ASS1 in RPTECs 
We sought to replicate our in vivo finding that ASS1 in lost in models of renal 
fibrosis in vitro. We transfected RPTECs with siRNA against ASS1 for 5 days 
and achieved 75% knock-down of ASS1 mRNA vs scramble control which 
reached significance (Mann Whitney test, p<0.001). Western blot analysis 
demonstrated that ASS1 protein was also depleted (Figure 4.12). There was 
no observable difference in cell morphology or size in ASS1 knock-down cells 
compared to scramble control.  
 
Figure 0.14: Knock-down of ASS1 in RPTECs. ASS1 was knock-down in PRTECs by 
transfection using stealth siRNA against ASS1 which was demonstrated by qRT-PCR (A) and 
Western blot (B) with ASS1 expression normalized to total protein and quantified using 
ImageStudio (C). Relative mRNA expression was calculated from ΔΔcT normalized to GAPDH 




In order to elucidate a mechanism whereby ASS1 loss may contribute to renal 
fibrosis, we assessed expression of a number of genes in knock-down vs 
scramble control which have been reported to be associated with renal fibrosis/ 
tubular injury/ de-differentiation (Figure 4.13). Firstly we assessed a number of 
fibrotic markers including COL1A1, MMP2 and TGFBR1 which all were 
significantly elevated in ASS1 knock-down RPTECs vs scramble control.  
Additionally, we assessed genes associated with cell-cell contacts including 
CLDN2 and OCLN. Both genes demonstrated significant downregulation in 
ASS1 knock-down cells compared to scramble control (Mann-Whitney test, 
p<0.001).  
As senescence is a hallmark of tubular injury we measured expression of p16 
(CDKN2A) and p21 (CDKN1A). Increased expression of these genes is 
indicative of tubular senescence. However, siRNA mediated knock-down of 
ASS1 did not induce upregulation of either of these genes. In fact, p21 
(CDKN1A) expression demonstrated significant downregulation in ASS1 
knock-down cells compared to scramble control (Mann-Whitney test p<0.05).   
As TNFα was shown to be an upstream mediator of ASS1, the expression of 
endogenous TNF from RPTECs was assessed in ASS1 knock-down RPTECs. 
TNF mRNA expression was found to be significantly depleted in RPTECs in 
siASS1 cells compared to scramble control. ICAM1 and CCL2 were also 
assessed as markers of an inflammatory response. ICAM1 exhibited significant 
upregulation in ASS1 knock-down cells compared to scramble control while 
CCL2 exhibited significant downregulation in ASS1 knock-down cells 
compared to scramble control (Mann-Whitney test, p<0.001). 
As ASL is the neighbouring enzyme of ASS1 in proximal tubular cells, the 
expression of ASL was measure in ASS1 depleted cells. There was no 
significant difference in ASL expression in siASS1 treated cells compared to 
scramble control (Mann-Whitney test, p<0.001). Finally, as HAVCR1 (kidney 
injury molecule 1) is used commonly as a marker of tubular injury, the mRNA 
expression of HAVCR1 was assessed in siASS1 RPTECs versus scramble 





Figure 0.15: Downstream effects of Ass1 knock-down in RPTECs. Relative mRNA levels of 
fibrosis genes (A), cell-cell contact genes (B), senescence markers (C), inflammatory markers 
(D) ASL (E) and HAVCR1 (KIM1) in RPTECs treated with siRNA against ASS1 (siASS1) and 
compared to scramble control (Scr) (n=3). Relative expression was calculated from ΔΔcT 
normalized to GAPDH housekeeper and compared to scramble control. * and ** represent 
p<0.05 and 0.01 respectively compared to control by Mann Whitney test. 
 
3.7.12 Pharmacological inhibition of ASS1 with MDLA 
Finally, I sought to reveal whether pharmacological inhibition of ASS1 activity 
exerted the same effects as genetic knock-down of ASS1. α-methyl-DL-
aspartic acid (MDLA) is a drug known to inhibit the active site of ASS1 (154-
156). RPTECs were treated with MDLA at a range of concentrations for 24 
hours before gene expression analysis by qRT-PCR was carried out. ASS1 
and ASL expression were assessed to elucidate whether pharmacological 
inhibition of ASS1 led to a change in the transcription of either of these urea 
cycle enzymes. Both ASS1 and ASL demonstrated a trend for increased mRNA 
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expression with increasing doses of MDLA. Subsequently, the expression of 
COL1A1 was measured to assess whether inhibition of ASS1 activity led to the 
same upregulation of COL1A1 mRNA seen after ASS1 knock-down. However, 
COL1A1 demonstrated a trend for decreased transcription with increasing 
doses of MDLA (Figure 4.13).  
 
Figure 0.16: Effect of ASS1 pharmacological inhibition in RPTECs. Relative mRNA levels ASS1 
(n=2) (A), ASL (n=1) (B) and COL1A1 (n=2) (C) were assessed in RPTECs treated with an ASS1 
inhibitor, MDLA (α-methyl-DL-aspartic acid), at increasing doses (0, 0.5, 1 and 2mM) and 
compared to untreated RPTECs. Relative expression was calculated from ΔΔcT normalized to 






This chapter successfully utilised RPTEC/TERT cells to characterise the role 
ASS1 plays in human renal proximal tubular cells. I found that ASS1 is highly 
expressed in RPTEC/TERT cells and that its site of expression varies 
according to the proliferative state of the cell. It was revealed that TNFα 
stimulation and subjection to hypoxia resulted in the downregulation of ASS1 
mRNA expression. This demonstrates that TNFα and hypoxia are capable of 
mirroring what is seen in vivo (Chapter 3) by downregulating ASS1 expression. 
However, the classical pro-fibrotic cytokine, TGFβ, did not influence the 
transcription of ASS1 although it did induce a fibrotic response and reduce the 
maximal respiratory capacity of RPTECs. Finally, by recapitulating was is seen 
during fibrosis in vivo, ASS1 was successfully knocked-down in RPTECs. 
Depletion of ASS1 resulted in differential expression of a number of genes that 
are involved in the development of fibrosis. Genes known to upregulated in 
fibrosis included collagen, matrix metalloproteinases and the TGFβ receptor 
exhibited elevated expression. Conversely, genes involved in cell-cell contacts 
demonstrated downregulation. Depletion of ASS1 did not induce a senescent 
phenotype but these transcriptional changes could reflect a de-differentiated 
phenotype. Tubular de-differentiation is a well described event occurring during 
the onset of fibrogenic mechanisms. These transcriptional changes seen after 
ASS1 knock-down were not recapitulated by pharmacological ASS1 activity 
inhibition by MDLA. A schematic of my current working hypothesis for the 




Figure 0.17: Schematic of hypothesised mechanism of action of loss of Ass1 in vitro.  
  
RPTEC/TERT provided an ideal cell model for investigating the role that ASS1 
plays in the proximal tubule in vitro. These cells are derived from human, 
therefore more relevant to patients than studying cells derived from rat or 
mouse. Although these are not primary cells, RPTECs retain many of the 
characteristics of proximal tubular epithelial cells seen in vivo (133,138,157). 
This chapter demonstrated that RPTECs were relatively slow growing and 
could be investigated in a proliferative state and a fully confluent state. RPTECs 
could be grown for at least 14 days as a fully confluent monolayer which 
expressed tight-junction genes and showed evidence of solute transport by the 
presence of domes. Presence of domes indicates that RPTECs are capable of 
active transport. HK-2 cells, which are another commonly used immortalized 
proximal tubule epithelial cell line, do not inherently have the ability undergo 
active ion transport which is evident by lack of dome formation in these cells 
(158). Therefore, RPTECs provide a more differentiated model of proximal 
tubular epithelial cells compared to HK-2 cells. As it is important to replicate as 
much tubular physiology as possible when using in vitro models and RPTECs 
provide a superior cell model. This chapter also demonstrated that RPTECs 
provide an excellent cell model for measuring oxygen consumption rate and 
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extra-cellular acidification rate. Here, RPTECs exhibited very stable 
measurements with treatment of oligomycin, FCCP and antimycin and 
rotenone. Many cells, such as HK-2 cells and HKC-8 cells not only exhibit less 
stable measurements throughout the run but they also demonstrate generally 
lower OCR values. (64,159). This indicates that RPTEC/TERT are much more 
metabolically active, which reflects what is seen in PTECs in vivo (160). 
Furthermore, in this chapter, RPTECs demonstrated an ability to double their 
oxygen consumption rate after mitochondrial uncoupling by FCCP when 
seeded the night before which indicates that RPTECs have a large respiratory 
reserve. A similar pattern of OCR was seen by Secker and colleagues during 
their assessment of mitochondrial activity in RPTEC/TERT (161).  
This chapter, for the first time, has described the subcellular localisation of 
ASS1 in human renal proximal tubular cells. Previously ASS1 intracellular 
expression in the kidney has been vaguely described as “cytoplasmic” (121). 
This study showed that ASS1 expression had differential subcellular 
expression dependent on the proliferative state of RPTECs. While proliferating 
cells exhibited strong perinuclear staining and staining adjacent to spindles 
during mitosis. However, differentiated cells showed diffuse staining throughout 
the cytoplasm. This provides evidence that ASS1 plays a different role in 
proliferating cells versus differentiating cells. Polarisation of RPTECs did not 
alter the expression pattern of ASS1 which remained cytoplasmic and did not 
favour the apical or basolateral side of RPTECs. Furthermore, unlike 
hepatocytes, ASS1 staining was not confined around mitochondria (162). This 
provides evidence that ASS1 could be playing a differential role in proximal 
tubular epithelial cells and hepatocytes.    
Next we investigated the effect of pro-fibrotic and pro-inflammatory signalling 
on RPTEC respiration and ASS1 expression. TGFβ is known to induce a fibrotic 
response in tubular epithelial cells and is also known to decrease mitochondrial 
activity and respiration in vitro (141). Here, RPTECs showed upregulation of a 
number of genes known to be elevated during fibrosis which is in keeping with 
other in vitro data (163). Additionally, here, it was demonstrated that TGFβ did 
not influence basal aerobic respiration but did markedly reduce the maximal 
respiratory capacity of RPTECs. It is known that TGFβ directly and indirectly 
influences respiration and ATP production in the kidney. TGFβ has been shown 
to abrogate fatty acid oxidation by targeting metabolic regulators such as 
PPARGC and also has a direct impact on mitochondrial biogenesis and ATP 
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production (64,164). This is in keeping with the TGFβ mediated decrease in 
reserve respiratory capacity seen in the chapter. A depleted spare respiratory 
capacity indicates that cells have a decreased ability to increase their ATP 
production under times of stress or increased energy demand. This could be 
as a result of decreased mitochondrial number or decreased mitochondrial 
complex activity. There is a link between a higher spare respiratory capacity 
and enhanced survival and resistance to hypoxic injury (165). Therefore, in 
RPTECs, TGFβ-mediated reduction of spare respiratory capacity may sensitise 
cells to hypoxic injury. However, despite the fact that TGFβ induces fibrotic and 
metabolic changes within RPTECs there was no effect on ASS1 expression 
after TGFβ stimulation. This indicates that ASS1 transcription is not TGFβ 
dependent and Ass1 depletion observed in vivo (chapter 3) must occur as a 
result of other signalling pathways.     
Inflammation is another common pathology that exists in many human renal 
diseases and all the mouse models of renal fibrosis used in chapter 3 
(66,166,167). TNFα levels are elevated during the progression of renal fibrosis 
in mice and patients (168). Pro-inflammatory signalling by TNFα activates the 
NF-kB signalling cascade which is a common feature of renal disease and 
fibrosis. During activation, NF-kB is released from its cytoplasmic anchor, IKK, 
which allows translocation to the nucleus and NF-kB-mediated transcription of 
the plethora of genes (169). Promoter analysis carried out here showed a likely 
NF-kB binding site in the ASS1 promoter which was confirmed by a dose-
dependent inhibition of ASS1 transcription after 72 hours of TNFα stimulation 
in RPTECs. A link between ASS1 and TNFα has been recognised, however, 
previous studies have found TNFα stimulation to upregulate ASS1 transcription 
(170). This effect was seen in ovarian cancer cell lines and no investigation 
until now has investigated how TNFα and ASS1 interrelate in the kidney. It is 
unusual that TNFα stimulation caused a downregulation in transcription as NF-
kB is normally associated with an induction of inflammatory gene transcription 
such as ICAM1 (171). However, NF-kB subunits have been implicated as 
transcriptional repressors in different settings. The p65 subunit of NF-kB was 
found to be a potent inhibitor of gastrin transcription in vitro. Chromatin 
immunoprecipitation (chIP) revealed the presence of histone deacetylase 1 and 
NF-kB p65 with nuclear corepressor on the gastrin promoter.  Together this 
complex was found to inhibit gastrin transcription (172).  Other NF-kB subunit 
combinations have also been found to act as transcriptional repressors in the 
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setting of cancer with repression of anti-apoptotic gene transcription (173). 
Future experiments should be carried out using NF-kB inhibitors to confirm that 
ASS1 transcriptional repression is mediated by NF-kB subunits and not by non-
canonical TNF induced pathways such as MAPK or JNK signalling (174).  
The consequences of TNFα stimulation on RPTEC cellular respiration was 
investigated in this chapter. In previous studies, TNFα stimulation led to 
decreased basal respiration in neuronal cells in a dose-dependent manner as 
soon as 1.5 hours after first treatment (151). Additionally TNFα stimulation led 
to a decrease in basal, ATP-linked and maximal respiration of cardiomyocytes 
after 24 hours (175). The same was seen in primary proximal tubular epithelial 
cells which exhibited decreased basal and maximal respiration after TNFα 
treatment in a dose and time-dependent manner (176). Conversely, in this 
chapter, TNFα did not exert significant inhibitory effects on basal or maximal 
respiration as measured by OCR. However, there was a small inhibitory effect 
that was not statistically significant. In future, subsequent experiments 
assessing the OCR of RPTECs should be assessed to elucidate if a larger “n” 
would lead to a significant result. Additionally, a higher dose of TNFα may be 
required in this cell model to induce a discernible decrease in respiration.  
The final upstream stimulus assessed in this chapter was hypoxia. Hypoxia is 
a key feature of renal fibrosis and progressive renal disease due to 
microvascular rarefaction and metabolic abnormalities (177). In this chapter, 
24 hours of hypoxia induced transcriptional repression of ASS1 in RPTECs but 
did not affect the transcription of ASL. The main transcription factor responsible 
for hypoxia-mediated effects is HIF1α. The same has been seen in cancer cells. 
HIF1α was found to downregulate ASS1 expression by binding to an E-box in 
the proximal region of the promoter (178).  Furthermore, HIF1α mediated 
repression of ASS1 expression is regulated by a clock protein; DEC1 (deleted 
in oesophageal cancer 1) (179). It is clear that transcription of ASS1 is 
controlled at many levels and its behaviour varies according to cell type. Future 
work should be conducted in RPTECs to elucidate exactly how TNFα and 
HIF1α exert their repressive actions on ASS1. Chromatin immunoprecipitation 
could be adopted to detect which transcription factors and inhibitors of 




The final part of this chapter addressed the consequences of ASS1 loss within 
RPTEC/TERT. ASS1 knock-down was adopted to echo ASS1 depletion within 
tubular cells in vivo.  Knock-down induced several transcriptomic changes 
within RPTECs which altered their phenotype. These effect were independent 
of depleted enzymatic activity of ASS1 but by knock-down of ASS1 protein. 
ASS1 depletion markedly induced COL1A1 expression as well as MMP2 and 
TGFBR1 expression. These transcriptomic changes are similar to those seen 
after TGFβ stimulation of RPTECs which suggests RPTECs adopt a more de-
differentiated, pro-fibrotic phenotype after ASS1 depletion. Additionally, 
increased expression of the TGFBR1 indicates that RPTECs may become 
more sensitive to TGFβ stimulation after ASS1 knock-down. However, 
HAVCR1, the marker of tubular injury, was not upregulated in ASS1 depleted 
RPTECs (180). This suggests that although ASS1 knock-down cells 
demonstrate a pro-fibrotic phenotype, this phenotypic change has not led to an 
injurious response. Further experiments should be conducted to assess the 
effects of TGFβ stimulation on ASS1 knocked-down RPTECs. In this way, one 
could investigate whether the pro-fibrotic response of RPTECs to TGFβ is 
exacerbated after ASS1 depletion.  
Further to this, cell-cell contact and tight junction genes were significantly 
depleted in ASS1 depleted RPTECs which is highly indicative of de-
differentiation. ASS1 depleted RPTECs actually responded to trypsinisation by 
losing their adhesions more quickly than control cells. This indicates that ASS1 
knocked-down cells have a less robust monolayer with fewer cell adhesions.  
Cellular senescence is a common hallmark of tubular injury progressing to renal 
fibrosis and is an important mechanism driving CKD (46). Senescence, or 
permanent cell cycle arrest, is induced by DNA damage of as a result of 
oxidative and genotoxic stresses. Senescent tubular epithelial cells are 
resistant to apoptosis and often adopt a senescence associated secretory 
phenotype (SASP), whereby cells secrete pro-inflammatory and pro-fibrotic 
factors such as TGFβ, IL-1 and IL-6. Senescence in renal tubular cells is 
characterised by altered morphology as well as increased expression of cyclin 
dependent kinase inhibitors, p16 and p21. Additionally, as senescent cells have 
lost the ability to proliferate, they stop expressing markers of proliferation such 
as KI67 (181). In this chapter, I wanted to reveal whether ASS1 depletion in 
RPTECs led to induction of senescence. ASS1 depleted RPTECs 
demonstrated downregulation of KI67, suggesting that these cells have a lower 
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proliferative capacity compared to control cells. However ASS1 depleted 
RPTECs did not exhibit increased expression of either cyclin dependent kinase 
inhibitor, p16 (CDNK2A) or p21 (CDKN1A). In fact, p21 exhibited 
downregulation in ASS1 knocked-down RPTECs. These results are somewhat 
contradictory as ASS1 depleted cells have a decreased ability to proliferate but 
do not show signs of cell cycle arrest. Furthermore, ASS1 knocked-down cells 
did not exhibit a SASP phenotype are there was no evidence of increased 
TGFB1 or IL6 transcription. These results confirm that ASS1 knock-down in 
RPTECs does not induce a senescent phenotype but could have inhibitory 
actions on proliferation.  
As TNFα was identified as an upstream modulator of ASS1 expression, I next 
sought to reveal whether knock-down of ASS1 induced a proinflammatory 
phenotype. As mentioned earlier, PTECs are capable of secreting a number of 
proinflammatory cytokines and expressing pro-inflammatory chemotactic and 
adhesion molecules which promote an inflammatory response and contribute 
to renal injury and fibrosis (182). Firstly, TNF mRNA transcription demonstrated 
downregulation in ASS1-depleted RPTECs. As recombinant TNFα induced a 
decrease in ASS1 expression it was interesting to see this reciprocal effect. 
This suggests that loss of ASS1 may exert a negative feedback loop with TNF 
signalling. Next, I wanted to investigate the effect of ASS1 knock-down on 
ICAM1 and CCL2 (MCP-1) expression. Both these cell surface molecules have 
been shown to be upregulated on tubular epithelial cells and promote the 
recruitment of immune cells which exacerbate renal injury and contribute to 
fibrosis (144). In ASS1 depleted RPTECs, ICAM1 demonstrated upregulation 
while CCL2 demonstrated downregulation compared to control cells. Moreover, 
as mentioned previously ASS1 knock-down did not induce the expression of 
IL-6. It appears that RPTECs which lack ASS1 do not exhibit many 
characteristics of a pro-inflammatory phenotype. However, ICAM1 upregulation 
is associated with increased tubular epithelial cell adhesion of lymphocytes 
whereas CCL2 upregulation is associated with recruitment of monocytes 
(71,171). This suggests that ASS1 depletion may promote tubular interactions 
with T-cells but not with monocytes. Increased ICAM1 expression has been 
reported in mouse models and in vitro models of renal disease which is 
associated with increased recruitment of T-cells in vivo (183).  Although 
understudied, T cells have been shown to play an important role in the 
progression of AKI to CKD (184). Furthermore, increased TEC adhesion of T 
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cells has been found to be an important underlying mediator of T cell mediated 
inflammation and renal injury after ischaemia reperfusion injury (185).  
Data from chapter 3 indicated that ASL, the neighbouring enzyme of ASS1, 
demonstrated a similar pattern of expression to ASS1 in murine models of renal 
fibrosis. Furthermore, Erez and colleagues have reported ASS1 and ASL to 
exist in a protein complex with NOS3 in lung tissue (186). Here, ASL expression 
was measured in ASS1 knocked-down RPTECs to reveal whether loss of ASS1 
induced the depletion of ASL. ASS1 knock-down did not influence ASL 
expression. Moreover, upstream ASS1 inhibitory stimuli, TNFα and hypoxia, 
had no effect on ASL transcription. While other studies conclude that ASS1 and 
ASL are inextricably linked, data from this chapter demonstrates differential 
upstream signalling between ASS1 and ASL which indicates, in tubular 
epithelial cells, ASS1 and ASL may play functionally distinct roles.  
The final experiment of this chapter endeavoured to reveal whether inhibiting 
the active site of ASS1 pharmacologically exerted similar effects of depleting 
ASS1 protein levels. In this way we could reveal whether the disturbance of the 
amino acid, citrulline, was responsible for the downstream effects of ASS1 
knock-down or whether absence of ASS1 protein itself induced these effects. 
Pharmacological inhibition of ASS1 activity by MDLA led to a dose dependent 
increase of ASS1 and ASL transcription. This indicates that inhibition of 
citrulline-aspartate ligation by ASS1 led to an increase in citrulline and 
aspartate which resulted in upregulation of ASS1 and ASL to rectify the amino 
acid imbalance. MDLA has been shown previously to increase and decrease 
levels of citrulline and argininosuccinate respectively (187). In future, the levels 
of citrulline and aspartate as well as arginine should be assessed in the media 
of MDLA-treated RPTECs to confirm this effect in this cell type. Subsequently, 
the expression of COL1A1 was assessed to determine if MDLA led to the 
marked upregulation seen after ASS1 knock-down. COL1A1 was chosen as to 
test this hypothesis as it was the gene that was most markedly upregulated 
after ASS1 knock-down and it was very tightly negatively correlated with ASS1 
expression. However MDLA treatment did not induce an upregulation of 
COL1A1. In fact COL1A1 demonstrated evidence of downregulation after 
MDLA treatment. Although this experiment needs to be repeated once more in 
order to detect if any of these changes are statistically significant, it provides 
convincing evidence that inhibition of ASS1 activity does not exert the same 
effects as ASS1 knock-down. 
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The data from this chapter has confirmed that ASS1 is highly expressed in 
RPTECs and downregulation of transcription is achieved by both TNFα and 
hypoxia but not by TGFβ. TNFα and hypoxia are important hallmarks of renal 
fibrosis and their inhibitory effects on ASS1 expression mirror what is seen in 
vivo. Replicating ASS1 loss in RPTECs led to phenotypic changes that reflect 
a de-differentiated, pro-fibrotic cell with some capacity for pro-inflammatory 
signalling. Furthermore, these effects are independent of urea cycle amino acid 
disturbance. This project for the first time has elucidated loss of ASS1 in 
RPTECs may be important in linking proinflammatory and hypoxic signalling 













Chapter: 4 Chapter 5- Phenotype of Ass1 tubular 
knockout mice 
4.1 Introduction 
4.1.1 Cre-lox system  
Cre-lox technology is a widely used biological tool capable of deleting, inverting 
or translocating genetic material by utilising the ability of the Cre recombinase 
enzyme to recognise specific DNA sites, termed Lox. This genetic engineering 
technology has harnessed these tools from the bacteriophage P1. Cre 
recombinase functions to recombine two LoxP sites surrounding a specific 
portion of DNA (188). Cre recombinase can be adapted to serve different 
purposes including inducible Cre, promoter specific Cre and fluorescent Cre. 
Inducible Cre requires stimulation by a drug, often tamoxifen, in order to 
activate the enzymatic activity of Cre (189). Promoter specific Cre results in 
Cre only being expressed in cell types which express a specific promoter and 
thus Cre recombination only occurs in these cells. Finally, fluorescent Cre 
comprises a fluorescent tag fused to Cre which emits a signal upon successful 
activation of Cre and is used as a reporter (190). Floxed constructs include two 
LoxP sites flanking a region of genomic DNA. Design of these constructs can 
result in activation of Cre mediated gene expression, Cre-mediated gene 
knockout and also Cre-mediated gene switching. As DNA constructs can be 
easily introduced into the mouse genome in a heritable manner, the Cre-Lox 
system can now be used to great effect in transgenic mice by crossing a Cre 
expressing mouse with a mouse expressing LoxP flanked DNA of the desired 
target gene (191,192). The Cre-Lox system was employed in this project to 
allow tubular specific inducible knockout of Ass1.    
4.1.2 Pax8 CreERT2 mouse  
Several kidney specific Cre expressing mouse lines are used in renal research. 
As the kidney is composed of many different cell types, it is important to choose 
the Cre expressing mouse under the control of the correct promoter which will 
result in genetic manipulation in the correct cell type. For example, Cre 
activation under the regulation of the podocin promoter results in recombination 
occurring specifically in the podocytes of the kidney (193). Additionally, Cre 
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recombination occurs specifically in the collecting duct of the kidney with the 
aquaporin-2 Cre mouse line (194).  
In this project, a tubular specific Cre expressing mouse was required and the 
Pax8-CreERT2 transgenic mouse was utilised. This transgenic mouse line was 
generated to use the Pax8 promoter to direct Cre recombination in tubules of 
the kidney. Pax8 is expressed in the proximal and distal tubules as well as the 
collecting duct, therefore Cre is expressed in all segments of the tubule. 
Additionally the Pax8-CreERT2 mouse is inducible by tamoxifen administration. 
To generate this mouse, a fusion protein of the Cre DNA sequence and a 
mutant form the oestrogen receptor (ERT2) which only contains the ligand 
binding domain was constructed. This allows temporal control of Cre activation 
with the administration of a ligand which binds the oestrogen receptor: 
tamoxifen. Administration of tamoxifen triggers the release of bound ERT2 which 
then is translocated to the nucleus and initiates recombination. Inducible Cre is 
especially important to avoid targeting the gene of interest during development 
if the genetic knockout is embryonically lethal (189,195).  
4.1.3 Ass1 floxed mouse 
Genetic manipulation of the Ass1 gene has been adopted in several different 
mouse lines. Global genetic deletion of Ass1 was achieved by disruption of 
exon 4 of the Ass1 gene which resulted in 0% enzyme activity in the liver. Mice 
missing the Ass1 gene survived gestation but did not live more than 2 days 
after birth due to citrullinemia and hyperammonemia. This mouse was 
generated to mirror what is seen in severe neonatal citrullinemia type I (CTLN1) 
(196). Other mouse lines with naturally occurring mutations have been 
investigated in the setting of CTLN1 including the fold mouse and the bar 
mouse. These Ass1 hypomorphic mice display less severe symptoms 
compared to the global knockout and have been investigated to elucidate the 
mechanisms ongoing in patients with CTLN1 (197). The only available floxed 
Ass1 transgenic mouse was generated by the Lamers group. They engineered 
LoxP sites to flank exon 13 of the Ass1 gene. Non-recombined Ass1 flox/flox 
mice develop normally and exhibit no phenotype. However, upon 
recombination by Cre in intestinal enterocytes, Ass1 was entirely knocked out. 
This group showed that deletion of exon 13 of the Ass1 gene was sufficient to 
knock Ass1 out in the organ of interest (198). 
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Therefore, crossing the Pax8-CreERT2 mouse with the Ass1 flox/flox mouse 
would result in knockout of Ass1 specifically in the tubules of mice after 
tamoxifen administration. This would allow interrogation into the spatiotemporal 
role that Ass1 plays within the tubular compartment of the kidney, while 
circumventing Ass1 knockout in any other cell type or organ (Figure 5.1). 
 
Figure 4.1: Schematic of Pax8CreERT2 and Ass1 flox/flox breeding to yield tubular knockout of 
Ass1 in the Pax8Cre x Ass1 fl/fl mouse 
   
4.1.4 Ai14 tdTomato reporter mouse 
It is important to confirm site-specific Cre recombination when using a specific 
promoter driven Cre mouse line. The Cre mouse in question should be crossed 
with a reporter mouse to allow detection of Cre recombination in the desired 
cell type only, without any off target expression (192). Reporter mice often 
express fluorescent proteins which are activated upon Cre recombination. The 
Ai14 tdTomato mouse is created using a construct with a LoxP flanked stop 
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codon upstream of the tdTomato reporter. Upon introduction into a mouse and 
recombination by Cre, the loxP sites recombine and the stop codon is excised. 
This results in constitutive activation of the tdTomato reporter (199). This red 
reporter can be visualised in tissue of interest using fluorescent activated cell 
sorting and immunostaining (Figure 5.2). 
 
Figure 4.2: Schematic of Pax8CreERT2 cross with Ai14 mouse to yield Pax8 driven tdTomato 
reporter mouse 
  
4.1.5 Aslneo/neo hypomorphic mouse        
ASS1 and argininosuccinate lyase (ASL) are linked in the urea cycle and ASS1 
provides arginine as a substrate for ASL. Argininosuccinate lyase deficiency or 
ASL-D is a heritable disorder which results in the enzyme, ASL, functioning 
incorrectly (see Section 1.1.15). The Aslneo/neo hypomorph mouse (Asl mutant) 
was developed to explore the phenotype of ASL-D while avoiding the neonatal 
lethality associated with Asl global knockout. These mice were developed by 
introducing a neomycin cassette into intron 9 of the murine Asl gene. This 
results in 25% residual mRNA, 25% residual protein and 16% enzymatic 
activity of ASL. These mice survive until 3 weeks of age before multi-organ 
failure ensues resulting in death. These mice display elevated circulating levels 
of argininosuccinic acid, citrulline and ammonia. Asl mutant mice display a 
number of pathological phenotypes affecting most organs. The renal 
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phenotype of these mice has not been extensively investigated however Asl 
mutants exhibit elevated blood pressure, decreased creatinine clearance and 
smaller glomeruli compared to wildtype counterparts (90,186). However, the 
tubular phenotype of these mice is relatively unexplored.   
121 
 
4.2 Aims and Hypothesis 
The hypothesis of this Chapter was as follows: 
Tubular specific deletion of Ass1 using a transgenic mouse model will induce 
some degree of tubular dysfunction and fibrosis.   
The aims of this Chapter are as follows: 
- To ascertain if Ass1 is differentially expressed in the kidney of the 
Aslneo/neo hypomorphic mouse and if there is a renal phenotype in 
these mice.  
- To validate the site-specific expression of Cre under the control of the 
Pax8 promoter within the tubular compartment of the kidney only 
- To assess any effects of deleting one copy of Ass1 in the Pax8Cre-
Ass1 wt/flox heterozygous mouse 
- To achieve tubular knockout of Ass1 using the Pax8Cre x Ass1 
flox/flox homozygous transgenic mouse 
- To investigate the renal phenotype of the Pax8Cre x Ass1 flox/flox 
transgenic mouse   
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4.3 Results  
4.3.1 Renal phenotype of Asl mutant mice 
Some patients with ASL (argininosuccinate lyase) deficiency have been 
reported to exhibit decreased renal function and elevated levels of serum 
creatinine. The Aslneo/neo mouse is a transgenic mouse which expresses a 
mutant copy of the Asl gene which results in 25% residual protein expression. 
Kidney tissue from 3 week old Asl mutant mice was kindly donated by Julien 
Baruteau from University College London.  
Gene expression analysis was carried out on renal tissue from Asl mutant mice 
and wildtype littermate controls. Expression of Asl was depleted as expected, 
however, Ass1 mRNA was also depleted to the same extent. Additionally 
expression of kidney injury molecule 1 (Havcr1) was significantly elevated 
indicating tubular injury (p<0.01, Student’s t-test) (Figure 5.1). The relative 
mRNA expression of Col1a1, Col3a1, Tnf and Tgfbr1 were also assessed in 
this cohort and there were no changes in expression between Asl mutants and 




Figure 4.3: Renal phenotype of Aslneo/neo hypomorph mice. Relative mRNA expression of Asl, 
Ass1 and Kidney injury molecule 1 in kidney tissue from Aslneo/neo hypomorph mice (n=3) 
compared to Wildtype mice (n=3). Relative expression was calculated from ΔΔcT normalized to 
Ppia housekeeper and compared to wildtype (WT). * and ** represent p<0.05 and 0.01 
respectively compared to control by Student’s t-test. 
 
4.3.2 Pax8 Cre recombination is specific to renal tubules 
Using the Pax8CreERT2 mice allowed selective, tamoxifen inducible 
recombination of Cre only in cells that express Pax8. In order to validate the 
expression profile of Pax8 specifically in the kidney, Pax8Cre mice were 
crossed with Ai14 tdTomato reporter mice. 
The offspring of these mice expressing Cre were given tamoxifen (n=4) or 
vehicle (n=4) at 6 weeks of age. Two weeks after tamoxifen administration, 
mice were culled in order to assess the extent of tdTomato positive cells in 
kidneys and livers in both groups. Flow cytometry was adopted to assess the 
number of tdTomato-positive cells which indicated successful Cre 
recombination. A gating strategy was set up to include only live single cells 
which were DAPI-negative (UV450). Subsequently the percentage of live cells 
which were tdTomato-positive were assessed (Figure 5.4). Unstained controls 
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and Pax8Cre x Ai14 kidneys treated with vehicle exhibited very few tdTomato-
positive cells as expected. The Pax8Cre x Ai14 kidneys treated with tamoxifen 
showed a wide-ranging level of recombination with tdTomato-positive cells 
varying from 4.47% to 66.9% (Figure 5.5). 
 
Figure 4.4: Gating strategy for Pax8Cre x Ai14 kidney cells. Kidney cell suspensions were 
analysed by flow cytometry to determine single, live cells which expressed tdTomato in vehicle 




Figure 4.5: Flow cytometry contour plots of tdTomato positivity in Pax8Cre x Ai14 kidney cells. 
Representative plots showing the percentage of live tdTomato-positive kidney cells (in black box) 
in Pax8Cre x Ai14 mice administered with vehicle control or tamoxifen. Positive staining was 




In order to characterise which kidney cells exhibited Cre recombination, frozen 
tissue was sectioned and visualised using a confocal microscope. Cre 
recombination shown by tdTomato expression was confirmed to have site 
specificity in the tubular compartment only and was absent in the glomeruli. 
There was no positive staining found in hepatocytes of the liver (Figure 5.6). 
Imaging was performed by Dr Duncan Humphries.  
 
 
Figure 4.6: Validation of site specific recombination with Pax8Cre-ERT2. Cre recombination was 
induced by 3 doses of 200mg/kg tamoxifen administration in Pax8Cre x Ai14 tdTomato mice. 




4.3.3 Pax8Cre x Ass1 wt/flox heterozygotes express normal levels of ASS1 
with no measurable phenotype 
Pax8Cre x Ass1 wt/flox heterozygotes were assessed for any 
haploinsufficiency effect as they should express only one copy of the Ass1 
gene. A time course study was carried out to investigate whether heterozygotes 
display a discernible phenotype. Cre recombination was induced by 
administration of tamoxifen at 6 weeks of age and three cohorts were allowed 
to age for 2, 4 and 6 weeks. These mice were compared to littermates which 
received a vehicle control instead of tamoxifen. 
Tamoxifen-induced heterozygous Pax8Cre x Ass1 wt/fl mice demonstrated no 
difference in body weight, heart, liver or kidney weight compared to vehicle 
control mice (Figure 5.7). Furthermore, there was no significant difference in 
ASS1 protein expression (p=0.3 and p=0.0971 at 2 weeks and 4 weeks 
respectively, Student’s t test)) or mRNA expression in heterozygous mice 
compared to vehicle control mice at any time point. Additionally, there was no 
significant difference in Asl mRNA expression between each group (Student’s 




Figure 4.7: Body and organ weights of tubular Ass1wt/fl heterozygous knockout mice. (A) 
percentage gain in body weight, (B) kidney mass, (C) heart mass and (D) liver mass of Pax8Cre 
x Ass1 wt/fl mice with (Ass1 wt/fl) and without (Veh control) tamoxifen administration. Organ 





Figure 4.8: Pax8 Cre x Ass1 fl/wt heterozygous mice do not exhibit haploinsufficiency. Western 
blot was carried out on kidney lysates from tamoxifen induced and vehicle control Pax8 Cre- 
Ass1 fl/wt mice at 2 weeks (A-B) and 4 weeks (C-D) after treatment with tamoxifen or vehicle. 
Protein expression was measured using the Licor system and normalized to GAPDH 
housekeeper. Relative mRNA levels of Ass1 (E) and Asl (F) in kidneys of tamoxifen induced 
Pax8 Cre- Ass1 fl/wt  (n=18) or  vehicle control Pax8 Cre- Ass1 fl/wt mice (n=12) at 2 weeks, 4 
weeks and 6 weeks after treatment with tamoxifen or vehicle. Relative expression was calculated 
from ΔΔcT normalized to Gapdh housekeeper and compared to vehicle control group. 
 
Expression of KIM1 (Havcr1) was assessed to determine whether there was 
any kidney injury in these transgenic mice. Havcr1 expression was consistently 
very lowly expressed in all 3 groups indicating no evidence of tubular injury by 
heterozygous expression of Ass1 or tamoxifen administration.  
Finally, blood pressure was measured in the 6 week cohort of Pax8Cre x Ass1 
wt/fl mice with or without tamoxifen administration. There was no significant 
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difference in mean arterial pressure between each group (p= 0.1665, Student’s 
t-test) (Figure 5.9).  
 
Figure 4.9: Mean arterial pressure of Pax8Cre x Ass1 wt/fl mice. Mean arterial pressure was 
calculated from systolic and diastolic blood pressure from tamoxifen induced Pax8Cre x Ass1 
wt/fl and vehicle control mice.  
 
4.3.4  Tubular specific homozygous knockout of Ass1 
Pax8Cre x Ass1 flox/flox homozygous knockouts (KO) were bred and 
recombination of Cre was induced with 200mg/kg tamoxifen at 6 weeks of age. 
10 weeks after tamoxifen administration, Pax8Cre x Ass1 flox/flox mice were 
culled and their organs harvested and compared to their Pax8Cre x Ass1 wt/wt 
wildtype (WT) littermates. Due to time constraints and delays with breeding, 
this cohort was made up of a small number of animals which were a mixture of 
male and female mice (Table 5.1). Furthermore there were not enough mice of 
the correct genotype in order to compare against as vehicle control group. Due 
to the small group size, statistics could not be carried out on data generated 
from this study.  
Genotype Males Females Total 
Pax8 Cre- Ass1 wt/wt (WT) 1 2 3 
Pax8 Cre- Ass1 fl/fl (KO) 2 2 4 
Table 4.1: Number of male and female mice in each experimental group  
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Kidney cortex lysates were prepared from WT and KO mice and ASS1 protein 
measured in both groups by western blot. ASS1 was detectable in all mice with 
only female KOs exhibiting depleted ASS1 protein compared to WT controls 
(Figure 5.10).   
 
Figure 4.10: ASS1 protein expression in tubular Ass1 KO and controls. (A) Western blot analysis 
showed ASS1 protein levels in kidney lysates of male and female tamoxifen induced Pax8Cre x 
Ass1 fl/fl mice (KO) and Pax8Cre Ass1 wt/wt (WT) controls. (B) Protein levels were normalized 
to total protein content of the membrane and quantified using the Licor system and ImageStudio. 
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At sacrifice, kidney and heart weights were recorded. Male mice exhibited 
heavier organs even when normalized to tibia length. KO mice did not 
demonstrate marked differences in kidney or heart weight compared to WT 
when sexes were pooled. However, when males and females were analysed 
separately, there was a trend for increased heart weight in females (Figure 
5.11). 
 
Figure 4.11: Organ weights of tubular Ass1 knockout mice. Organ weights were recorded at 
sacrifice, 10 weeks after tamoxifen administration of Pax8Cre x Ass1 fl/fl and wildtype controls. 
Organs were weighed using the same set of sensitive scales throughout and normalized to tibia 
length. 
Gene expression analysis using qPCR was carried out from kidney cortex of 
WT and KO mice. mRNA expression of Col1a1, Cubn, Cdh1, Tgfrb1 and 
Havcr1 were assessed and there were no differences in expression between 




Figure 4.12: Gene expression analysis of tubular Ass1 knockout cortex. Relative mRNA levels 
of Col1a1 (A), Cdh1 (B), Asl (C), Cubn (D), Tgfb1 (E), Tgfbr1 (F) and Havcr1 (Kim1) (G) were 
assessed in kidney cortex of tamoxifen induced Pax8Cre x Ass1 fl/fl mice  (n=4) and  wildtype 
littermate controls (n=3). Relative expression was calculated from ΔΔcT normalized to Gapdh 





4.3.5 Circulating urea cycle metabolites in tubular Ass1 knockout mice  
As ASS1 is part of the urea cycle, levels of circulating amino acids present in 
the urea cycle were assessed from WT and KO blood. Whole blood was 
collected from WT and KO mice 10 weeks after induction of Cre recombination 
by tamoxifen. Drops of whole blood were spotted on Guthrie cards and sent to 
University College London for processing by Julien Baruteau using mass 
spectrometry (90). 
Circulating citrulline showed no discernible difference between WT and KO 
when the sexes were pooled together. However upon inspection of males and 
females analysed separately, circulating citrulline was upregulated in female 
KOs compared to female WTs and males. Levels of circulating arginine 
demonstrated no difference between WT and KO but female KO levels were 
elevated compared to female WT. Circulating argininosuccinic acid levels were 




Figure 4.13: Circulating amino acid levels in tubular Ass1 knockout. Mass spectrometry was 
carried out on dried blood spots from Pax8 Cre x Ass1 fl/fl (n=4) and wildtype littermate controls 
(n=3) both treated with tamoxifen. Male and female data shown separately. (A-B) Citrulline, (C-




4.3.6 Urine and serum markers of chronic kidney disease in tubular Ass1 
knockout mice 
Several measures taken in urine and serum are commonly used to assess the 
progression of CKD in mice and also patients. Serum creatinine is the most 
commonly used measure of renal function and is used to calculate the 
estimated GFR. High creatinine values indicate decreased filtering of the 
kidney which is evidence of CKD (200). The levels of circulating creatinine were 
low in this cohort and the spread of creatinine values were large. There were 
no differences in serum creatinine between WT and KO mice. Additionally, 
serum urea was assessed, which is another common measure used in patients 
with CKD, referred to a blood urea nitrogen (BUN) (201). There were no 
differences in serum urea between WT and KO mice (Figure 5.14). 
 
Figure 4.14: Serum creatinine and urea measurements in tubular Ass1 knockout mice. Serum 
was extracted from whole blood which was taken at termination from Pax8Cre x Ass1 fl/fl (n=4) 
and wildtype littermate controls (n=3) 10 weeks after tamoxifen administration. Creatinine levels 





Urine albumin is also used to detect CKD. Albuminuria is present in patients 
with CKD and albumin should be absent from the urine in healthy individuals. 
Albuminuria is also present in mice with renal dysfunction as seen in the 
subtotal nephrectomy model in Chapter 3 of this thesis. This cohort of mice all 
demonstrated undetectable levels of albumin in their urine.  
4.3.7 Electrolyte levels in tubular Ass1 knockout mice 
Ass1 is highly expressed in tubules and tubular dysfunction can impact 
electrolyte balance including imbalance of sodium, potassium and chloride. 
Additionally ASL deficiency is associated with hypokalaemia and tubulopathy. 
The levels of sodium, potassium and chloride were assessed in serum and 
urine from our cohort of Ass1 tubular KO mice and WT mice.  
Serum sodium concentration was found to be consistent in WT and KO mice. 
Additionally there was no difference between males and females. Serum 
potassium was unchanged between WT and KO mice but females 
demonstrated lower serum potassium concentrations that males. Finally, 
serum chloride concentrations were consistent in male and female WT and KO 




Figure 4.15: Serum electrolyte levels in tubular Ass1 knockout mice. Serum was extracted from 
whole blood taken at termination 10 weeks after tamoxifen administration of Pax8Cre x Ass1 fl/fl 
mice (KO) and Pax8Cre x Ass1 wt/wt (WT) controls. Serum electrolytes were assessed using 
the Spotchem ELTM electrolyte analyser. Data is shown with sexes pooled (A) and separated (B). 
  
Levels of urinary sodium, potassium and chloride can be used to calculate the 
urine anion gap which indicates the ability of kidney to acidify urine and is an 
indicator of tubular function. The calculation to establish the urine anion gap is: 
 Na+ + K+ − Cl− 
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The levels of these electrolytes were measured in the urine of WT and KO mice 
to ascertain any differences in the urine anion gap. There were no appreciable 
differences in the urine anion gap in WT or KO mice. However there was a 
trend for female mice to exhibit is slightly lower urine anion gap (Figure 5.16).  
 
Figure 4.16: Urine anion gap in tubular Ass1 knockout mice. Mice were singly house and urine 
was collected using metabolic cages 10 weeks after tamoxifen administration in Pax8Cre x Ass1 
fl/fl (KO) mice (n=4) and wildtype littermate controls (WT) (n=3). Urine electrolytes were 
assessed using the Spotchem ELTM electrolyte analyser. Data is shown with sexes pooled (A) 
and separated (B). 
4.3.8 Blood pressure in tubular Ass1 knockout mice 
Ass1 is involved in the urea cycle which produces arginine within the kidney. 
Arginine can be utilised by nitric oxide producing cells for nitric oxide synthase 
in order to produce nitric oxide which exerts a number of effects including 
vasodilation. Therefore, we investigated whether blood pressure was 
influenced by tubular knockout of Ass1. Systolic and diastolic blood pressure 
was assessed using the tail-cuff method in WT and KO mice 8 weeks after 
tamoxifen administration. Animals were habituated to blood pressure 
measuring before final measures were taken. Mean arterial pressure (MAP) 
was calculated from systolic (SBP) and diastolic blood pressure (DBP). 
Mean arterial pressure exhibited a trend to increase in KO mice compared to 
WT mice. Additionally female WT mice demonstrated a trend for decreased 




Figure 4.17: Mean arterial blood pressure of Ass1 KO mice. Mean arterial pressure was 
calculated from systolic and diastolic blood pressure from tamoxifen induced Pax8Cre x Ass1 
fl/fl Ass1 knock out mice (KO) and compared to littermate wildtype controls (WT). Data is shown 
with sexes pooled (A) and separated (B).  
 





The final chapter of this thesis sought to reveal the effects of knocking out Ass1 
specifically within tubular epithelial cells of the kidney. In this way I sought to 
investigate whether tubular deletion of Ass1 had any impact on tubular function, 
tubular injury status and finally whether tubular Ass1 knock-out promoted 
fibrogenesis. In the short time available to me I investigated a small cohort of 
tubular Ass1 knock-out males and females. This preliminary study 
demonstrated that Ass1 deletion was more effective in tubules of female mice. 
Successful tubular knock-out of Ass1 led to a trend for increased circulating 
citrulline levels and may have increased mean arterial blood pressure. Other 
functional parameters measured in this study such urine albumin and 
electrolyte levels showed no discernible difference between Ass1 tubular 
knock-out and controls. Furthermore, assessment of tubular injury by Havcr1 
(Kidney injury molecule 1) mRNA expression demonstrated no measurable 
tubular injury in tubular specific Ass1 knockout mice. Gene expression analysis 
revealed there was no upregulation of genes commonly associated within 
fibrosis. For the first time, this study explored the effect of tubular deletion of 
Ass1. Although there was no strong evidence for renal pathological changes in 
these transgenic mice at baseline in this underpowered study, there is much 
further work to be carried out to investigate the role Ass1 plays in the 
development of fibrosis and the progression of CKD.   
This chapter also included some preliminary data investigating the effects of 
global Asl hypermorphism on the kidney. As well as the expected depletion of 
Asl mRNA expression, Asl mutant mice also demonstrated a pronounced 
downregulation of Ass1 mRNA within the kidney. This was unexpected as 
studies investigating lung tissue of Aslneo/neo mutant mice found ASS1 protein 
levels to be consistent in mutant and wildtype mice (186). This chapter only 
investigated mRNA levels of Ass1 in Aslneo/neo mutant mice kidney tissue. 
Therefore, a western blot or immunostaining of ASS1 protein levels should be 
conducted in renal tissue to ensure that ASS1 protein levels are diminished as 
well as mRNA levels. This chapter also demonstrated that Havcr1 (Kidney 
injury molecule 1) was significantly upregulated in Aslneo/neo mutant mice at only 
3 weeks of ages. This indicates that global depletion of Asl resulted in tubular 
injury. KIM1 is a commonly utilised marker of tubular injury and therefore other 
assessments of renal injury should be carried out in these mice. Other groups 
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have carried out some assessment of kidney function in Aslneo/neo mutant mice 
including revealing elevated serum creatinine levels and histological 
identification of smaller glomeruli compared to wildtype controls (186). 
However, more detailed assessment of renal function should be assessed 
including assessment of albuminuria, measurement of glomerular filtration rate 
and identification of fibrosis.  
One caveat of using Aslneo/neo global mutant mice to identify pathological 
changes in kidneys is that these mice exhibit multi-organ failure. They also 
exhibit elevated levels of circulating ammonia which is in itself toxic to the 
kidneys and would explain upregulated Havcr1 expression seen in this chapter. 
To avoid this caveat, the effect of Asl depletion should be investigated in the 
kidney in isolation. Our collaborators, Baruteau and colleagues, achieved 
correction of hyperammonemia in Aslneo/neo mutant mice by replacing the faulty 
Asl gene with a fully functional copy of Asl in the liver (90). As the liver is the 
main site of ammonia removal by the urea cycle, this was sufficient to prevent 
multi-organ failure and extend the lifespan of these treated mutant mice. As the 
viral vector they used to deliver Asl to the liver should not enter the kidneys, it 
would be interesting to see if evidence of renal failure persisted in mice which 
had hyperammonemia corrected. Indeed, elevated levels of citrulline seen in 
Aslneo/neo mutant mice was not corrected in mice with hepatic Asl gene transfer. 
If possible, further work should be carried out to explore the renal phenotype 
and manifestation of fibrosis in Aslneo/neo mutant mice with hyperammonemia 
and multi-organ failure corrected. This could elucidate the role that Asl and 
Ass1 play in tandem in the context of renal fibrosis.  
To circumvent the lethal phenotype of global Ass1 deletion, conditional gene 
targeting was adopted to ablate Ass1 expression selectively in tubular epithelial 
cells. The Pax8CreERT2 x Ass1 flox/flox mouse was adopted to be able to 
achieve conditional knockout of Ass1 within Pax8 expressing tubules 
(195,198). An advantage of using this mouse was that recombination of Cre 
was inducible by tamoxifen administration. In this way Ass1 knockout was 
controlled spatiotemporally and this avoided manipulating Ass1 expression 
during development. 
Initially we investigated whether heterozygous deletion of Ass1 in tubules 
induced any renal phenotype. This would indicate whether there was a gene 
dosage effect of partial Ass1 deletion. Studies investigating the effect of Mmp2 
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deletion found that, in the setting of ureteric obstruction, Mmp2 knockout 
significantly prevented renal fibrosis. Moreover, heterozygous mice with only 
one remaining Mmp2 allele (Mmp2+/-) also demonstrated effective protection 
against fibrosis to a similar extent as homozygous knockout mice (Mmp2-/-). 
The authors concluded an important gene dosage effect of Mmp2 deletion 
(202). In this chapter, the effect of tubular specific heterozygous Ass1 knock-
out (Pax8Cre x Ass1 wt/fl) was investigated. There was no significant depletion 
of renal ASS1 protein at any of the time points investigated after tamoxifen 
administration. Furthermore, there was no difference between groups when 
assessing Havcr1 expression or blood pressure. Therefore, the heterozygous 
Pax8Cre Ass1 wt/fl mice did not exhibit effective renal Ass1 deletion and there 
was no evidence of tubular injury or vasoconstriction.  
After a gene dosage effect of Ass1 partial deletion was disproved, full knock-
out of Ass1 in tubular epithelial cells was carried out with the Pax8Cre x Ass1 
fl/fl mouse. This study found that tubular knock-out of Ass1 was more efficient 
in females than in males. There could be several reasons for this including 
inefficient activity of Cre, incorrect induction of Cre recombinase by tamoxifen 
or inefficient recombination of loxP sites. It has been reported that in some Cre 
expressing models, Cre recombination can be more or less efficient depending 
whether the Cre was transmitted from the male or female parent (192). 
However, in this study, paternal/ maternal Cre transmission is irrelevant as all 
mice in this cohort were littermates with the same parents. Until a larger cohort 
of mice is investigated, it will not be clear whether the more successful knock-
out of Ass1 in females compared to males is a true biological effect or just 
chance. Furthermore, as evidenced by using the Pax8Cre x Ai14 reporter 
mouse, Cre recombination was highly variable and inadequate in some mice. 
This indicates that Cre recombination in the Pax8CreERT2 mouse could be 
inefficient and therefore larger groups of mice should be investigated in future 
to account for this. Another explanation for inefficient Cre recombination is that 
the dose of tamoxifen used to induce recombination was not sufficient. Mice in 
this study were treated with 200mg/kg tamoxifen for three alternate days. 
Future studies could investigate the effect of elevating the dose of tamoxifen 
and also could investigate the result of increasing the dosing regimen to every 
day for 5 days.    
This study showed that in female mice, in which tubular Ass1 knock-out was 
successful, there was a trend for increased circulating citrulline. As citrulline is 
143 
 
a substrate which the ASS1 enzyme anabolises, it fits that citrulline levels 
would be elevated due to decreased availability of ASS1 to catalyse the 
conversion of citrulline to argininosuccinic acid. When Ass1 was knocked out 
in enterocytes using the same Ass1 flox/flox mouse by Marion and colleagues, 
they also found citrulline levels to be elevated. (198). Elevated citrulline seen 
here, echoes what is seen in patients and animal models of CKD as assessed 
using metabolomics. Both patients with CKD and animal models of CKD 
demonstrate increased concentration of citrulline in the blood (107,111). As 
discussed in Chapter 1, elevated circulating citrulline seen in patients with CKD 
was a driver to investigate the role of Ass1 in the kidney. Therefore is it positive 
to see that a modest decrease in renal ASS1 expression seen in females of 
this cohort is sufficient to elevate circulating citrulline.      
The urine levels of sodium, potassium and chloride were measured to assess 
any evidence of metabolic acidosis in tubular specific Ass1 knock out mice. 
Metabolic acidosis is common in patients with CKD and manifests as 
decreased ammonium (NH4+) excretion which correlates with decreased renal 
filtration and reabsorption and late stage CKD (203). The urine anion gap is 
calculated from levels of Na+, K+ and Cl- and is used clinically as a surrogate 
measure of NH4+ excretion in the urine (204). A high urine anion gap is 
correlated with decreased ammonia excretion while a low urine anion gap is 
correlated with bicarbonate loss. These observations occur in renal tubular 
acidosis type 1 and type 2 respectively and can also be measured in mice 
(205). As tubular dysfunction can contribute to ion imbalance and acid 
imbalance, it was important to ascertain if there were any changes in the urine 
anion gap in tubular specific Ass1 knock-out mice to reveal if these mice had 
tubular dysfunction. In this cohort there was no difference in the urine anion 
gap between knock-outs and wildtype controls. This indicates that in the 
unchallenged state, tubular specific knock-out of Ass1 does not impact 
ammonia excretion or bicarbonate loss. This indicates that tubular mediated 
acid/base balance has stayed intact.  
Serum levels of sodium, potassium and chloride ions were measured to assess 
if renal transport of electrolytes was affected in tubular specific Ass1 mice. 
Furthermore, ASL deficient mice have been reported to exhibit hypokalaemia 
which has been attributed to a tubulopathy (131). Serum potassium was 
measured in our cohort to ascertain whether a similar effect could be seen. 
Levels of sodium, potassium and chloride ions in KO and WT groups were 
144 
 
unchanged. However, it was observed that female mice exhibited lower levels 
of potassium ions compared to males which is an observation also seen in 
human studies (206). These results demonstrate that tubular transport of these 
ions is unaffected by tubular specific knock out of Ass1 in the basal state after 
10 weeks.  
Blood pressure was assessed in this cohort of tubular specific knock-out mice 
to determine whether deletion of Ass1 within the tubular compartment 
influenced mean arterial pressure. There was an observable trend for an 
increase in blood pressure within the KO group compared to the WT group. 
This effect was most pronounced in females which had demonstrated depletion 
of renal ASS1 protein expression. This is in line with what is seen in mice 
globally deficient in ASL protein. Erez and colleagues showed blood pressure 
to be significantly increased in Aslneo/neo hypomorph mice compared to wildtype 
controls. The authors attributed this to depleted availability of arginine for use 
by nitric oxide synthase. However as ASL was mutated globally, the impact of 
ASL deficiency specifically within the kidney could not be investigated (186). 
ASS1 functions upstream of ASL and provides argininosuccinic acid as a 
substrate for ASL to yield arginine. Furthermore, the kidney is the main site of 
arginine production in the body. Therefore, lack of tubular ASS1 would 
theoretically deplete renal arginine levels which could impact nitric oxide 
synthase mediated production of nitric oxide. As nitric oxide is a potent 
vasodilator it could be hypothesised that tubular deletion of Ass1 depletes 
available nitric oxide resulting in vasoconstriction and elevated blood pressure. 
This is important in the context of CKD as hypertension and CKD are 
inextricably linked (207). While hypertension is one of the most important risk 
factors for developing CKD, hypertension can also occur as a result of CKD 
(208). Additionally, CKD with hypertension vastly increases the risk of a patient 
experiencing a cardiovascular effect such as myocardial infarction or stroke 
(209).   
Subsequent experiments with a larger cohort of male and female tubular 
specific Ass1 knockout mice should be carried out to determine if blood 
pressure is statistically significantly elevated in KO mice compared to WT and 
a vehicle control. If this is the case, the circulating levels of nitrate and nitrite 
should be assessed as an indirect method of assessing nitric oxide levels in 
the blood (210). This could confirm if tubular specific knockout of Ass1 directly 
impacts available circulating nitric oxide resulting in elevated blood pressure. 
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Furthermore, if blood pressure elevation is proven to be a pathological effect of 
Ass1 deletion in tubules, then an improved method of blood pressure 
assessment should be used. The tail cuff plethysmography method used here 
has several disadvantages. Physical handling and restraint of mice can induce 
stress and therefore increased blood pressure. The tail cuff method involves 
extensive handling, restraint and also mild discomfort for the animals which is 
likely to elevate their heart rate and blood pressure. Telemetry is now termed 
the “gold standard” for blood pressure assessment over time and is achieved 
by an implantable device that can measure blood pressure in undisturbed 
animals with consistent measures taken automatically over time. Telemetry 
provides superior, more accurate measures of blood pressure but these 
devices are expensive and implantation of the device requires surgical 
expertise (211).       
It was hypothesised that deletion of Ass1 in tubular epithelial cells would induce 
aspects of renal disease or fibrosis. Therefore, it was important to investigate 
multiple measures associated with renal disease and fibrosis to adequately 
characterise any potential phenotype. Measures assessed in this chapter have 
addressed many facets of renal function and disease. Measuring urine albumin 
and serum creatinine levels has addressed the filtering action of kidney in these 
mice, while measuring electrolyte levels has addressed the tubular phenotype 
of these mice. Gene expression analysis allowed the investigation of genes 
known to be markers of renal injury (Havcr1) as well as genes known to be 
involved in the development of fibrosis (Col1a1, Tgfb1 and Tgfbr1) and markers 
of tubular integrity (Cubn and Cdh1). Finally, measuring blood pressure has 
addressed that renal disease induces pathological systemic effects such as 
hypertension and associated cardiovascular disease. Although Pax8Cre x 
Ass1 fl/fl mice did not exhibit striking changes in many of these parameters, 
these mice should be utilised in future in vivo studies with an additional 
challenge such as ischaemia reperfusion injury.  
Transgenic mouse models can take significant amounts of time to develop 
pathological phenotypes. Moreover, organ specific transgenic mice may not 
induce any changes for many months and an additional challenge may be 
required to accelerate disease progression. Kruger and colleagues developed 
a transgenic mouse of proximal tubular mitochondrial overload by knocking out 
carnitine 29 acetyl-transferase (CrAT) specifically within the proximal tubule. 
These mice did not develop renal disease until 18-20 months of age. However, 
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an additional high fat diet challenge did accelerate the rate of renal disease 
development modestly to 12-15 months (212). The Pax8Cre x Ass1 fl/fl mice in 
this study were only investigated 10 weeks after knockout was induced by 
tamoxifen. The time scale of this project may not have been long enough to be 
able to detect any pathological changes that may point towards renal disease. 
Furthermore, tubular specific Ass1 KO mice may require an additional 
physiological challenge in order detect exacerbated renal disease in KO mice 
compared to controls. Indeed, Miao and colleagues found that proximal tubular 
specific knockout of the gene Crry did not induce any apparent renal disease 
when left unchallenged. Crry is involved in the complement cascade and 
knockout of Crry resulted in spontaneous deposition of C3 complement on the 
surface of proximal tubular epithelial cells as expected but with no associated 
renal disease. PT-Crry knockout mice were subjected to ischaemia reperfusion 
injury and this led to exacerbated renal disease in transgenic mice compared 
to controls. They exhibited higher blood urea, enhanced tubular injury and 
apoptosis as well as increased inflammatory infiltrates. They concluded that 
PT-Crry knockout sensitised mice to IRI and therefore Crry provided protection 
to proximal tubular cells from inflammatory kidney injury (213). Together these 
studies provide evidence that the tubular specific Ass1 knockout mouse 
warrants further interrogation over a much longer time scale than conducted in 
this chapter and also may require challenge with IRI to result in exacerbated 
injury.  
This chapter has investigated the effects of knocking out Ass1 within the tubular 
compartment of the kidney. While this study demonstrated no striking changes 
associated with renal disease or fibrosis, there are interesting trends 
demonstrating a potential blood pressure effect of tubular Ass1 knockout. 
Additional longitudinal studies over several months could be carried out to 
assess the long term effects of Ass1 knockout on tubular health and blood 
pressure. However, the most valuable experiment will be to induce an IRI in 
tubular specific knockout mice. I hypothesise that tubular deletion of Ass1 will 






Chapter: 5 General Discussion and Future 
Perspectives 
The studies presented in this thesis focussed on identifying novel pathways 
and mechanisms that may play a role in the progression of renal fibrosis and 
subsequent CKD. Arginine metabolism was revealed to be a metabolic 
pathway that was downregulated in the setting of renal fibrosis. Specifically, 
Ass1, the rate limiting step of arginine biosynthesis in the kidney, was identified 
as a gene which demonstrated downregulation in the kidney in three models of 
renal fibrosis. Ass1 is highly expressed in tubular epithelial cells and is absent 
in most other renal cell populations. Ass1 expression was depleted in live, 
transcriptionally active epithelial cells after obstructive injury and expression 
levels were recovered after reversal of obstruction. After Ass1 loss was 
identified as a common hallmark of all three in vivo models, the role that Ass1 
played in RPTECs was investigated. Ass1 was found to be highly expressed in 
human RPTEC/TERT cells and Ass1 loss was mediated in vitro by TNFα and 
hypoxic signalling. Furthermore, transcriptional inhibition of Ass1 was found to 
be independent of classical pro-fibrotic TGFβ signalling. Depletion of Ass1 in 
vitro resulted in a phenotypic change that was characterised as pro-fibrotic and 
de-differentiated but not senescent. These phenotypic changes are 
synonymous with tubular injury and the promotion of renal fibrosis. Finally, loss 
of Ass1 was induced in vivo by inducible tubular specific knock-out of Ass1 
using the Pax8CreERT2 x Ass1 flox/flox mouse. In a short time frame in an 
unchallenged state, Ass1 tubular KO did not induce any transcriptional 
changes seen in vitro after Ass1 depletion. Nor did Ass1 tubular KO result in 
any renal functional changes associated with CKD. However tubular Ass1 KO 
did perturb urea cycle amino acids in the kidney and resulted in elevated 
circulating citrulline. There was also some indication that Ass1 tubular KO did 
increase mean arterial blood pressure which indicated that Ass1 depletion may 
have abrogated arginine production in the kidney which is involved with nitic 
oxide signalling and vasodilation.  
CKD is a growing problem worldwide and there has been a lack of new 
therapeutics which halt the progression of CKD. Additionally, an aging 
population, the increased prevalence of type II diabetes and obesity will 
undoubtedly increase the incidence of renal failure. This “silent tsunami” will 
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greatly impact healthcare systems across the world (214). Therefore, new 
therapeutics need to focus on targeting the pathophysiological processes 
driving the early stages of tubular injury and TIF. Reversing fibrosis is possible 
as was shown in a patient with diabetic nephropathy who received a pancreatic 
transplant. This transplant and subsequent correction of hyperglycaemia 
allowed the reversal of renal fibrosis shown by histological analysis of biopsies 
over 10 years (215). However, although physical manifestations of fibrosis 
were reversed, there was no evidence of any improvement to renal function. 
Therefore, we must tackle mechanisms driving renal fibrosis before renal 
function can no longer be rescued. Superior biomarkers of early-stage renal 
fibrosis must be developed as well as therapies that abrogate early-stage 
events such as immune cell recruitment and maladaptive tubular 
dedifferentiation and senescence. Additionally, due to the elevated risk of 
developing CKD in patients who have previously experienced an AKI (216), 
these patients should be monitored closely in order to diagnose early-stage 
disease as soon as possible. Patient stratification either by genetic 
predisposition or AKI history will be important in the future to tailor correct 
treatments based on individual differences (217).    
CKD is driven by a number of processes but the common driving pathological 
mechanism for all forms of CKD is renal fibrosis. Tubular injury has now been 
identified as an initiating mechanism in the progression of renal fibrosis and 
tubular phenotypic changes such as de-differentiation and senescence have 
been shown to be responsible for initiating the fibrotic response (46,160). Ass1 
is highly expressed in the kidney and its expression is confined to tubules and 
predominantly the proximal tubule. Tubular cells are attracting attention as 
potential new druggable targets for the prevention of the initiation of renal 
fibrosis after acute kidney injury (AKI). AKI has been found to significantly 
increase the likelihood of developing progressive CKD and tubular cell 
dysfunction is central to this phenomenon (218). Studies have demonstrated 
that inhibition of histone deacetylase 1 resulted in tubular de-differentiation and 
subsequent increased proliferation of tubular epithelial cells after acute kidney 
injury. This de-differentiation and proliferation of tubular cells accelerated 
recovery and reduced fibrosis in zebrafish and mouse models of AKI. 
Furthermore administration of a drug which inhibited histone deacetylase was 
found to be affective several days after AKI. This is highly clinically relevant as 
patients rarely get treated for AKI until the injury has already established. This 
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provides evidence that correcting dysfunctional mechanisms ongoing in tubular 
cells is an effective therapeutic strategy against renal fibrosis (219,220). 
Previously, fibroblasts were seen as the most promising cellular targets for anti-
fibrotic therapies in CKD, however anti-TGFβ based therapies have yielded 
disappointing results (32). Therefore, studies from this thesis may provide 
insight into how tubular cells undergo de-differentiation via Ass1 loss in a 
TGFβ-independent manner.  
The Denby lab previously identified miR-214 as pro-fibrotic microRNA which 
exerted its effects in the kidney in a TGFβ-independent manner (94). This 
thesis identified Ass1 mRNA as a likely target of miR-214 binding and 
repression. The precise mechanism whereby miR-214 performs its pro-fibrotic 
role has not been fully elucidated but repression of Ass1 in tubular cells may 
be a mechanism which miR-214 adopts to augment fibrogenesis. miR-214, 
TNFα and hypoxia are all stimuli are present in most renal diseases. All three 
of these upstream modulators exert an inhibitory action on Ass1 transcription. 
This provides strong evidence that Ass1 downregulation is an important 
mechanism in the progression of renal fibrosis as three different signalling 
pathways present in the fibrotic milieu lead to the same downstream effect. 
Although the consequences of genetic downregulation of Ass1 in vivo were not 
fully elucidated here, there is much work still to be carried out using the 
Pax8Cre x Ass1 fl/fl mouse.  
The experiment which should be carried out next is ischaemia-reperfusion 
challenge in Pax8Cre x Ass1 fl/fl mice. This study would definitively show the 
effect of tubular Ass1 loss in the setting of renal injury and fibrosis. I 
hypothesise that tubular knockout of Ass1 would exacerbate the effects of renal 
IRI and would increase the extent of renal fibrosis. The same parameters 
adopted in chapter 5 should be used to assess the renal function of Pax8Cre x 
Ass1 fl/fl subjected to IRI. Additionally, the extent of fibrosis should be assessed 
by gene expression analysis and histological analysis to ascertain the extent of 
tubular injury and ECM deposition in the kidney. This study should be 
adequately powered and conducted with the correct control mice in order to 
make valid comparisons. Pax8Cre x Ass1 fl/fl mice induced with tamoxifen 
should be subjected to sham or IRI surgery. Additionally, Pax8Cre x Ass1 fl/fl 
mice administered with vehicle control should be subjected to sham or IRI 
surgery. Furthermore, male and female mice should both be assessed 
separately. Chapter 5 demonstrated the need to evaluate the physiology and 
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genetics of males and females individually and CKD itself demonstrates 
unequal prevalence among males and females. While more females are 
diagnosed with CKD, it has been observed that the disease is more severe in 
men with more men progressing to ESKD (221,222). Furthermore, female rats 
have been reported to have increased protection against an experimental 
model of CKD than male rats. Male rats developed higher levels of albuminuria 
and more severe glomerulosclerosis compared to females after L-NAME 
induced CKD (223). Until recently, in vivo studies involving kidney disease have 
used only male mice. It is growing increasingly more important to evaluate the 
results of studies in males and females within the field of renal research.    
If tubular knockout of Ass1 led to increased sensitivity of tubular cells to 
ischemia reperfusion injury mediated fibrosis, further studies should be carried 
out to abrogate the downregulation of Ass1 in vivo. One methodology to 
reinstate normal Ass1 expression would be to target one of the upstream 
modulators of Ass1 expression. Anti-miR-214 has already been adopted by the 
Denby group to prevent the progression of renal fibrosis (94). If Ass1 is found 
to be a validated target of miR-214 then antagonism of miR-214 would prevent 
Ass1 downregulation and therefore would prevent Ass1-loss-mediated effects. 
Another course of action would be to target TNFα. Anti-TNF therapeutics are 
already licensed to be used in patients and have passed safety requirements. 
TNFα blockade has shown promise in diseases such as rheumatoid arthritis, 
spondyloarthritis and other chronic inflammatory diseases. Anti-TNF therapies 
currently function to neutralise endogenous TNFα and take the form of full 
length monoclonal antibodies (adalimumab, golimumab and infliximab) as well 
as a soluble TNF receptors (etanercept) and most recently a PEGylated Fab 
fragment of a monoclonal antibody (certolizumab) (224). These therapies must 
be administered intravenously or subcutaneously and incur a high cost to the 
NHS (225). TNFα blockade has been found to be successful in improving the 
quality of life for patients who have chronic forms of arthritis, however, it has 
been reported that there is a high rate of non-responsiveness in certain patients 
and there is a high risk of developing serious chronic infections as an adverse 
effect (226,227). These drugs are still in their infancy but they do provide 
effective treatment for diseases which are driven in part by TNFα. As TNFα is 
upregulated in patients with CKD and inflammatory pathways are strong 
initiators of renal fibrosis, TNFα blockade may provide an effective therapy to 
abate CKD progression. Additionally, antagonising TNF mediated signalling 
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may prevent Ass1 downregulation, thereby retaining tubular Ass1 expression 
and preventing Ass1-mediated de-differentiation.  
The studies presented in the thesis highlight the complexity of fibrotic signalling 
within the kidney. This complexity has stunted the finding of new therapeutics 
to treat patients with CKD. This body of work has identified Ass1 as a potentially 
important gene in the setting of renal fibrosis. This tubular gene may provide a 
mechanistic link between pro-inflammatory, hypoxic and miR-214 mediated 
signalling and tubular de-differentiation and fibrogenesis. The elucidation of 
Ass1 as an important gene is the development of renal injury and fibrosis may 
provide insight into novel druggable mechanisms which may benefit patients 
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